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Abstract 
This thesis assesses the methods used in economic evaluation, the relationship of 
economic evaluation to decision-making and investigates the possible limitations of 
economic evaluation as it is currently used to support policies aimed at maximising 
population health gain. It then evaluates alternative methods of analysing data from 
economic evaluations to better inform policy decisions. 
The hypothesis of this thesis is that a greater use of subgroup analysis in policy decisions 
could potentially improve the efficiency of allocating scarce health care resources. This 
study aims to investigate the impact on population health gain and service cost- 
effectiveness of using subgroup analysis within defined parameters to derive and evaluate 
estimates of effect, and compare it to the more traditional methods of statistical inference. 
Data from existing large trials are used to calculate cost-effectiveness ratios for the total 
study population and for subgroups. Total and subgroup estimates of cost-effectiveness 
are applied to patient populations through simulation, and outcomes predicted on the 
assumption that treatment decisions are guided by estimates derived from the trial. The 
distribution of cost-effectiveness ratios based on different rules for `allowing' the use of 
subgroup analysis results is compared with the distribution of cost-effectiveness ratios 
based on aggregate analyses. 
Results show that pre-selected subgroups can provide a stronger likelihood of maximising 
overall health gain. This thesis argues for optimisation in the use and interpretation of 
results rather than an over reliance on certainty and the resulting restriction on the use of 
available data. It concludes that under the scrutiny of a health care system for which the 
primary goal is health gain maximisation within resource constraints, policy decisions 
made using the results of subgroup analysis could result in a more efficient allocation of 
resources. 
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1. Introduction 
The goal of normative economics is the maximisation of the welfare of the population. 
Since there are not enough resources to provide all the medical care demanded, choices 
are inevitable. Within most health care systems the objective is to maximise social 
welfare in terms of total health benefits or outcomes, but the measurement of these 
outcomes and the decision of the priority given to the different calls upon these resources 
is where economic theory must meet practical application. 
The aim of this thesis is to look at the methods used in economic evaluation, its 
relationship to decision-making in health care, to investigate possible limitations of 
economic evaluation as it is currently used in terms of supporting policies to maximise 
population health gain and to suggest better methods. The first section gives an overview 
of the three fields of interest; 
" economic evaluation in health care and the relationship between research and 
decision-making 
" the contrasting methods available to analyse economic data and their roots in 
probability theory 
" Methods of data analysis that incorporate or accept the heterogeneity of the studied 
population 
The second section looks in more detail into the theory behind subgroup analysis. It takes 
forward the probability theories outlined in the first section and explains the intrinsic 
logic behind subgroup analysis that leads into the conceptual framework of the thesis. 
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It then assesses the theoretical argument for the use of subgroup analysis and probability 
and outlines the potential gains that could be found when making resource allocation 
decisions in health care. 
The third section compares subgroup analysis results against the results from the analysis 
of the data set as a whole. Initially concentrating on the relationship with cost and then 
with cost-effectiveness ratios. The value to decision-makers of a greater use of subgroup 
analysis is assessed by comparing the usefulness of evidence gained through subgroup 
analysis with those gained from traditional analysis of cost-effectiveness ratios. The thesis 
concludes with a discussion on the relevance of the results of this study to policy makers 
and what further work should be done to further clarify the role of subgroup analysis in 
decision-making. 
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2. Economic evaluation and decision-making in health care 
2.1 Introduction 
Recently there has been a growth in the number of clinical trials that have included a form 
of economic evaluation'. The aim has been to compare the costs and benefits of new 
treatments or prevention strategies with other more commonly used methods. The 
primary objective of trials has been the evaluation of both the safety and efficacy of 
treatment. However, consideration is now being given to other facets such as resource 
use. A world-wide increase in health care expenditure has been linked, among other 
things, to the emergence of new medical procedures. Several countries now require 
information on the cost-effectiveness of new drugs (e. g. Australia' and Canada) and any 
new health care programme (e. g. in the Netherlands4) to ensure greater efficiency in the 
use of resources. 
Closer to home, the recent introduction of the National Institute of Clinical Excellence 
(NICE) has been set up with the primary aim to ensure that new technologies are assessed 
for cost-effectiveness as well as clinical effectiveness. The primary purpose of NICE is 
summarised as follows; 
"NICE will produce clear guidance for clinicians about which treatments work 
best for which patients. It will assess new drugs, treatments and devices for their 
clinical and cost-effectiveness. " 5 
The main reason for this shift has been the recognition of the fact that diffusion of many 
medical interventions takes place prior to the associated costs and benefits being 
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determined'. The early inclusion of economic analysis can provide useful information to 
assist in the rational diffusion of new innovations in health care'. Economics can be used 
in conjunction with clinical trials to help answer the question "should we do this? " rather 
than confining the conclusion of the trial to the question "does it work? " That is, in 
comparison with current or alternative treatments, do the marginal benefits of the new 
treatment outweigh any additional costs? The application of economics to clinical trials 
does not necessarily mean that less can or should be spent, but rather that the use of 
resources might be more efficient. 
It is argued that clinicians should have an intrinsic responsibility to society as well as to 
the individual, and that these responsibilities should be incorporated into clinical 
decisions'. Most clinicians would agree that the extra money spent on achieving 
insignificant improvements in outcome is often not worthwhile. The extra resources used 
could have been used elsewhere in the health care system achieving greater benefit. These 
ideas come directly from an understanding of the limitations of finite resources and an 
aim of maximising health gain through the allocation of these resources. The term "health 
gain", in this thesis, is defined as a positive change in the status of the health of ` 
communities. It occurs if an intervention either initiates or accelerates an improvement in 
the health of a community, or if it prevents or delays deterioration in the health of a 
community. 
The areas in which economics has the ability to have an impact on improving outcomes 
are first, to reach definitive conclusions on the most efficient use of health care resources, 
and second, to provide evidence to enable decision makers to set priorities in the 
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allocation of total resources between prevention and treatment. However, there is often a 
sizeable gap between what researchers consider to be good evidence and what decision- 
makers believe to be good evidence. This concept is not in any way confined to economic 
evaluation but encompasses clinical trials9 and operational research1°. 
Despite the enormous investment in research, which consumes around $55bn World- 
wide, every year", there is evidence to suggest that little of this research provides 
evidence which is then used in practice for either policy or clinical decisions`2"3 Most of 
the literature14as. '6 on this gap between research evidence and decision-making focuses on 
better use of and easier access to the information produced by research, and often 
overlooks issues raised more specifically by decision-makers, that of interpretation and 
generalisation of research evidence". This chapter aims to give an overview of the 
problems of economic evaluation both in terms of its methodology and its relationship 
with policy and decision making. 
2.2 The theory of economic evaluation 
Economic evaluation is a two dimensional measurement of the effectiveness of an 
intervention, where an intervention is assessed by it's ability to produce positive benefits 
within the constraints of a set level of resources. Resources are usually presented as their 
equivalent in a monetary currency such as pounds or dollars. The type of economic 
evaluation will determine the method in which benefits are presented. 
Economics looks at how best to allocate scarce, or limited resources to best satisfy 
unlimited or infinite demand. All resources are scarce, so no matter how much there is of 
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something it will eventually run out. Economists attempt to maximise aggregate benefit 
from within the restriction of limited resources. The theory of benefit maximisation is 
best described in terms of allocative, or Pareto efficiency. 
Pareto efficiency was named after the economist who first presented this theory, Vilfredo 
Pareto. He stated that any redistribution of resources would improve efficiency if it made 
at least one person better off without making anyone else worse off. Society would, 
therefore, be most efficient where it is impossible to redistribute resources to make 
someone better off without simultaneously making someone else worse off. There could 
be a number of different permutations of resource allocation that resulted in Pareto 
efficiency, but they would all produce the exact same level of aggregate benefit. This is 
perfectly acceptable in theory but becomes difficult to measure in practice. For example, 
how is benefit defined? Do some things benefit some people more than others? 
The concept is developed further by the compensation principle introduced by Kaldor18 
and Hicks19. It adds the concept of relative or net benefit, making the model more flexible. 
If a redistribution of resources results in gainers and losers, it is a move towards Pareto- 
efficiency only if the aggregate benefits of the gainers outweigh the costs of the losers. In 
principle the gainers can then compensate the losers while still achieving a net benefit. 
Kaldor and Hicks proposed that the measurement of benefit should be directly 
comparable with the costs of redistribution and, as such, benefits should be given a 
monetary value. 
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These are the roots of the economic evaluation method known as cost-benefit analysis 
(CBA), the aim of which is to measure the effect of changes in resource allocation in 
terms of the net benefit to society. 
The other form of economic efficiency is technical efficiency. The definition of technical 
efficiency is that of a production process that utilises the minimum resources. In terms of 
health care, technical efficiency is achieved where a utilisation of resources produces a 
level of benefit that cannot be exceeded by utilising those resources in any other way. It is 
this view of efficiency that forms the basis of cost-effectiveness analysis, which does not 
attempt to measure benefits against cost, but generally aims to compare interventions with 
the same goal. Comparisons are made by fixing either the costs or the outcomes, and 
comparing the remaining variable. 
There are limitations with this method in terms of comparing different strategies or 
intervention that may have different outcome measures. However, a version of cost- 
effectiveness analysis (CEA), known as cost-utility analysis (CUA) attempts to overcome 
this by using a common measure of outcome, so the relative cost-effectiveness of all 
interventions can be compared. In CUA the benefits are expressed in terms of quality- 
adjusted-life-years (QALYs), disability-adjusted-life years (DALYs) or, the more recently 
introduced healthy-year-equivalents (HYEs). These methods can be used to compare 
interventions with different outcomes. 
Although CBA is the original method of economic appraisal, CEA is now preferred by 
decision makers because it doesn't require the translation of health consequences into 
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monetary units (i. e. quantifying the value of human life). However, there have been signs 
recently of a re-emergence of CBA20, with the introduction of a number of new methods 
that have made the valuation of health consequences less problematic. CUA continues to 
be the fastest growing form of economic evaluation, although there is an ongoing debate 
about the use and calculation of the generic measure of benefit, be it QALYs, DALYs or 
HYEs. 
The application of these methods is under continuous review, lacking any consensus of 
opinion21. The choice of method is often not straightforward. Options may be limited due 
to the type and quality of the information available, as well as possible restraints on time 
and resources. Although the ideal method can be identified it may not be possible to 
conduct given such restraints. The goal must therefore be to maximise what can be 
achieved and to choose the method most appropriate to the data. 
A key issue which must also be considered before embarking on an economic evaluation 
of any kind is the economic viability of economic analysis, i. e. whether it is worthwhile 
spending resources on the evaluation. The quality or the availability of information for 
economic analysis may be such that it is not perceived efficient to conduct an economic 
evaluation due to the unreliability of the results. Ideally economic evaluation, with its 
associated costs, should only be undertaken if the benefits of improving efficiency in the 
use of health care resources outweigh these costs. Conversely it may not be worthwhile 
undertaking the evaluation because the evidence already exists to substantiate the cost- 
effectiveness. 
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2.3 Research evidence and decision-making 
There has long been an underlying tension between decision-makers and researchers. 
Much of this tension comes from the belief that those doing research do not understand or 
appreciate the complexities involved in decision-making. No matter how impressive or 
definitive the research, it still has to be interpreted at a local level. The problem is due to 
the fact that researchers, who are trying to reach the widest audience, tend to generalise 
upward towards a generic or "average" result, whereas those who wish to take advantage 
of this evidence are trying to generalise downward within a specifically defined 
population. The result is a dichotomy of interest between both players. 
Classical statistical techniques compound this problem by limiting results of trials to a 
simple right or wrong (or better or worse) outcome, across a general sample. There has 
been a growing movement towards alternative methods of statistical proof and the 
summarising of trial results for the benefit of decision-makers. Most of these have tended 
towards either greater sensitivity analysis or the use of alternative statistical techniques 
such as Bayesian theory or decision analysis (defined in detail in chapters 3 and 4). The 
advantages of Bayesian techniques lie in the fact that it is possible to incorporate 
additional information into the analysis of a particular study (such as specific patient 
characteristics). This makes it easier for the decision-maker to apply the results of generic 
research to specific situations and allows the formal inclusion of the heterogeneity of 
populations into analysis of data, something that cannot be done when using classical 
statistical techniques. 
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For example, consider a study that shows that intervention "A " leads to a lower rate of 
post-operative infection. The results using classical statistics will only show the mean 
difference in infection rate between those who received the intervention and those who 
didn't, along with a significance test to inform the decision-maker of the likelihood of the 
results of the trial being true. The decision-maker, however, is also aware that there are a 
number of other aspects of the treatment that a surgical patient can receive that would also 
affect the post-operative infection rate, for example, whether they received blood or not. 
In Bayesian analysis the relationship between the presence of a blood transfusion and 
post-operative infection rate would have been included in the analysis as prior 
information, thus the results of the analysis would be more appropriate for decision- 
makers. 
It is not only in the clinical trial arena that there is a need to bridge the gap between 
research and policy, but also in the field of economic evaluation. There has been much 
progress in the methods used for economic evaluation in health care in recent years. The 
majority of the mathematical work has centred on improving the measurement of the 
statistical inference of cost-effectiveness ratios, rather than the search for alternative 
methods of presenting economic information and improving its application in decision 
making22,23"24,25 However, there is a growing body of research that has started to challenge 
the use of classical statistics to present economic data and a move towards methods which 
b . are more relevant for decision-making' 
Claxton and Posnet", along with many others, express the view that a decision-analytic 
framework should be pursued when attempting to answer economic questions. The reason 
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for this view is that traditional trial design is not consistent with the concept of efficiency, 
whereas the decision-analytic approach is as well as with methods used to set priorities in 
service provision. Claxton and Posnet also state the advantage of incorporating "prior 
information" as being "handled consistently and open to criticism, alternative formulation 
and empirical testing, " whereas, classical statistical techniques exclude the use of related 
or prior information in producing results. 
Lilford et al16 also supports the incorporation of prior information via the use of Bayesian 
statistical methods. They argue that conventional statistical testing is "an improper basis 
for making decisions because they dichotomise results according to whether they are or 
are not significant, and do not allow decision makers to take explicit account of additional 
information. " Similar arguments are found in Hornberger et a129, Van Hout et al3° and 
McCloskey et a131. 
2.4 The relationship between economic evaluation and decision making 
Evidence suggests that economic evaluations are seldom used as a tool for decision 
making in policy or management32,33'34'35 These studies concluded that the majority of 
economic evaluations have been done by researchers without prior consultation with 
policy makers, however, changes are beginning to take place. For example in the UK the 
Cochrane Collaboration and NICE are initiatives aimed at boosting the acceptance of 
evidence-based medicine in practice. In Australia a set of economic evaluations36 have 
been done in collaboration with the appropriate decision-makers in health departments, 
which had a definitive impact on policy. This supports the theory that an increased 
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involvement with decision-makers would improve the impact economic appraisals have 
on health care policy. 
The connection between research and policy has always been a tenuous one, and as 
economics is still a relatively new facet to the measurement of the effectiveness of health 
care interventions, the connection with policy is even more tenuous. Australia and Canada 
are the only countries to have affected an introduction of mandatory economic evaluation 
for new pharmaceutical products37, however a number of other countries are now 
requesting information on economic evaluation in order to aid decisions such as Finland, 
Switzerland, Sweden and the UK. 
A review38 has cited how economic evaluation has grown in the past three decades. In the 
five years from 1970-74 there were just 56 published economic evaluations whereas in 
the period 1985-89 there were 718. The majority of these have been cost analyses and 
cost-effectiveness analyses. There is evidence, then, that the use of economic evaluation 
in policy and decision-making is starting to grow. Nevertheless there is still scepticism 
about the value of economic evaluation in health care, due, in part, to the wide variety in 
the quality of published economic evaluations. In response to this a number of guidelines 
on conducting and reporting economic evaluations (e. g. the BMJ guidelines) have been 
developed to help define appropriate methodological standards". 
One of the major reasons cited by decision makers", for not using information from 
economic evaluation, is the inability of economists to present the results of their research 
in a way that is both agreeable and useable for people in the position of making decisions. 
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If the results of economic evaluations are to be considered in clinical decision-making, a 
common language must be found between clinicians and economists. Although economic 
evaluations have increased in both quantity and quality over the years, their acceptance 
and influence on decision-makers has not grown significantly. The question, therefore, is 
what forms of clinician/manager education and/or changes in presentation of 
methodologies and results are required? There have already been a number of 
developments that have aided the communication. Firstly there is the introduction of 
health outcomes as a measure of productivity or benefit. There have been a number of 
innovations in health outcome measures, for example quality adjusted life years, which 
combined the outcomes of mortality and morbidity into one measure40. Second, decision- 
making has started to move away from the benefit of the individual and towards being 
based on the benefits to society as a whole. This makes it easier to understand the need to 
compare benefits with costs. 
In addition to the need of presenting economic evaluations in such a way that is both 
understandable and generalisable to decision-makers, there is also the more practical 
problem of integration of economic analysis into routine decision-making. 
An article by John Hutton4' recently highlighted the fact that economic evaluation is only 
done on a one-off basis to solve a specific problem and very rarely used routinely. Hutton 
drew parallels with the evolution of economic evaluation and Lewis Thomas' 
classification of medical technologies. Here he states that economic evaluation has 
moved on from being a non-technology to a half-way technology, but for it to become an 
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advanced technology it would have to become routine, and an accepted part of clinical 
decision-making. 
2.5 Summary 
Economic evaluation, despite the lack of direction of its methodologies and the 
difficulties of it being accepted in practice, has the potential to be a very valuable tool in 
helping to maximise health gain within the restraints of limited resources. However 
evidence suggests that the current methods of presenting results of economic evaluations 
are not consistent with this goal. Although there has been much talk of bringing economic 
information and clinical decision making closer together, there has been less evidence of 
it happening. A first step must be to shift the goals of economic evaluation in terns of the 
presentation of results closer to those that are relevant and practical to those making the 
decisions. 
The relationship between research and policy is of vital importance, to both groups. They 
rely heavily on each other for their continued existence, yet often seem to have no 
common language. There is a growing belief among some that movement away from the 
strict rules of classical statistics and a wider acceptance of new techniques that take into 
account the issue of heterogeneity should be considered. These techniques have the 
advantage of incorporating the specific characteristics of both patient and population, 
methods such as Bayesian statistics, decision analysis and subgroup analysis could bring 
the information requirements of the policy maker and the research efforts of the 
economist closer together. 
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3. Incorporating heterogeneity into data analysis 
3.1 Introduction 
The aim of this thesis is to investigate the possibility that for the purpose of answering the 
question, "which health care interventions should be provided and for whom? " we need to 
focus more on the relative cost-effectiveness, both costs and outcomes, of health care 
services within different subgroups. 
When policy makers decide what health care interventions should be funded they do so on 
a basis of knowledge of the demands of their population. Where a population has a high 
incidence of a certain disease investment in treatment of that disease may take priority 
over another. Despite the acknowledgement of the heterogeneity of populations there is 
little acceptance that evidence on the cost-effectiveness of these interventions for different 
groups within the population itself may be useful in making these decisions. 
The purpose of the next two chapters is to look at the theory behind three methods most 
associated with analysing data sets which take into account the issue of heterogeneity. 
These are Bayes theory, decision analysis and subgroup analysis. Bayes theory brings the 
incorporation of prior evidence to the issue of heterogeneity; subgroup analysis 
concentrates mainly on the issue of heterogeneity alone, and decision analysis takes the 
complex issue of the non-homogenous effects of interventions into the realm of decision 
making. 
& 
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Many of these alternative methods of analysis of clinical trial data have been the subject 
of widespread debate4'. In order to assess the relative benefits of all three and to 
understand how they incorporate the issue of heterogeneity these methods and the theory 
underlying them will be reviewed in detail. 
This chapter reviews the importance of heterogeneity and looks in more detail at the 
potential benefits and problems with subgroup analysis. Chapter 4 then goes onto review 
the theoretical concepts underpinning these alternative methods and assesses in more 
detail the techniques of Bayesian and decision analysis. 
3.2 The potential benefits of incorporating heterogeneity into analysis 
The benefits of incorporating heterogeneity when undertaking analysis of data is best 
shown graphically as in figures 3.1 and 3.2. Figure 3.1 shows the average cost- 
effectiveness ratios for a general population with the minimal data on the characteristics 
of the population and their impact on cost-effectiveness. Within the block where the 
resource constraint falls, a proportion of people who have an average cost-effectiveness 
ratio of "x" will forgo treatment even though some of the people who receive treatment 
will have a cost-effectiveness ratio lower than "x" and some who don't receive treatment 
will have a cost-effectiveness ratio greater than "x". Figure 3.2 demonstrates that with 
greater information on the characteristics of the population and the relationship between 
those characteristics and cost-effectiveness a clearer picture emerges of the proportion of 
the population likely to benefit most. This would result in a more efficient allocation of 
resources. The average cost-effectiveness ratio of those receiving the intervention in 
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Figure 3.1 would be "x", and the average cost-effectiveness ratio of those receiving the 
intervention in Figure 3.2 would be between "x" and "y", approximately (x +y) / 2. 
This method could also help us to achieve a more efficient balance between different 
sectors of health care. For example let us assume that there are only two interventions in 
the prevention and treatment of colorectal cancer, screening and surgery. These 
interventions would have marginal cost-effectiveness ratio curves (see figure 3.3) and 
these curves would be made up of subgroups of the population and could be listed in 
order (see figure 3.4) to give a picture of the extent to which resources are better spent on 
surgery or screening. 
Y- 
r 
C'/F 
Y 
X 
number of people covered 
Figure 3.1 Figure 3.2 
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number of people covered 
C/E ratio 
surgery screening surgery screening 
Figure 3.3 Figure 3.4 
In many trials in addition to the main outcomes there are often other results based on one 
or a number of specific subsets of the population studied. These subsets, or "subgroups", 
are connected by a specific common characteristic, such as age, sex or some other 
common demographic, diagnostic or biological trait. The reason they are highlighted is 
usually because the group in question is shown to derive a much greater benefit or are at a 
higher risk from the intervention being studied. This would seem to be a potentially useful 
source of information. However it is often argued that subgroup analyses is used without 
due regard to protocol, and furthermore to produce positive results in any form is 
surrounded by a degree of scepticism". This has meant that attempts to produce useful 
insights into the relative effectiveness of interventions across populations with different 
characteristics have been looked upon with distrust, regardless of their scientific strength 
or importance. In reality the identification and use of subgroups in this way may allow a 
more efficient use of resources. 
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Like most studies, subgroup analysis uses a sample of a population to draw conclusions 
about the population as a whole. Also like most studies the results are always at risk of 
interference from confounders and bias. A number guidelines have been published44 21'22 
suggesting that subgroup analysis must be treated with extreme caution and that a number 
of steps must be taken to minimise the possibility of chance entering into the results, as 
well as how to interpret the results if you are the intended audience. These guidelines and 
checklists could be equally applicable to any form of trial analysis. 
3.3 The potential pitfalls of subgroup analysis 
It has been reported that subgroup analysis can be misleading, and that there has been a 
tendency to over emphasise the importance of subgroup analyses without attention paid to 
statistical rigour. However, the majority of criticism aimed at published subgroup 
analyses has been concerned with the potential dangers of misinforming decision-makers 
while avoiding a more constructive view that points out the poor practical applications of 
the method. Like any other form of analysis, statistical or otherwise, if undertaken 
without due regard to the rules by which it is drawn, the results will be unreliable. 
For clinical trials good design requires elements of randomisation, masking, completeness 
of follow-up, and other methods associated with minimising both error and bias. A 
number of papers have attempted to summarise the problems with conducting and 
interpreting sub-group analyses'. 46,47 Consensus moves us to list four main areas of 
concern. These are; 
1) Statistical significance, 
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2) Clinically important difference, 
3) Hypothesis preceding analysis, 
4) Dose response and indirect evidence to support the findings. 
Statistical significance is an important issue. Subgroup analyses will always include fewer 
patients than does the overall analysis and as such carries a greater risk of a type II error* 
There are a number of techniques for conducting subgroup analyses that are suggested to 
reduce this such as the Bayesian method4a. °9 or those used in decision analysis models. 
Statistical significance is, however, only a tool for assessing the likelihood of an observed 
event happening by chance. The possibility of the result being due to chance can be 
minimised, but never dismissed entirely. This leads onto the second point, the importance 
of observing a clinically important difference. No trial can control for everything and as 
such there will always be a measure of difference between different subgroups. It is only 
when the difference is large enough does the interaction warrants attention. There are no 
ground rules for size of effect, but generally the larger the difference between a particular 
subgroup and the overall effect, the more likely that it will be real. 
The third factor is the issue of the hypothesis preceding the analysis. It is generally 
believed that sifting through data for possible interactions is bad science. There are a 
number of examples of studies finding "apparent" interactions in subgroups where none 
were found in the overall population. Nevertheless, the issue of whether a hypothesis 
preceded analysis is not always a cut and dried one. At one end of the spectrum you might 
have unexpected results in a subgroup detailed after the event that cannot be explained, 
where a relationship shown is more likely to be due to chance. 
29 
whereas at the other end, you may have a subgroup result clearly explained in a protocol 
beforehand that was suggested by previous research. Between these two extremes are an 
infinite number of combinations. It is normal to discourage conclusions to be drawn from 
an unexpected correlation, however, if they possess a degree of statistical power they may 
form a very useful hypothesis for future research. 
This brings us to the last point, where results of subgroup analyses may be strengthened 
by a dose-response or by indirect evidence such as known human biology or behaviour. 
An example may be where an intervention has minimal benefits across a population, but 
in older age groups its effects are more pronounced. The effects of the lower age groups 
may have pulled down the overall average. The evidence could be supported if there was 
a linear trend in dose-response across the age groups or if there was a physiological or 
psychological reason why the intervention would be more likely to benefit older people. 
3.4 Summary 
When studying a multidimensional subject such as a population, there are inevitably 
issues surrounding the heterogeneity of that sample. It is not under debate that this 
heterogeneity exists or that there are groups within the population defined by certain 
characteristics that will mean that a given health care intervention is more or less likely to 
be cost-effective for them. What is an issue of conjecture is whether this information and 
these relationships are attainable and whether knowledge of them can be used to improve 
efficiency in resource allocation. 
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Subgroup analysis or the measurement of the relative cost-effectiveness of groups within 
a population, rather than the population as a whole can theoretically improve the 
efficiency of health care systems. Despite the concern surrounding the methods 
employed to undertake subgroup analysis, most of these can be overcome with a 
concentration on good science and the use of accepted methods of measurement. 
Having given an overview of the importance of heterogeneity and the value of subgroup 
analysis, the next chapter will review the theory behind the two more mainstream 
methods associated with heterogeneity-friendly data analysis, Bayes and decision 
analysis. 
31 
4. Probability, inference and decision analysis 
4.1 Introduction 
To understand where the heterogeneous methods differ from the more common classical 
analysis, we must go back to the roots of inference with a description of probability 
theory and its relation to the various theories of inference and decision analysis. Once we 
have described the varying theories of probability and their perceived strengths and 
weaknesses, the mainstream methods of Bayesian inference and decision analysis will be 
reviewed. 
This chapter then goes on to provide a critical analysis of both of these methods in 
comparison to subgroup analysis. It will look at the strengths and weaknesses of these 
methods both in terms of the information it provides to decision makers and the 
acceptance of the tools it uses to achieve these results. 
4.2 Theories of Probability. 
All theories of statistical inference are rooted in probability theory. Looked at 
simplistically, it could be said that each different classification of probability theory has 
led to a theory of statistical inference. As will become apparent, this is not necessarily so. 
There are no fixed boundaries in terms of belief of one particular theory of probability 
that automatically disqualifies you from any one theory of statistical inference, but there 
are some obvious common links that obviate likelihood of one over that of another. 
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There are basically four theories of probability; the classical, the frequentist, the logical or 
objective, and the subjective or personalistic theory. 
All theories of probability have a number of simple properties. The most obvious of these 
is that if we have a set of events that are mutually exclusive and which include all the 
possible events in the given circumstances then the sum of the probabilities of these 
events happening will be one. The set of these probabilities makes up a probability 
distribution. Of the four theories of probability, the oldest and simplest is the classical 
theory of probability. 
4.2.1 Classical probability 
The first recognisable work on probability was done in the 1600s and centred itself on a 
framework of "equally likely" outcomes. At this stage there was no attempt to define 
probability, although some years later Laplaces'S° classical definition ofprobability as the 
ratio of the number of outcomes favourable to the event to the total number of possible 
outcomes, each assumed to be equally likely became the accepted definition. Although 
forming the roots of modern day thoughts and theories of probability the classical view of 
probability is generally thought not to stand up to modem methodological standards, 
mainly due to it's reliance on the concept of "equally likely" outcomes'. 
The definition of "equally likely" is thought to come from the symmetry or homogeneity 
of the experimental situation. If a two-sided coin is spun, what reasons are there for one 
side to be favoured over the other? Are the outcomes, therefore, equally likely? This is 
known as the "principle of cogent reason". The difficulty arises when we study the basis 
of such reason, for on what basis do the physical properties of such objects imply equal 
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probability? The basis for the reasoning seems to rely on some prior knowledge about the 
effect of these physical properties, and at this point the theory becomes somewhat 
circular. What is really being considered is a theoretical coin that approximates to our 
chosen coin. 
The other attitude to this concept is the "principle of insufficient reason", which argues 
that if we have no good reason to believe that either side of the coin is more likely to fall 
face-up, then we must assume that both sides are equally likely to appear. This then 
becomes a subjective argument based on the level of information we may or may not have 
about the properties of the coins. 
These restrictions aside, the concept of equally likely outcomes can conceivably be used 
in only a small number of basic problems. Most attempts to use classical probability 
theory in more widely defined terms have tended to move more towards introduction of 
the concept of "frequency" probability theory, with the connection of the principle of 
cogent reason. 
4.2.2 Frequency probability theory 
A frequency theory of probability started to arise from the attempts to study more diverse 
topics with the more limited classical theory. Venn52 first formally defined it as 
expressing "probability in terms of the limiting values of relative frequencies in infinite 
sequences of repeatable situations". The mathematical basis for the frequency theory was 
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not developed until much later by von Mises53, who, rejecting the limitations of the 
classical standpoint, saw frequentist probability as 
"the rational concept of probability... (applying) only to problems which either the 
same event repeats itself again and again, or a great number of uniform elements 
are involved at the same time. In order to apply (this) theory of probability we 
must have a practically unlimited sequence of uniform observations. " 
In essence the restriction of the use of frequency theory seems to be that within the 
collective or group of identical events being studied, along with the condition of 
uniformity is a condition that requires the properties of these events are not restricted by 
their position within the collective. This means that if a selection or subset of those events 
were selected according to some specific rule, the properties of those events would tend 
towards the properties of the whole. The basis of this limitation von Mises calls the 
principle of randomness" 
It is the inclusion of this concept that differentiates frequency theory from that of 
subjective probability theory, as in the former an event is not specific but typical. That is, 
the probability of an event is the probability that the coin will fall heads face-up at any 
observable occasion. Whereas the subjective viewpoint takes a more personal view of 
each event, looking to assess the probability of the coin coming up heads on the 10th or 
11th toss. 
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It is may be suggested by subjective probability theorists that like classical probability 
theory, frequency probability theory has implied limitations to where it can be used. It's 
use and wide acceptance, as the basis for much of the statistical methods used in 
population sciences, tends to suggest that these limitations are not very important. 
The views range from the admission that situations that do not encompass repetition of 
events of uniformity are not within the realm of vigorous statistical enquiry. Whereas 
other go so far as to suggest that this concept itself makes frequentist theory untenable in 
the study of complex bodies such as populations. It all depends on your viewpoint on the 
uniformity of the events in question, and how important any amount of lack of uniformity 
is to the outcomes being studied. No doubt any collective being studied using these 
concepts could be acceptably defined as uniform or heterogeneous, depending on the 
viewpoint of the discussant. 
4.2.3 Logical probability theory 
The logical theory is thought to be somewhat of a bridge between the frequentists and the 
subjective probability theorists with an objective and typical approach to the collective, 
but also with an aim to incorporate the degree-of-belief approach. The logical view of 
probability stands in contrast to the classical or frequentist views of probability, in that it 
is not designed to be applied to everyday problems of uncertainty. Logical probability is 
the implication of a certain piece or set of information that makes up evidence, E, to a 
likely outcome, 0. It is the degree to which E implies 0, what has been called the 
"credibility" of 0, given E. 
Iýz 
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The background of logical probability is said to come from an intention to understand the 
formal structure of probability, rather than to formulate an application to problem solving, 
while others have used logical probability in conjunction with frequency theory, arguing 
that the different theories have their roles in distinct circumstances. 
With their insistence on the fact that there is no need for numerical values to represent 
these probabilities, without a great deal of justification, the main criticism of the logical 
view is precisely that. That is the method of calculating or measuring an appropriate 
rational degree-of-belief. Subjectivists go further, in criticising the concept of uniqueness 
of these probabilities. They state that probability will always relate to the individual, as 
inherent within that individual is a set of information and body of evidence that is unique. 
4.2.4 Subjective probability theory 
This viewpoint is an important part of subjective probability theory, in that it's most 
prominent concept and that which holds it apart from the other theories is its 
concentration on the personal, and it's insistence on the heterogeneity of these persons. It 
is essentially a personal degree-of-belief model, but can be used to assess probability just 
as well. The manufacturing of a probability score is in reality simply the representation of 
someone's degree of belief. In each case subjective probability measures the probability 
of an event based on conditional information specific to said individual. It contrasts with 
the logical view only in that it supposes no common rational thread of common 
circumstance that weighs the subjectivity independent of the individual. 
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In attempts to quantify a formal theory of subjective probability, the emphasis has been 
on expressing the probability of an event through betting situations. It is the price an 
individual would be willing to pay for an amount of money on condition of an event, E, 
occurring. For example if a coin was thought to be unbiased, one half of that unit would 
be the maximum that individual would pay in exchange for one unit of that money 
conditional on the coin landing head-up. Where subjective probability differs is in that the 
conditions and the probability considered for that toss of the coin are specific only to that 
toss. If the coin falls head-up what will the individual be willing to `bet' on a head for the 
next toss? This is a separate event and as such does not use the same conditions and 
information as the original toss of the coin. 
There has been movement away from the bet analogy in subjective probability theory, as 
the rational effect of the size of stake became embroiled in criticism of the theory. The 
concept is irrelevant, but nevertheless was thought to detract from the purpose of the 
analogy. The concept of comparison of propositions was used first by Ramsey". Here the 
approach uses an expression of personal probabilities for two events, a head on a toss of a 
coin and the likelihood of rain before Thursday. If the individual has no reason to believe 
that the coin is biased, the degree-of-belief of the individual concerning the outcome of 
imminent precipitation can be measured relative to that of the coin toss. This method does 
not completely overcome the issue of the need for measures of relative utility connected 
with different outcomes or events, but subjective theorists argue that this is irrelevant to 
the proposal of the underlying concept of individual subjectivity in probability. 
Nevertheless, most work on subjective probability has tended to combine subjective 
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probability theory with utility to understand the behaviour of individuals in circumstances 
of uncertainty. 
4.3 Probability theory and statistical inference 
The evolution of these different theories discussed above can in part be explained by the 
reason for their original contemplation. Taking the two most commonly considered of the 
two theories to simplify the argument. The frequentist views came primarily from 
wanting to understand and solve problems associated with uncertainty. A rational, 
measurement-based approach to the problem caused by uncertainty and how to overcome 
them, prior to making the decision. The subjective approach on the other hand comes 
from the act of decision making itself. A study of why decisions are made, the reasons 
why individuals make the choices they do and why different individuals make different 
decisions. Studied after the event of the decision itself 6. 
At first glance the former methods seem the more rational and the more easily quantified. 
These are important factors when the consideration is how best to judge the effectiveness 
of health care interventions. Is what is required here certainty, a method based on good 
science and rationality? Almost certainly the answer is yes, but these methods are also 
marked by a lack of flexibility. 
The frequency theory is a straightforward one. If a coin is completely unbiased and is 
tossed an infinitesimal number of times, half of the time the coin will land head up. There 
is no need for subjectivity here. There is, nevertheless, a reliance on the coin being 
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unbiased, a prior conception based on the theoretical nature of the idea, and due in no 
small part to the construction of theory at a point before the decision takes place. How 
easy is it to ensure an unbiased coin? How many foibles does the average coin possess? Is 
it more than the hypothetical, unbiased, coin? 
If a coin were found to be more aerodynamic on one side (heads) than the other (tails), 
then while in the air it would spend fractionally more time head up, with the less 
aerodynamic side (tails) fighting against air resistance, than tail up. This would lead to an 
inevitable higher likelihood of landing in that position. Head up. If we accept this to be 
true, then there is additional information that can be drawn on to come to a more accurate 
conclusion of the probability of a `heads' outcome for any one coin. 
It is these foibles or imperfections, both in coins and in people, which give us reason to 
consider the use of subjectivity in the study of the effectiveness of health care 
interventions. The knowledge that an average person studied will gain four additional 
quality-adjusted life years at a cost of £20,000 is useful information in the decision on 
how to treat all the average people in the population. The question is, how useful is this 
information in deciding how to treat the rest of the population? 
There is a similar dichotomy when taking these theories forward into the world of 
statistical inference. This separation is caused by the need to use information to make 
decisions under circumstances of uncertainty. Where data is used to inform or to describe 
a situation is by definition inferential. Whereas where the aim is to go one step further and 
use these data to inform a decision under uncertainty, this goes beyond simple statistical 
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inference and into statistical decision making. Although most commentators believe the 
functions to be inter-linked or at least reliant57'58, there is still no consensus on where, if at 
all, subjectivity becomes relevant. 
The classical approach to inference is designed specifically for the reporting of data 
alone. It does not attempt to enable decision-making. Neither does it consider prior 
information or the consequences or costs. This additional or prior information may affect 
the decisions on what to test using the classical inference approach, but this informality is 
thought to be imprecise and lacking a scientific basis, the exact criticism classicists have 
about the more subjective theories. This said, it is widely accepted that were there 
instances where there was no prior information on the subject at stake, then there is no 
need for subjectivity. The problem is, how much is there that we can say we know 
absolutely nothing about. 
With the Bayesian or decision-analytic approaches being rooted in subjective 
probability, sample data is combined with prior information and utility measures 
respectively. Thus making results immediately attributable to a probability interpretation. 
The problem arises in the quantification of this information. Sometimes this information 
is easily quantified while other times it is less so. Theoretically purist subjectivists would 
argue that the uniqueness and complexity of individual cases within each sample would 
make it almost impossible to apply universal affects of any prior information or utility 
values. The virtues of this approach are weighted on reliance of both the quality of the 
information available and its relationship to the outcomes studied. 
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The only pure decision making approach is the decision-analytic approach, or decision 
theory. This method again uses both sample data and prior information but also 
incorporates the quantification of losses and gains. Whereas the other two systems aim to 
show only the likelihood, probability or risk of events, the decision theory model goes 
one step further and attempts to answer the question of what to do rather than just giving 
you information on likely outcomes. 
In essence the movement between these three methods is an increase in risk and belief in 
the ability to quantify the previously unquantifiable. The classical approach is ruled by 
certainty. Information that is subjective, or even directly attributable, to data being studied 
is ignored either because of a lack of belief in the stated relationship or scientific 
obstinence against quantifying these relationships. The Bayesian accepts the existence of 
other information that helps to explain the behaviour of the studied variables and attempts 
to quantify it. Similarly decision theory tells us that as we can quantify external factors 
influencing our chosen variables, we can also quantify the importance of the various 
outcomes. 
This movement away from certainty and towards taking a greater risk with the data in an 
attempt to reach more truly representative outcomes is not just an issue of scientific 
rigour, but a moral one. A debate between the gains of improving the efficient use of 
resources and taking risks with outcomes that are thought of as "life-dependent". 
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Having described and discussed the various theories on probability and how they relate to 
the movement towards classical or heterogeneous methods of analysis, we now describe 
the methods of both Bayesian inference and Decision Analysis. 
4.4 Bayes Theory 
Bayesian statistical inference was the earliest, and is still the accepted, method of 
calculation of subjective or additional information in inference. The statement of Bayes 
theorem comes directly from a statement of probability, where A; is a collection of events, 
of which one will happen, and Y is another event. Taking the multiplication rule of 
probability theory, the probability of A; given Y is the probability of both events divided 
by the probability of the event of Y, or: 
P(A, Y)_ 
P(4&Y)_`Mý ___ 
the probability of events A; and Y can be shown as the probability of Y given A; times the 
probability of A.. For a number of events j this is shown as: 
p(AIIY) _ 
P(")P(A-) 
,; 
' 
(11 AJ) P(AJ ) 
None of this, as theory, is seen as particularly contentious by frequentist or subjectivist 
alike. The area of disagreement is it's use in practice and the ability to scientifically 
quantify A. as a statement of belief or as a hypothesis about the relationship between the 
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subjector and the subjected. Thus Bayesian inference involves making subjective 
statements about probability and quantifying them in a way classical inference and 
frequentist probability theorists believe to be unscientific. Their view being that 
subjectivity is an issue outside inference that must be used in addition to the results of 
classical inference in making decisions. The opposing view of the Bayesian is that it is in 
fact unscientific to ignore the potential effect of subjective information at this stage, as 
any results would be misleading. 
Bayesian analysis uses what it calls priors as an addition to sample data. Let us go back 
to our coin, not the hypothetical one, but the real one (the one with the foibles), and we 
assume that we believe that the curving of one of the surface edges discussed earlier gives 
the coin an increased probability of landing heads up. We also quantify as the likelihood 
of this as saying that it will land head-up 75% of the time. I will come back to the issue of 
quantification later. We can also state that we are 95% certain of this effect. We can then 
state the probability of a heads outcome at this stage as: 
P (h = 0.75) = 0.95 
P (h = 0.50) = 0.05 
The next step is to undertake our trial. We toss the coin one hundred times and it lands 
head-up sixty times of that hundred. Our sample data on it's own suggests to us that P= 
0.6. Combining our prior information and our sample data we can produce a third version 
of our probability of heads, known as the posterior. This combines our prior knowledge 
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of the likelihood of the event with the information we have gathered on this from our 
sample. Writing the equation in the form, 
P(AIIY) °: PM4)I'(`ß) 
(where the proportionality applies over different choices of i, and the denominator is a 
constant independent of i) 
Our priors were, P (h = 0.75) = 0.95 
P (h = 0.50) = 0.05 
Our likelihoods are, f (Y (h=0.75) = 0.756 * 0.25' = 0.0028 
f(Y Ih=0.50) = 0.506 * 0.503=0.0019 
Our posteriors become, P (h 0.75 1 Y) oc 0.95 * 0.0028 = 0.00266 
P (h = 0.501 Y) x 0.05 * 0.0019 = 0.000095 
The denominator in Bayes is the sum of these, 0.002755, so the correct posteriors are, 
P (h = 0.75 1 Y) = 0.00266 / 0.002755 = 0.97 
P (h = 0.50 1 Y) = 0.000095 / 0.002755 = 0.03 
We are now even more certain that the curving of the surface has an effect on the 
likelihood of the coin landing head up. The measure of our belief has risen from 95% to 
97%. Realistically we would not limit our data to point estimates but have distributions 
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around a mean. For example Ph has a Normal distribution with mean of 0.75 and standard 
deviation of 0.01, similarly the prior and hence the posterior will possess these attributes. 
The weakest part of Bayesian theory lies not in its use of subjective information within 
the formula of inference but in the quantification of such information. When the basis of 
the formula relies on the level of trust or knowledge invested within one individual, it 
loses a degree of certainty. The question for debate is whether this loss of certainty 
outweighs the benefits in terms of added information brought to bare on the task of 
answering the question in hand. Classicists say that it must (or that at least it is impossible 
to say), Bayesians that it does not. 
4.4.1 Quantifying prior information 
For simplicity, let us assume an economic evaluation has been undertaken to compare two 
interventions, A and B, which show mean ICERs of p. and µB, with variance a'. An 
additional question is being asked of the data, regarding the difference of effectiveness 
within two distinct subgroups. Let us say that a proportion PIA receives treatment A and 
P, B receive treatment B in subgroup 1. Denote the observed difference in means between 
treatment A and B in stratum 1 as d where d, is the sample estimate of A the unknown 
mean difference in effectiveness for these patients. Denote the same for subgroup B, 
where P2A =1- PIA and P2B =1- PIB, as shown in table 4.1. 
We now use the Bayesian method to incorporate our previous evidence of the effect of 
our chosen subgroup strata 1 and 2, what we will call p and a, 2, and attempt to estimate 
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the unknown effect in subgroup 1. This estimate, denoted by M,, is the posterior mean of 
A1. 
Table 4.1: Samples and mean differences of subgroups 
Subgroups Number of patients Observed mean Unknown mean 
Treatment A Treatment B difference difference 
1 nPIA nI'is d, A, 
2 nP2A nPss d2 A2 
Total n n 
Firstly we calculate the quantities which measure the precision of the sample information 
in each stratum relative to the corresponding amount of prior information. These 
quantities are given as, 
r,. = QP / Var(d, ), i = 1,2. Where Var(d j) denotes the sampling variance of d;. Thus 
large values of r, and r2 imply that there is relatively little prior information available to 
the investigator as compared to the information supplied by the sample data. From table 
1, Var(d) can be calculated as, 
Var(d, ) = are(nPiA 
1+1i=1,2, 
nP .e 
)' 
where a2 may be estimated from the sample observations. The posterior mean can now be 
derived59 as, 
_ 
r, [rz(1-pZ)+1]dl+r2pd2 M' 
{[r(1-p2)+1][rz(1-p2)+1]-p2}/(1-p2) 
Thus M, is a linear function of d, and d2, whose coefficients depend on the values of r r2 
and p, and can be interpreted as the most likely value of 0, given all the available 
information. At p= 0, M, = (dlrl)/(r1+1) and thus, as would be expected with 
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independent subgroups, the value of d2 has no effect on d, or A,. A small value of r that 
is strong prior evidence to suggest that a large value of A, is unlikely, will tend to pull 
back the estimated effect towards zero. Alternatively as p tends towards unity, it can be 
shown that, 
__ 
rld, + r2d2 M' 
r, +r2+1 
Therefore in the limiting case where A, and A2 are regarded as indistinguishable, d, and d2 
are weighted by the values of r, and r2, respectively, although strong prior evidence of a 
lack of difference will tend to pull back the estimate, M towards zero. Furthermore by 
altering the values of p and apZ in M, to represent differing degrees of belief, the 
relationship between the strength of prior belief and various levels of confidence intervals 
can be explored. 
To describe the use of this method here, we have used a continuous response variable 
with only two strata of subgroups. For dichotomous variables, the normal approximation 
to the binomial distribution may be used if the number of cases in each stratum is 
relatively high. For the case of more than two strata, Donner60 has derived general 
expressions for the stratum specific posterior means M M2,.... Mk of a normally 
distributed response variable under the assumption of a k-dimensional multivariate prior. 
Moreover the results here may be generalised to include different prior variances, non- 
zero means and other distribution shapes61. 
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4.5 Decision theory 
The use of subjective probability and the incorporation of such information into a 
decision-making tool rather than simply for inference is only tackled in decision theory. 
The primary distinction of decision theory is of course that it aims not only to give best 
evidence or merely to inform, but also to direct towards a best course of action under 
particular circumstances. As a result the expression of results of decision theory are not 
expressed in probability terms, as in classical and Bayesian methods. Decision theory 
prescribes a course, or courses, of action based on average benefit or loss. A disadvantage 
being that there is no recognition within the final result that the relative advantages of one 
over another may vary in relation to the probability of it occurring. This is a problem that 
will be discussed in more detail later. At the same time there is an obvious advantage to a 
mechanism designed specifically for prescription of action in the face of uncertainty, 
rather than simply minimising uncertainty on the issue and leaving the decision unmade. 
To illustrate the basic formula of decision theory, the example of a cancer-screening 
programme is used. Apologies are made for any simplification of the issues, but these will 
be explained and justified as we progress. People are screened for presence of colorectal 
carcinoma using a faecal occult blood test (FOBT). These people then present with either 
a negative or positive result. We are interested only in those who present with a positive 
result. 
Looking at the problem under the framework of decision theory, there are two 
possibilities, or what is known in decision theory as two possible "states of nature'62. 
These are that the individual has a presence of small polyps, that may or may not lead to 
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cancer, or that the presence of blood in the stool is unrelated to the presence of cancer or 
polyps. We therefore have two actions open to us. One is to repeat the FOBT test at 
another time. This assures us that the reason for the positive result is more likely to be 
cancer-related, or to refer the individual straight away for a colonoscopy, an invasive 
procedure that can detect the presence of polyps and tumours as well as being able to 
remove polyps. If we denote actions by a and states of nature by 0 then we have: 
a, = second FOBT, 
a2 = colonoscopy, 
8, = no presence of tumour, and 
02 = presence of tumour. 
Dependent on the different states of nature, the actions will have different implications. If 
we limit these implications to cost, ignoring the ethics of subjecting a host of healthy 
individuals to a colonoscopy. We can produce a cost table, or what is known as a "table of 
losses", that covers each eventuality. Let us assume that an FOBT costs £200 and a 
colonoscopy costs £500. 
Table 4.2: Table of losses 
e, eZ 
a, E200 £700 
a2 1 £500 £500 
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If we knew 0 for every individual, there would be no decision problem, but it is this very 
`state of nature' that is not known. Although we do not know 0 for each individual, we do 
have information of the specificity of the single FOBT. Evidence suggests that only 30% 
of those with an initial positive result on the first FOBT will have a tumour. Therefore we 
have some prior probability for 0, and therefore for 02. With this information we can now 
calculate the average loss from taking action a, and a2; 
a, = (200 * 0.7) + (700 * 0.3) = £350, and 
a2 = (500 * 0.7) + (500 * 0.3) = £500. 
So in the long run it is worth giving all positives a second FOBT. The result of course 
relies heavily on the specificity of the test. If this were as high as 70%, then the loss table 
would point to a system that would mean lead us to give colonoscopies to everyone. If 
this was the case, and a group of people with irritable bowel syndrome came along, then 
under this form of decision theory, they will just have to suffer. 
This is where the concept of the prior information and subgroups enables us to take this 
system further, and make it more reactive to a particular set of individuals. Let us 
consider other information on these individuals that we are presented with. For each of 
our number who has tested positive we have additional information on symptoms. Either 
they have; 
x, = they also complained of pain when passing faeces, 
xz = they also complained of diarrhoea, and 
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x3 = no additional symptoms, other than the positive FOBT. 
Such information gives us additional information on the relationship to the state of nature 
due to the likelihood principle. This could be known from past records, from published 
literature or from expert opinion. Suppose that from a mixture of these, we create a 
likelihood table: 
Table 4.3: Likelihood table 
X, X2 X3 
e, 0.1 0.4 0.5 
e2 0.7 0.2 0.1 
We can now use this additional information on x to help guide our decisions, by taking 
different decision rules or strategies. A decision rule, 6(x), determines what action to take 
given x. In our example there are eight possibilities: 
Table 4.4: Decision rule table 
1 8,82 83 64 65 66 67 8 
X, a, a, a, a, a2 a2 a2 a2 
x2 a, a, a2 a2 a, a, a2 a2 
x3 a, a2 a, a2 a, a2 a, a2 
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In terms of likelihood alone, x, favours 82, whereas x2 and x3 support A,. From the loss 
table, table 1,8, seems to be intuitively correct as it reads a2 a a,. Whereas S4 seems 
intuitively to be the worst. However, looked at with recourse to the rule of decision theory 
that states that we represent each decision as an average loss over all different values of x 
in each state of nature, we represent the decision rule of x, S(x), as a pair of representing 
0, and 02 calculated from the risk function; 
R(8,9) = L[ö(x), 9]pe(x) , where 0= (01,02) X 
For example, for S5 we have (R5,, , R5,2 .... ), where, 
R(S5, O) = L(a2,01) pe1(x1) + L(a,, 01) peI(x2) + L(a» 01) pe1(x3) 
= 500 * 0.1 + 200 * 0.4 + 200 * 0.5 
= 230 
This gives us a risk function table for all our decision rules, as follows; 
Table 4.5: Risk function table 
81 82 83 g4 85 86 67 68 
01 
02 
200 350 320 470 230 380 350 500 
700 680 660 640 560 540 520 500 
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Once calculated, we can see that no one decision gives us least cost for both states of 
nature, even though some can be immediately ruled out as having higher costs for both 
events. These are S2 S3 S4 and S6. 
A principle that comes from game theory is often considered for making a final choice 
between the remaining decision strategies, known as the "minimax" principle. This aims 
to choose the decision where the maximum possible risk is minimised. This would leave 
us with 6, the choice to refer to colonoscopy whatever the circumstances, as at maximum 
risk this produces the lowest overall costs. This, though, is the pessimistic, slave to 
certainty attitude that with decision theory we are trying to escape. How can we logically 
base our actions on the most pessimistic outlook of an event, a point that is all likelihood 
at the tail-end of a probability distribution. 
This brings us back to the use of prior information, the knowledge we have on the 
likelihood of 0, that is the specificity of our first FOBT. Using this in conjunction with 
our data on symptoms we can use the prior probability information to avoid both 
pessimism and over reliance on certainty. Using Bayes equation for posterior probability 
(page 38) we can create a measure of "posterior expected loss" for the decision rule 8, as 
follows, 
r (8,7r) = R(S, 91) ir(91) + R(8 9 82) ßc(02) , where (7t9) is prior probability of 81 9 02 
It seems reasonable, now to choose the so-called Bayes' decision rule (or Bayes' 
solution), where r (6,7t) is minimised. This is known as the Bayes' risk. Therefore 
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returning to the specificity of the FOBT at 30%, we have 7r(6, ) = 0.7 and 7E(9Z) = 0.3. This 
gives us values for Bayes' risk as below 
Table 4.6: Bayes risk table 
S, 62 83 S4 85 86 67 88 
r (6, ir) 1 350 449 422 541 329 428 401 500 
Therefore the Bayes' solution is S5, which dictates that for those presenting with a 
positive FOBT and also complaining of pain when passing faeces, they should be referred 
directly for a colonoscopy, whereas those with no other symptoms, or those with 
diarrhoea should undertake an additional FOBT. 
This gives us an average loss (or cost) of £329 compared to our minimax principle ruling 
of an average loss of £500 and the initial choice of universal action of a, of £350. The 
saving of the Bayes' solution of the initial decision is just £21. Therefore the transactions 
costs involved in acquiring the additional symptom information must have an average 
cost of less than £21 to make it the allocatively efficient choice. 
So far we have limited our information; losses, probabilities, risks and priors as point 
estimates. Without great over complication it is possible to incorporate distributions as 
well as means for these variables63. This enables us to incorporate the strength of the data 
55 
being used as well as the shape of the distribution of each variable, which will lead to a 
more representative picture of risk and hence overall average loss. 
4.6 Critical appraisal of heterogeneous methods 
It is evident that both of these methods of analysis carry the same potential benefits of 
subgroup analysis, or indeed any other methods that incorporate heterogeneity, in that 
they tend towards optimisation and away from an over reliance on certainty and risk 
minimisation. Nevertheless it is only subgroup analysis as explained in the previous 
chapter that retains the objectivity of interpretation that both Bayes and decision analysis 
methods do not. 
This is not a criticism of the methods themselves but more a criticism of the approach 
used. The difficulty with which the pro-Bayes and pro-Decision-analysis lobbies have had 
in incorporating these systems into mainstream economic evaluation is a sign of the 
mistrust of the scientific establishment of the use of subjective information. It may be too 
much to expect the acceptance of incorporating the opinions of experts and the 
independently constructed values of benefit, when the community has been brought up to 
base their decisions on nothing less than certainty and proof. 
The difficulties with the more heterogeneous methods of analysis come from what many 
consider to be its strengths, the use of subjective or value judgements within the 
framework. Both Bayesian and decision theories attempt to take a further step towards 
answering the question that reduces the need for subjective interpretation of the data 
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policy decision makers are presented with. Bayesian data analysis takes uncertainty and 
tries to make it seem more certain. This is a laudable cause but it relies still heavily in 
both belief in the method being used, and a strong subjective element for which there will 
always be room for disagreement. 
Decision theory has the strongest acceptance of the presence of heterogeneity, as it uses 
probability rather than inference and values rather than outcomes. Once again the 
movement towards a greater incorporation of the subjective, this time through 
incorporating the `values' of different outcomes is a movement towards bridging the gap 
between research and decision making. Once again it relies on the acceptance by all 
concerned on the values it lays down in order to construct the answers it produces. 
It is the belief of this thesis that the use of subgroup analysis framework for evaluation of 
cost-effectiveness data has the benefit of incorporating heterogeneity without 
compromising the objective nature of conventional methods of analysis. Although, in the 
following chapters consideration will be given to moving the levels of acceptance away 
from that of the 95% confidence interval, throughout the process of subgroup analysis all 
evidence used will be empirical and objective. 
4.7 Summary 
It is deep within the construction of inference methods derived from the various theories 
of probability that we find justification for examining the value of the less popular, but 
perhaps more appropriate, methods of inference in reference to economic decision 
making. Techniques such as Bayesian and decision analysis enables greater utilisation of 
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information and is more geared towards an action-orientated approach. It is the movement 
out of the traditional realm of providing information and into the process of decision 
making that has required the introduction of more subjective measurement. Subgroup 
analysis itself has many of the advantages of these methods and in addition has the 
advantage of providing the decision-maker with more objective information. 
It is the belief of this thesis that subgroup analysis is the preferred method for 
incorporating heterogeneity into data analysis. The next chapter looks in more detail at 
subgroup analysis alone and discusses the theory and conceptual background of the use of 
subgroup analysis as a tool for decision making. It is then followed by a description of the 
research question and the methods that will be used to test the hypothesis that subgroup 
analysis can improve resource allocation and efficiency. 
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5. Conceptual framework 
5.1 Introduction 
Very large sums of money are spent every year on clinical trials and economic 
evaluations. Conventionally these are designed to produce `average' results for groups of 
subjects. Conclusions are typically of the form `treatment X was/was not found to be 
more cost-effective than the existing standard'. Some trials are designed to provide 
estimates for specific subgroups of subjects but this adds to the costs through the need for 
greater sample size. Also researchers and decision-makers are cautious6' about estimates 
with low precision and are particularly on their guard against false positive results 
The pursuit of health gain requires an efficient use of health care resources which in turn 
relies on the presence of allocative efficiency, i. e. in order to maximise overall benefit, 
priority for treatment should be given to patients with the greatest benefit/cost ratio. The 
finer the differentiation between patients in this respect, the more efficient allocative 
decisions can be. The crucial difficulty is between-patient variability in response to a 
given treatment. If patient response is highly uncertain, prioritisation in pursuit of 
efficiency is made much more difficult. For the pursuit of allocative efficiency, the ability 
to differentiate between groups, which within them have a greater certainty of patient 
response, leads to a higher benefit/cost ratio, and resource efficiency becomes more 
attainable. 
The debate over QALYs65 and the Oregon experiment66, for example, has drawn attention 
to the difficulty of seeking to blacklist treatments which can be shown to be beneficial in 
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some cases, while giving undiscriminating priority to other treatments which are in some 
cases ineffective and in others potentially harmful. 
However, there is a deep-rooted concern among scientists that subgroup analysis may 
propagate untrue statements. As a result, there is a preference for giving broad-brush but 
reliable messages about average patients, and leaving clinical decision-makers to bridge 
the gap between the average and the specific as best they may. This protects the integrity 
of science, but denies decision-makers evidence that could be more informative because 
there is a risk that it could be misleading. However, a utilitarian approach to efficiency 
would suggest that the pursuit of health gain at a population level would imply that 
getting decisions wrong sometimes is the price to be paid for getting them right as often 
as possible. 
The purpose of this thesis is to explore the trade-off between the needs for more specific 
information for decision making and the loss of precision this leads to. This question is 
inherently asking whether or not current attitudes to subgroup analysis, which tend 
towards scientific caution, are having adverse effects on health gain. The literature on this 
issue is sparse. An approach to the question is suggested by some recent work on the 
construction of confidence intervals for cost-effectiveness ratios. It found that "non- 
parametric boot-strapping"t provided the best results when costs and effects were 
positively correlatedb'"68. However, discussion of subgroup analysis has mainly been from 
an epidemiological or statistical perspective, rather than a public health or economic 
tA method of simulating confidence intervals for cost-effectiveness ratios. 
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one69'70'". The tension involved, or echoes of it, occasionally surfaces in the literature, but 
mostly in the form of theoretical discussions" or disputes in correspondence7'. 
There has been no research so far that has looked at the effect a variety of rules for 
identifying or accepting subgroup analyses, could potentially have in terms of health gain. 
Being a methodological study, the impact of this thesis could potentially be pervasive. If 
it transpires that the current cautious approach to subgroup analysis is appropriate, the 
study will strengthen the hand of advocates of caution and make a small contribution to 
the avoidance of inappropriate care. If on the other hand it transpires that a less cautious 
approach can be justified, then this could be a precursor of changes in the approach to the 
analysis of current and future trials. The extent of the effect on actual health gain and 
service cost-effectiveness will depend on the heterogeneity of effect among subgroups in 
different trials, and on clinical judgement, but it should be widespread. 
The advancing cause of evidence-based health care has brought into focus the gap 
between the evidence provided by scientists and the information needed by decision- 
makers. The response to this has been the introduction of institutions such as NICE, but 
to make appropriate decisions they will still require the right tools. Pressure on scientists 
for more subgroup analyses is likely to grow, and the response to this pressure needs to be 
demonstrably appropriate. 
It is on the axes of the relationship between information and decision making that these 
issues lie. Classical statistical analysis provides us with clear and distinct information 
about the effects of an intervention throughout a population. Unfortunately this 
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information, or the form, in which this information is presented, is not always helpful to 
decision-makers. 
5.2 Conceptual approach to subgroup analysis 
The problem we have is that an intervention is generally assigned a cost-effectiveness 
ratio that is taken to apply to all subjects. The cost-effectiveness of an intervention is 
measured, with some exceptions, as the mean of a sample (with a range within which the 
mean of the population is expected to lie). In fact the cost-effectiveness of an intervention 
is a distribution, both in the case of the sample studied and the population it represents. 
This may or may not approximate to a Normal distribution, but whatever the shape of the 
distribution, for approximately half of the sample the cost-effectiveness of the 
intervention will be higher than the stated mean. Additionally, for the other half of the 
sample the intervention will have a level of cost-effectiveness that is lower than the mean. 
Mean 
J 
vanance 
Figure 5.1: little variance 
about the mean. 
Mean 
variance 
Figure 5.2: Large variance about the mean. 
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Therefore let us assume a limit is set where provision is too costly for the obtained 
benefits. If the measure for our chosen intervention lies above that, then it is assumed that 
this intervention is cost-effective for the population as a whole. If the distribution of 
relative cost-effectiveness throughout the population is wide, then in reality there is every 
likelihood that if policy decisions are made using this information, for much of the 
population this intervention may not be cost-effective under the same constraints. If this is 
so then resources are being inefficiently allocated. 
The importance of the variability of this distribution is the key to the extent of this 
inefficiency. If variance is small (fig. 5.1), any possible benefits lost or increased costs 
incurred will be correspondingly small, but if variance is high (fig 5.2), then the 
inefficiency and inequity resulting could be large. 
It is therefore the degree of variation and the kurtosisx in this distribution, which is of 
most interest to us. Where this variation is large (or the distribution is platykurtic) a large 
sample is needed to demonstrate a difference in mean effects between intervention and 
control groups. However, in some cases there is a large average effect, but also a large 
variance (e. g., in cases where the new treatment can be seen as `kill or cure'). Even when 
this is the case it is normal for the recommendation from the trial to adopt the new 
treatment on grounds that this will increase health gain. Implicitly this is supporting the 
introduction of treatment that may be systematically inferior for some of the patients. 
I the depth and shape of the distribution. 
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In figure 5.3 the incremental cost effectiveness ratio (ICER) of an intervention is shown, 
(CT 
- 
CC) 
marked with the sparsely broken line that goes through the origin, with its confidence 
intervals shown as the more regular broken lines either side, tangential to the circle. Our 
chosen limit for assessing the cost-effectiveness of new interventions is shown as a thick 
line. Axes are shown as difference in effectiveness (ET-Ec) and cost (CT-Cc) between 
treatment and control groups. 
For our intervention to be cost-effective the ICER slope of the intervention must be 
shallower and hence below this line. In the case of our intervention it clearly is not. Figure 
5.4 shows the intervention split into clearly defined subgroups. Here the mean of one of 
the groups (m3) is clearly below the line. Unfortunately we cannot say with 95% 
confidence that the mean of this population will lie under our hypothetical limit. What we 
can say about these results is that the probability that the slope of the population mean is 
in the positive section below the thick line is higher than the probability of it being above 
the line. 
(E*r - Ec) 
(CT - CC) 
Figure 5.3: Mean and confidence intervals 
of an intervention, with the thicker line 
marking the acceptable limit of ICER. 
(Er - Ec) 
Figure 5.4: Means of sub groups 
and their confidence intervals. 
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It is therefore "probable" that a specific subset of the population can be cost-effectively 
treated with this intervention, but under normal circumstances will either receive no 
intervention or will receive an alternative intervention that is less cost-effective. Therefore 
in most circumstances we are likely to have one of three possible alternatives: 
1) There are no discernible differences between the cost-effectiveness of an intervention 
across the whole population (sample) and the cost-effectiveness of that intervention 
within specific subgroups of that population. 
2) Although the intervention is not seen as cost-effective across the whole population, it 
is seen as cost-effective within one (or more) distinct subset(s) of the population at a 
statistically significant level. 
3) Although the sample size may not allow sub-group analysis to produce differences that 
are detectable at conventional levels of significance, subgroups can be identified as 
being distinct at lower than conventional significance levels. What this may say is that 
one tail of the distribution is in the area that defines the limits between "positive" and 
"negative" results. 
It is this third group which is the area of debate in the probability theory and statistical 
inference, the concept of the trade-off between certainty and optimisation. Summarised by 
Fry 74 when he says, 
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"How much more conclusive must the test data be.... To accept too little implies 
running greater risks or error than we often desire. To demand too much spells 
extravagance" 
It is the trade-off between optimisation and certainty that is at the heart of the debate 
around greater use of the data available from trials. The historical link between traditional 
inference and the need in medical trials to show safety as well as effectiveness as pushed 
economic evaluation medical interventions towards a greater reliance on certainty than it 
should. It is the belief of this thesis that greater use of subgroup analysis can go someway 
to remedying this. 
5.3 Summary 
The purpose of this chapter was to consider the conceptual and methodological bases of 
the system proposed to overcome the issues associated with improving evidence for 
decision-makers. The use of subgroup analysis in achieving solutions has the advantage 
of both utilising all available information, while being both internally and externally 
objective with its use of the evidence. 
If this conceptual approach to subgroup analysis works in practice it could potentially 
lead to an improvement in overall health gain for society. This benefit comes with a trade- 
off against certainty of results (although not likelihood) and it is by no means certain that 
such a wide distribution of patient specific cost-effectiveness ratios across a diverse 
sample exists in any or most studies. Even, if such variance does exist it is known 
whether this level of uncertainty around the mean can be put to use advantageously by the 
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selection of subgroups with specific characteristics. However, it is the intention of this 
thesis to find out whether it is possible and whether such methods can be productive. 
The next chapter will look at the practical steps of selecting and undertaking a subgroup 
analysis. 
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6. The Research Question 
6.1 Introduction 
The purpose of this chapter is to define the research question and to outline the plan of 
investigation. The hypothesis is that a cautious attitude to subgroup analysis has had 
adverse consequences for clinical decision-making and public health, because it 
potentially recommends inappropriate treatment and a less resource efficient package of 
services. This study aims to investigate the impact on population health gain and service 
cost-effectiveness of a variety of `rules' for deriving and evaluating estimates of cost- 
effectiveness. 
The study involves using data from existing large trials to produce a series of datasets, 
yielding different estimates of costs and then cost-effectiveness, in aggregate and for 
subgroups derived by different rules. In the second study aggregate and subgroup 
estimates of cost-effectiveness will then be used to make hypothetical resource allocation 
decisions, the outcomes of which will be discussed. 
6.2 Methods 
Subgroup analysis itself is not a complex procedure. It is simply the analysis of a 
particular group within a studied data set, which are identified by one or more common 
characteristics. What makes subgroup analysis complex is the lack of empirical rules 
associated with its execution. Subgroup analysis, when not used properly, can do more 
harm than good in terms of providing decision-makers with information on relative 
effectiveness. This is why there is the need to lay a number of ground rules on exactly 
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how we will select, or determine our subgroups and how we will calculate ICERs for 
subgroups. Each of these areas will be discussed in turn. 
6.2.1 Subgroup selection 
There are three important, as well as interrelated, points often quoted when discussing the 
issue of subgroup selection 75.76"". The time at which the subgroup is identified, the reason 
for selecting a particular subgroup and the source of the reasoning for it's identification. 
As has been discussed in chapter three it is generally accepted that the risk of erroneous 
results emanating from subgroup analysis can be greatly reduced if subgroups are 
identified prior to analysis, or where possible prior to randomisation and data collection. 
Additionally it is preferable to have some degree of justification for the choice of this 
grouping, such as previous evidence of a relationship between the variable concerned and 
the outcome being measured. 
The choice of variable for grouping will be based on a combination of both practical and 
theoretical grounds. On the practical side it will be limited to variables that are either 
collectable or already contained within the data set, as well as being limited to variables 
that, for obvious reasons, can be identified before the intervention in question takes place. 
The theory on which selection is based will be an accepted or empirically proven reason 
for likely differences in cost-effectiveness. In short these variables can be classified into 
three distinct groups; 
" demographic, 
" diagnostic, and 
" characteristic. 
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Demographic involves the variables of age and sex. Diagnostic includes the specifics of 
any diagnosis, for example stage of disease, as well as other factors relating to likely 
prognosis, such as co-morbidity and risk factors. Characteristics contain all other 
population grouping variables such as social class, education or ethnicity. For some 
characteristics the variables may overlap into other areas, for example age may well be a 
risk factor for certain interventions. The classification of variables into one group or 
another is nevertheless irrelevant, it does not change the analytical method used but is 
merely there for simplicity of explanation. 
The final element of the selection process involves the source of the reasoning behind the 
selection of the subgroup. There are three types of evidence that can be used for the 
specification of subgroups; published and non-published research evidence, and expert 
opinion. Expert opinion is often difficult to quantify and may be unreliable as a source of 
information, and as such the intention is to limit the evidence for subgroups in this model 
to published data that show a statistically significant relationship between the variable 
concerned and the primary outcome. 
6.2.2 Measurement of ICERs 
The calculation of ICERs will be done taking the incremental change in cost and 
incremental change in effectiveness. The two methods used to calculate the ICER of a 
specific subgroup, once selected, will be the bootstrapping approach using a Monte Carlo 
simulation°. Unlike those methods, used by Morris78 and others, such as by Rubin79 and 
A detailed description of these methods is shown in appendix 3. 
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that used by Laird and Louis80, the method we will use does not attempt to counter any 
effect of regression to the mean. 
This problem of regression to the mean lies in the fact that subgroups that lie to the end of 
a distribution, tend to infer that the reason for any increase (or decrease) in cost- 
effectiveness could have been for mathematical reasons rather than relating to the chosen 
variable of study. It is considered not to be an issue of importance in the calculation of 
ICERs for the following reasons. 
Let us assume that the individuals being studied were, for example, in an anti-obesity 
intervention. At the beginning of the trial, some of these people could have been very 
overweight. Therefore at the end of an intervention that attempts to help people to reach a 
target body mass index (BMI), the net difference of these individuals is more likely to be 
higher than those people just slightly overweight, regardless of the relative effectiveness 
of the intervention upon those individuals. They just had more to lose. In essence the 
method used by Morris, similar to the others, shrinks the point estimate of the subgroup 
towards the overall estimate of the intervention. 
The problem of regression to the mean is only relevant, when particular outcome 
measures are being used. Measures such as height, weight, BMI and blood pressure are 
obviously effected by this. The question is are the outcomes used in the construction of 
ICERs liable to be affected by regression to the mean? These being costs and measures 
such as QALYs and "Life years gained". If an individual within the study is associated 
with larger than average incremental change in life years gained, or indeed costs, this is 
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unlikely to be due to the fact that at the start of the trial we expected him or her to live to 
be a hundred and fifty. It is more likely to be the fact that this individual is more likely to 
have possessed a number of characteristics that enable the studied intervention to be more 
effective. If it is the latter, which is the more logical, then it is part of what we are trying 
to discover an integral part of the outcome. As such there is no reason for this to be of 
concern when dealing with incremental cost-effectiveness ratios. 
6.3 Plan of investigation 
The aim is to use data from a randomised controlled trial which has reported the overall 
cost-effectiveness of an intervention and demonstrate that for many patients in the trial 
the statement made on cost effectiveness (be it positive or negative) will not be true. 
These are the cases where use of data on the differences in subgroups is most likely to 
yield increases in expected health gain. 
The basic procedure will be as follows: 
1. Choose a trial. 
2. Select a number of subgroups for which the variable concerned has an empirical 
relationship with the primary outcome as dictated by a published study that shows 
a statistically significant odds-ratio at the 5% level. 
3. Derive an estimate of overall incremental cost-effectiveness, and measures of 
variance, for the main comparison groups using Monte Carlo simulation. 
4. For each subgroup derive estimates of the incremental cost-effectiveness ratios, 
and measures of variance, using Monte Carlo simulation. 
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5. Compare both the ICER 95% confidence intervals surrounding both subgroups 
and the overall trial effect 
6. Compare the likelihood of outcomes for both subgroups and the overall trial effect 
7. Assess the likely health gain from a policy decision based on the overall trial 
results against the use of the evidence from subgroups. 
There will be a number of variants on this basic procedure, with rules for choosing 
subgroups being derived from the literature. The baseline is `no subgroup analysis'. 
Subgroups will be chosen according to a priori biological, behavioural or organisational 
plausibility, ignorant of any subgroup results from the trials. 
The `baseline' estimation procedure in this case will involve standard methods 
appropriate to the outcomes at issue. The fewer the subjects in any given subgroup, the 
greater the variability of derived parameter estimates in relation to the actual true values. 
6.4 Trial selection 
Two trial data sets have been identified. They involve both the measurement of costs and 
the measurement of the cost-effectiveness of health care interventions. The first is The 
PRAIS UK study that is a resource-use study on people presenting with acute coronary 
syndrome. The purpose of the analysis of this first data set is to look at how the 
characteristics of certain subgroups can have a sizeable effect on cost alone, and as such 
why subgroup analysis can be so important in the measurement of cost-effectiveness. 
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The second data set is from the Extracorporeal Membrane Oxygenation (ECMO) study, 
which is a study comparing the cost-effectiveness of extra corporeal membrane 
oxygenation with conventional management in neonates born with serious respiratory 
disease. It is with this data set that a practical attempt to compare the cost-effectiveness of 
subgroups versus the overall study results will take place. 
6.5 Summary 
Having outlined the methods to be used to test the value of subgroup analysis these will 
be put into practice in the next two chapters. Firstly, chapter 7 looks at the value of 
subgroup analysis in looking at the variation in cost distributions alone, whereas chapter 8 
looks at cost-effectiveness ratios under subgroup analysis compared to traditional 
methods for summarising study data. 
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7. Variation in cost 
7.1 Introduction 
This is the first of two chapters that use actual data sets to test the theory that subgroups 
can provide worthwhile additional information to the decision-maker. The cost- 
effectiveness ratio is made up of two parts; the cost of an intervention and the 
effectiveness of that intervention in achieving a desired outcome. In both traditional and 
subgroup analysis the measurement of cost-effectiveness has traditionally centred on the 
movement of the level of effectiveness within a population and given little consideration 
to the patient specific cost of interventions. 
More recently methods of economic evaluations have moved more towards incorporating 
patient specific cost data and as a result more consideration is given to the distributions 
and variation in costs as compared to effects. This chapter looks at the value of using 
subgroup analysis in the evaluation of costs and their distributions. 
It starts by looking at the shape of a cost distribution and the strengths and weaknesses of 
classical methods of describing these distributions. It addresses how the debate around 
cost measurement has led to costs being estimated for individual patients so that the 
distribution tends to be a specific shape and form. 
The traditional methods used for measuring inference in costs and the limitations of this 
information for decision making is assessed. Alternative descriptive statistics are 
evaluated leading to a discussion of the value to decision-makers of pre-selected 
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subgroups of costs and whether they are in fact being undervalued as a source of 
information to the decision maker. Finally these theories are tested when cost data from 
an audit of patients presenting with myocardial infarction (MI) are analysed for inference 
and variance by subgroup. These distributions are then simulated using the Monte Carlo 
technique, from which conclusions are drawn on the value of the various descriptive 
statistics. 
7.2 The shape of a cost distribution 
The distribution of individual patient costs tends to have a very specific pattern, with the 
majority of values being grouped around a mean at the lower end of the range, with a long 
flat tail. This is both empirically common81 and makes intuitive sense. With most cases 
being closely grouped around a mean there tends to be a minimum or fixed cost element 
for every value of each process being studied. 
wR--_ 
No. 
Cost 
Figure 7.1: Right-skewed curve and histogram most closely associated with a cost 
distribution 
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Because of this the possibility of having outliers to the left of the mean is theoretically 
impossible. Whereas the possibility of outliers to the right of the mean is quite probable 
as variation in the requirements of each individual case allow high variation in the other 
element of each value, that of variable cost. We therefore tend to have the shape shown in 
figure 7.1, one that is skewed to the right rather than symmetrical around the mean82. 
7.3 Measurement of cost 
There is much debate surrounding costing of interventions in health economicsas, sa, as, most 
of which can be summarised into a debate surrounding the trade-off between 
generalisability of costs to wider settings and the detail required to estimate the `true' 
costs of the intervention being studied. 
The generalisation camp argue that as costs become more and more detailed within the 
intervention being studied, the more it will incorporate elements of geographical and 
organisational specificity. For example, it is thought to be unhelpful, or at least not 
resource-efficient to cost in detail the transport costs of a community-nursing project that 
was evaluated in a rural area, which will make the results irrelevant to an urban setting. 
Similarly the costing of a medical intervention being evaluated in a city teaching hospital 
will not be generalisable to smaller suburban district or community hospitals. As such it 
puts forward a proposal to use nation-wide or other representative average costs so that 
firstly decision-makers can interpret them themselves, and so that different costs within 
economic evaluations can be comparable" 
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The alternative view is that measuring cost is an integral part of economic evaluation and 
that true cost will, by definition be explicit to the intervention being studied and hence to 
the outcomes the costs are being associated with87 88. For example the cost of employing a 
specialist nurse in a particular field should be emphasised as a part of the intervention 
itself, and that assuming a national average cost of a nurse, gives the wrong message to 
the decision maker as to the true value of the resources used. 
It is widely acknowledged that this is a true trade-off and as such there may not be a 
`right' answer to the problem89. Therefore a best-fit approach is usually suggested, most 
of these suggestions rely on a greater degree of transparency of the costing process and 
the splitting up of costing into two parts; resource-use and unit costs3. 
A measure of resource-use is simply a measure of the amount or degree of a specific 
resource being used. This can be a bed, or a drug or a nurse or doctor. It is this that 
attempts to deal with the problem of specificity. Once a measure of this resource has been 
calculated, a unit cost is attributed to it. These are usually based on national averages or 
other pooled sample data, hence approaching the problem of generalisability. 
7.4 Statistical inference and measuring cost 
The other advantage of the resource-use measurement method is that each individual 
being studied has a specific cost for the intervention, rather than being limited to taking 
an average of all subjects. There has been a tendency to assume a normal distribution 
around this mean as in the equivalent measure of effectiveness, which makes up the other 
side of the cost-effectiveness ratio'. It is here where we can begin to approach the problem 
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of using confidence intervals for assessing value of the evidence of cost. Economics 
concerns itself with finding the optimal use of resources within a population, whereas 
confidence intervals are used to specify the level of confidence we have in an average. 
In statistical inference confidence intervals that surround a mean are a measure of the 
level of confidence that the mean itself will lie within this range, not a level of confidence 
that the majority of the distribution of values itself will lie within this range. 
As a decision-maker, the information you really need to assess whether an intervention is 
likely to be an efficient use of resources is the total cost and total benefit of the 
intervention under local conditions. If the distribution around the mean used to create 
cost-effectiveness ratios is normal then this information may" be useful, but we know that 
in the case of cost, this is not true. When measuring the cost in a cost-effectiveness ratio, 
consideration has to be taken of the shape of the distribution, as well as the mean itself. If 
the long tail associated with cost distributions is not accounted for, there is a risk that a 
programme set up on the basis of a cost-effectiveness ratio will create higher costs than 
expected. 
In essence the message is that the length of the tail, or the width of the range of true 
values within a sample are as important an indicator of cost as the mean cost and the 
confidence intervals surrounding it. It is imperative then that we incorporate the 
" The word `may' is used because even where the distribution is normal the kurtosis and/or range of the 
distribution of true values may be significantly different to that of the confidence intervals. So even then 
the decision-maker does not have a true representation of the cost of the intervention. 
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measurement of both the skew of the distribution and the kurtosis, or shape of the 
distribution. 
7.5 Measuring the shape and range of a distribution 
The shape and size of a distribution can be measured in a number of ways. The three key 
elements are length or width of the points in a distribution, the shape of the distribution 
and symmetry of the distribution. The width or length of a distribution, which shows the 
distance between the lowest point on the distribution and the highest, is known as the 
range of the distribution. Another measure which is useful for measuring the size of 
distribution that have long tails is the inter-quartile range, which measures the range 
between the 25' and 75`h percentile of all points within the distribution. Probably the most 
vigorous method, though is the standard deviation. 
The standard deviation is measured as the square of the differences between each value 
within the distribution and the mean. The differences are squared only because if they 
were not they would add up to zero, the squaring process is therefore used to get rid of 
negative values. If a distribution is wide it will tend to have values of difference with the 
mean that are high, and therefore a high standard deviation. Similarly with a narrow 
distribution this will give a low value for the standard deviation. The formula for the 
standard deviation (SD) is thus: 
SD =1 -xy n-1E(x' 
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The shape of a distribution has two areas of comparison; its symmetry and its relative 
weighting across the range. The symmetry of a distribution is measured by its degree of 
skew and the weighting by the measure of kurtosis. The first graph in figure 7.2 is 
symmetrical and has zero skew, whereas the second graph is positively skewed, or 
skewed to the right. The relative distance between the mean of the distribution and the 
median measures the degree of skew. 
Skew is a measure of the asymmetry of the data around the sample mean. If skew is 
negative, the data are spread out more to the left of the mean than to the right. If skew is 
positive, the data are spread out more to the right. The skew of the normal distribution (or 
any perfectly symmetric distribution) is zero. 
The skew of a distribution is defined as: 
y= E(x - µ)3 
Cy3 
where E(x) is the expected value of x. 
The inter-quartile range of a distribution (IQR) computes the difference between the 75th 
and the 25th percentiles of the sample in X. The IQR is a robust estimate of the spread of 
the data, since changes in the upper and lower 25% of the data do not affect it. If there are 
outliers in the data, then the IQR is more representative than the standard deviation as an 
estimate of the spread of the body of the data. The IQR is less efficient than the standard 
deviation as an estimate of the spread, when the data is from a normal distribution. 
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Figure 7.2: Graphical representation of relative mean and inter-quartile range, of a 
symmetrical and positively skewed distribution. 
Kurtosis is a measure of how outlier-prone a distribution is. The kurtosis of the normal 
distribution is 3. Distributions that are more outlier-prone than the normal distribution 
have kurtosis greater than 3; distributions that are less outlier-prone have kurtosis less 
than 3. A flat-topped distribution tends to have a low value of kurtosis and is said to he 
platykurtic (flat bulging). A sharp-peaked distribution will tend to have a high value of 
kurtosis and is called leptokurtic (thin bulging). The kurtosis of it distribution is defined 
as: 
k=E(x-µ)4 
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where E(x) is the expected value of x. 
Plcatykurtic Leptokurtic 
Figure 7.3: Graphical representation of platykurtic and leptokurtic distributions 
It is the shape and size of cost distributions that makes the mean and confidence intervals 
an insufficient means of summarising the data. When making a decision based on 
expected costs of an intervention the degree to which the distribution of costs is skewed is 
likely to be of some importance. If there is a likelihood that a proportion of those 
receiving the intervention may cost well in excess of the average cost for the intervention, 
this provides an added risk to funding the intervention. Similarly if the cost distribution is 
particularly platykurtic this also implies a degree of unpredictability of the likely cost of' 
any individual. 
r ý-r 
In theoryihe decision as to whether to fund an intervention relies heavily on the level of 
risk associated with the probable cost and benefits of any particular individual. The 
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average costs and benefits across a wide and varied population, although providing a 
guide, may not be all that helpful to a decision-maker if this means it is not representative 
of the vast majority of individuals within the population. 
7.6 The measurement of the distribution and confidence in the mean 
It is the relative importance of both the shapes of the distribution and confidence in the 
mean, which is of interest to us in the issue of using evidence from subgroup analysis. 
The reason for this is that confidence intervals are heavily affected by sample size, which 
is inevitably smaller in subgroup analyses than in the sample as a whole, hence subgroups 
will always have relatively wide confidence intervals. 
The confidence intervals around a mean are a constant (for example for 95% C. I. it is 
96) multiplied by the size of the standard error around the mean. The standard error in 
turn is reliant on two measures, the sample size (n) and the level of variance, measured by 
the standard deviation of the distribution (a), in the formula; 
SE =QI, In. 
In terms of the range of values, if subgroups are selected due to a predicted variance in 
outcome, in this case cost, it is likely that the chosen variable is a key cost driver. Given 
this it is acceptable to assume that the variance within the subgroups is likely to be 
narrower than in the sample as a whole. The effect will be twofold, a reduction in the 
numerator due to lower variation and a reduction in the denominator due to a smaller 
sample size. In reality the effect on reducing sample size has a disproportionately large 
effect on the standard error as although the measure of variance is an average across all 
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variables, the sample size is a sum. Therefore any reduction in sample size is unlikely to 
be offset by reduced variance within the sample. 
In addition under the method used for calculating confidence in the mean the measure of 
variance is solely based on standard deviation, and takes no account of skew. This is 
because methods of statistical inference were devised for calculations inferred from a 
normal distribution, which is rarely seen with cost data. As a result we have a trade-off 
between restricting the unpredictability of the cost of treating each individual and keeping 
narrow confidence intervals for the mean. This is shown graphically in figure 7.4. Either 
we have a reliable estimate of the mean when concentrating on the total sample, at the 
expense of a leptokurtic, heavily skewed distribution. Or we have the possibility of a less 
skewed more playtykurtic distribution with a less reliable mean. 
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Figure 7.4: A graphical representation of the hypothetical mean, confidence 
intervals and distribution of costs of a total sample (top) and a pre-selected 
subgroup (bottom). 
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The intention of this thesis is to evaluate whether resource allocation decisions can be 
aided by considering the extra information that analysing both costs and outcomes by pre- 
selected subgroups can achieve. To do this we need to answer two questions; firstly do 
pre-selected subgroups tend towards having the characteristics discussed above, while 
secondly does this information provide us with a better way of measuring, or drawing 
conclusions from cost information? 
7.7 Evaluation of cost data 
7.7.1 Methods 
To test the value of describing distributions of cost with measures of shape and form as 
well as inference of data from a study into patients presenting with an acute myocardial 
infarction was analysed. The Prospective Registry of Acute Ischaemic Syndrome 
(PRAIS) was designed as a prospective observational cohort registry of patients admitted 
to UK hospitals with Acute Coronary Syndrome (ACS). A total of 56 UK hospitals 
participated. Each hospital was asked to collect data on 20 consecutive patients admitted 
with ACS without ST elevation, irrespective of admission location or consultant team. 
Patients had a follow-up visit at 6 months following their initial hospital admission. A 
total of 1046 patients were entered into the registry from 56 participating centres between 
23' May 1998 and Yd February 1999. 
Information was collected on events, treatment and resource-use across the duration of the 
admission and a follow-up period of the next six months. Table 7.1 lists the measures of 
resource-use, the unit cost attributed to them and it's source. These unit costs, along with 
the measure of resource-use from the PRAIS data, are used to create an estimated total 
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cost for each patient presenting. Figure 7.3 is a histogram of total initial admission cost 
for all patients in PRAIS. 
A literature search was conducted using `PubMed', `Medline' and `HealthPro', looking 
for evidence of any relationship between a series of patient characteristics at admission 
and total cost of intervention in the treatment of suspected myocardial infarction (MI). A 
search was made for published research showing a strong relationship between cost and 
the following characteristics; sex, age, ECG reading, previous history of event and 
previous diagnosis of CHD. 
The selected subgroups for cost variation were age90, B' (below 65,65 -74,75+) and ECG 
category (normal or complications)"', 93,9a, 9s. 96 These were selected for having a strong 
empirical relationship with levels of cost or resource-use. The empirical evidence of the 
relationship between cost and sex, previous history of event and previous diagnosis of 
CHD, was either too small or inconclusive. 
The intention is to compare the relative value of the various statistical descriptive 
measures of each distribution, both the overall data and the individual subgroups, for 
relevance to the decision-maker. Also to discover whether the affect that reduced sample 
size has on measures of inference of subgroups is likely to be similarly negative or 
conversely positive when measuring distribution shape. The distribution of each subgroup 
will be plotted and all the descriptive statistics discussed above will be calculated for 
each. This will then be used to construct probability distribution simulations using the 
Monte Carlo technique. 
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The Monte Carlo simulation takes a sample distribution and translates it into a probability 
distribution where the likelihood of each outcome has a probability and where the 
probabilities of all possible outcomes sum to one. This helps us gauge the likelihood of 
one and a group of outcomes. With only one uncertain variable, cost, the shape of the 
probability distributions will be the same as the sample distributions. 
Table 7.1 Resources, unit costs and sources. 
Resource Unit cost (£) 
1998-9 prices 
Source 
Hospital stay (LOS x 1) 
CCU bed-day 348 CHD costing study 97 
Medical bed-day 119 CHD costing study " 
In-hospital events 
Angiography 500 Literature 98 
PTCA 1428 CHD costing study " 
CABG 2310 CHD costing study 
Stress test 110.50 Literature 99 
Drugs (daily dose x LOS-except TT) 
aspirin 0.10 British National Formulary 
beta blocker 0.40 BNF '99 
calcium antagonist 0.42 BNF '99 
nitrate(oral) 0.29 BNF '99 
potassium channel opener 0.33 BNF '99 
nitrate(IV) 16.50 BNF '99 
GPIIb/IIla 1.00 BNF '99 
Oral anticoagulant 0.89 BNF '99 
Thrombolytic therapy 85.00 BNF '99 
heparin 0.62 BNF '99 
drugs on discharge (per month) 
antiplatelet (aspirin) 1.55 BNF '99 
beta blocker 11.20 BNF '99 
calcium antagonist 11.85 BNF '99 
nitrate (oral) 8.17 BNF '99 
potassium channel opener 9.93 BNF '99 
statin 29.69 BNF '99 
lipid-lowering (other) 13.38 BNF '99 
anticoagulant (oral) 24.92 BNF 99 
ACE inhibitor 13.43 BNF 99 
Angiotensin 2 inhibitor 15.75 BNF '99 
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7.7.2 Results 
The distributions of the `cost per admission by individual' for the study as a whole and 
for the pre-selected subgroups were analysed for both measures of variance and for 
inference around the mean (table 7.2). As anticipated confidence intervals around the 
mean were much wider in the subgroups than in the sample as a whole, with sample sizes 
much smaller but with only marginal differences in standard deviation. In terms of 
measures of variance, there was a tendency for subgroups to have lower values for skew 
and kurtosis. This was not universal but where the skew or kurtosis of a subgroup was 
higher than the total it was predictable. For example, the ageband subgroup of patients 
over the age of 75, it would be anticipated that a large proportion of the skew of the total 
was due to outliers in the highest ageband and because of this their length of stay is the 
least predictable. 
An example of the limitation of the confidence interval when dealing with the value of 
subgroups is illustrated with the comparison of the cost distributions of the total data set 
and the subgroup of patients who's ECG was normal. As would be expected the subgroup 
with its smaller sample size (141 versus 868 in the main sample) has far wider confidence 
intervals (£275 versus £153). But within the smaller subgroup distribution there is far less 
variance (SD of 825 versus 1145), far less skew (2.14 versus 2.92) and far less kurtosis 
(4.98 versus 11.67). 
This would suggest that the probability of the cost of a random patient being close to the 
mean is higher in the subgroup than in the main sample. This is the essential difference re- 
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between what the confidence interval on a cost distribution tells us, compared to the 
information as to the probability of random subject having a cost close to the mean. 
Table 7.2 Descriptive statistics of the distributions of subgroups 
Group N Mean SD Skew Kurtosis 
Total 868 1092.76 1145.59 2.92 11.67 
Age 
< 60 263 1030.63 1079.58 2.29 6.31 
60-74 364 1128.83 1210.49 2.73 9.68 
75+ 241 1106.09 1116.22 3.88 20.76 
ECG 
Normal 141 852.55 825.22 2.14 4.98 
Complications 731 1130.03 1192.70 2.89 11.21 
Distributions and details of simulations can be found in Appendix 1 
Group Mean 95% confidence intervals Range of CIs 
Total 1092.76 1016.45 1169.08 152.63 
Age 
< 60 1030.63 899.55 1161.71 262.16 
60-74 1128.83 1004.06 1253.60 249.54 
75 + 1106.09 964.45 1247.73 283.28 
ECG 
Normal 852.55 715.15 989.94 274.79 
Complications 1130.03 1043.57 1216.48 172.91 
Distributions and details of simulations can be found in Appendix 1 
To take our example further we have simulated both of the distributions using the Monte 
Carlo method to estimate the likelihood of a random patient falling within the inter- 
quartile range of the given distribution as compared to the 95% confidence interval range. 
The distribution of both groups was simulated using the descriptive statistics of the 
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distributions shown in tables 7.2 and 7.3. Simulations were repeated for a series of 
iterations between 100 and one million, but little change was seen in the results beyond 
10,000". Table 7.3 shows a comparison of the simulations of the total data set against the 
subgroup for Normal ECG. 
Table 7.3 Results of Monte Carlo probability distribution simulation 
Group All patients ECG-Normal 
subgroup 
Ratio 
(All / subgroup) 
Mean 1065.87 851.09 
Standard deviation 1102.86 815.51 
Skew 2.91 2.16 
Kurtosis 14.60 7.92 
First quartile 395.03 396.08 
Third Quartile 1207.25 965.88 
Inter-quartile range 812.22 569.80 1.42 
5"' percentile 207 189 
95`h percentile 3391 2606 
90 percentile range 3184 2417 1.32 
95% C. I. 
lower 1016.45 715.15 
upper 1169.08 989.94 
range 152.63 274.79 0.55 
The simulation shows that although the confidence intervals surrounding the mean are 
narrow in the main sample, the likelihood of a random patient falling into this range is 
relatively low due to the shape and variance of the distribution, which in turn is due to its 
unpredictability regarding outliers. The proportion of values within the inter quartile 
tt Distributions and details of the simulations are shown in full in appendix 1. 
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range that are likely to fall into the range of the confidence interval is just 19% in the 
main sample as compared to 48% in the subgroup. To give some idea of the importance 
of predicting the effect of the variance within a distribution, for all the distributions 
simulated the average proportion of total costs in the upper quartile was 60%. 
7.8 Summary 
The purpose of this chapter was to show that as well as measures of effectiveness, costsi 
can also be affected by characteristics of the population and as such are just as likely to 
benefit from subgroup analysis. The example shown in this chapter also shows that, 
although confidence intervals are a good gauge of the predictability of the mean value, 
because of the shape of cost distributions they may not be the only measure needed for 
decision makers to make definitive choices on resource allocation. 
The measurement of the mean, and confidence in that mean, are an important descriptive 
of a distribution. If the distribution is a normal one, it can be argued that it is the only 
descriptive required to make conclusions of that distribution. Where a distribution is not 
normal, there are other factors to take into account. When assessing the likely cost of an 
intervention it is the area under the curve that guides the decision-maker and the likely 
effect that outliers may have on total cost. The examples analysed in this chapter show 
that cost distribution can be skewed to the extent where 60% of total costs will be due to 
25% of the sample. It is therefore important that the analysis of a cost distribution 
incorporates a measure of the variance and shape of the distribution. 
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This chapter has also shown that pre-selected subgroups for which there is good prior 
evidence of a dependent relationship may in fact be being undervalued by the limits 
enforced by the measurement of a sample based purely on confidence intervals. With an 
objective of minimising the risk of unpredictable costs, pre-selected subgroups have been 
shown to be a potential tool in cost analysis. The next section will take this further by 
looking at measures of effectiveness and its combination with cost information to inform 
cost-effectiveness. 
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8. Measurement of cost-effectiveness 
8.1 Introduction 
The potential advantages and dangers of using evidence from subgroup analysis to inform 
policy decisions have been discussed in detail. In the previous chapter we started to look 
at the characteristics of subgroup analysis in comparison to traditional analysis. We have 
shown that costs as well as outcome measures can have strong relationships with 
covariates and that when the relationship is strong, the variance around the mean of a 
subgroup can be smaller than the study data as a whole. This chapter takes the theory of 
the potential advantages of subgroup analysis one step further and looks at both the costs 
and effects of a specific intervention. 
Here we look at the data from a trial that evaluated the incremental cost-effectiveness of a 
new technology in treating severely ill new born babies, the Extracorporeal Membrane 
Oxygenation (ECMO) trial. First we give details of the background to the ECMO trial, 
and the results and conclusions that were published. The data is then re-analysed to obtain 
the measures of variance that had not been calculated in the original study. We then 
calculate ICERs for selected subgroups and assess the potential value of this information 
in improving overall health gain. 
8.2 Extracorporeal Membrane Oxygenation (ECMO) Trial 
The ECMO trial looked to compare the costs and outcomes of conventional treatment and 
the incorporation of the ECMO technology. Conventional treatment for infants in 
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respiratory failure is ventilation with high level oxygen. Extracorporeal membrane 
oxygenation is a technique that oxygenates blood outside the body, obviating the need for 
gas exchange in the lungs, and, if necessary, providing cardiovascular support. Intention 
to treat analysis showed that extracorporeal membrane oxygenation was highly clinically 
effective". 
A preliminary economic evaluation carried out before the trial suggested that 
extracorporeal membrane oxygenation was probably more effective and more expensive 
than conventional management1°'. It also showed that the existing evidence on cost 
effectiveness was inadequate for setting priorities because the uncertainty surrounding the 
data was too great'oz 
The economic evaluation of the ECMO trial was a cost-effectiveness analysis comparing 
extracorporeal membrane oxygenation with conventional management based primarily on 
the principal clinical outcome of the trial (survival without severe disability at age 1 year). 
The economic evaluation was conducted from the viewpoint of the NHS and so includes 
only direct costs to the health service'o3 
Extracorporeal membrane oxygenation was provided in five centres and babies were 
recruited from 55 UK neonatal centres. Babies were eligible for the trial if they were 
mature new-born infants with severe respiratory failure. They were randomised either to 
be transferred for extracorporeal membrane oxygenation or to receive conventional 
management. There were 185 babies in the trial, of which 93 (50.3%) were randomised 
into the ECMO arm with 92 (49.7%) in the conventional treatment arm. A summary of 
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descriptive variables comparing the two groups at randomisation is shown in Table 8.1, 
with results at the end of the year one follow-up in Table 8.2. 
Health service use was divided into three components: mode of transport used for 
transfers made after randomisation until discharge; services received in the initial hospital 
inpatient stay after randomisation, subdivided by level of intensity; and use of health 
services from discharge up to 1 year of age. The babies' initial hospital treatment was 
described in terms of five levels: days receiving extracorporeal membrane oxygenation; 
days receiving maximal intensive care (more than 90% oxygen); days on a ventilator 
(receiving less than 90% oxygen); days on supplementary oxygen; and days in normal 
care. 
Health service costs for each patient were calculated for initial hospital stay, post 
discharge health service utilisation and transport costs. The initial stay was estimated 
based on unit costs of days under extracorporeal membrane oxygenation, days under 
maximal intensive care (more than 90% oxygen), days on a ventilator (receiving less than 
90% oxygen), days on supplementary oxygen and days in normal care. The costs for each 
group are outlined in Table 8.3. 
Table 8.1: Comparison of ECMO and `conventional treatment' arms 
Mean Age (hours) 
Mean Gestation (weeks) 
Mean Birthweight (grams) 
Most recent Oxygenation Index (01) 
ECMO (n=93) Conventional (n=92) 
47.2 57.6 
38.8 39.2 
3261 3346 
69.4 72.1 
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(Source: Roberts TE, 1998 `) 
Table 8.2: Outcomes at one year of ECMO and `conventional treatment' arms 
ECMO (n=93) Conventional (n=92) 
Death 30 54 
Severe disability 1 1 
Impairment and some disability 12 4 
Impairment and no disability 4 5 
No impairment or disability 45 27 
Lost to follow-up 1 1 
(Source: Roberts TE, 1998 4) 
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Table 8.3: Costs at one year of ECMO and `conventional treatment' arms 
ECMO (n=93) Conventional (n=92) 
£f 
Initial hospital stay 1,603,267 476,409 
Additional cost of death 30,352 58,536 
Transport 150,146 20,475 
Post discharge health service utilisation 153,059 88,739 
Total 1,936,824 644,180 
Mean cost per case 20,826 7,002 
(Source: Roberts 7 
A cost-effectiveness ratio for ECMO in new-born babies was constructed using the data 
set described above. The mean cost per case in the conventional management arm was 
£7,002 compared to £20,826 in the ECMO arm, a difference of £13,824 (95% C. I. £9,660 
-; E 17,984). The primary outcome of the intervention was number of lives saved without 
resulting in severe disability. For the conventional arm the resulting outcome was 
achieved in 36 of 92 (39.1 %) whereas in the ECMO arm this was achieved in 61 of 93 
(65.6%), a difference of 26.5% (95% C. I. 12.4% - 40.5%). The resulting incremental cost 
per life without severe disability achieved can be estimated as £52,244 within the 
parameters of the calculations shown in table 8.4. 
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Table 8.4: Cost-effectiveness estimation at one year of ECMO over conventional 
treatment. 
ECMO (n=93) Conventional Conventional # -1 
(n =92) (n equivalent 93) 
Initial hospital stay £1,603,267 £476,409 £481,587 
Additional cost of death £30,352 £58,536 £59,172 
Transport £150,146 £20,475 £20,698 
Post discharge costs £153,059 £88,739 £89,704 
Total £1,936,824 644,180 £651,161 
Survival no disability 61 36 36.4 
Average cost per survival 
with no disability £31,751 £17,894 
Incremental cost of ECMO £1,285,663 
Incremental cost per extra 
survival with no disability £52,244 
# `Conventional' costs have been weighted so as both sets of costs relate to 93 patients. 
(Source: Roberts TE, 1998 4) 
The conclusions of the study group were that the evidence so far suggests that 
Extracorporeal membrane oxygenation can be as cost effective as many other life 
extending technologies regularly used in developed countries. However, it does include 
the caveat that until the results of the long term follow up studies become available, this 
conclusion should be viewed with some caution. 
8.3 Stochastic measurement of cost-effectiveness of ECMO 
As has been discussed in earlier chapters, cost-effectiveness analysis has moved on 
recently in an attempt to incorporate measures of uncertainty and this has in general been 
through the introduction of confidence intervals for cost-effectiveness ratios. The 
ii , 
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derivation of ICERs where there are individual measures of effectiveness and cost of n 
patients allows us to calculate a stochastic ICER. Stochastic measurement is where 
variables are determined from data sampled from the individuals in the study, as 
compared to deterministic measurement where variables are analysed as point estimates. 
If both costs and effects are determined from data sampled from the individual patients in 
the study, variances are available and so formal statistical tests can be performed on 
observed differences in costs and effects. 
Here effectiveness is measured as a binary outcome where 1 denotes survival without 
severe disability and 0 denotes death or the presence of severe disability. Our ICER is 
calculated as 
R= (CT - CC) / (ET - Ec), where CT and Cc are the cost of new treatment and conventional 
treatment respectively and ET and Ec are the effects of each. 
This gives us a two-dimensional box with the confidence intervals for both our effects and 
cost sizes, which gives us a quasi-confidence area shown in figure 8.1. In reality the 
probability of the true ICER of the ECMO intervention lying on either slope X or Y is 
very low, less than 0.5%, and that both intuitively and mathematically the true confidence 
interval area is likely to be elliptical in shape1'. 
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Figure 8.1: Incremental cost-effectiveness ratio (ICER) of ECMO 
technology on likelihood of survival without severe disability 
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The next step is to move towards this true form of our confidence area through the 
estimation of the sampling distribution of the ratio. The most common application for this 
has been non-parametric bootstrapping10s, 'ob The observed data for cost and effects are 
treated as an empirical probability distribution that is resampled with replacement a given 
number of times. Each resample is used to give an estimate of R. These estimates are then 
used to create an empirical distribution of R from which the confidence intervals are 
constructed. The results of such an exercise with the ECMO data are shown in figures 8.2 
and 8.3 and summarised in table 8.5. 
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Figure 8.2: Scatterplot of (CT -C, ) against (EE - E(. ) on cost-effectiveness plane 
103 
Figure 8.3: Histogram of bootstrap replicates of R (ICER) probability distribution. 
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Table 8.5: Resulting 95% percentile ranges from bootstrap replication of ICER. 
Variable Mean 95% confidence interval 
Incremental cost of ECMO 
Incremental likelihood of survival 
Incremental cost-effectiveness ratio 
£13,824 (£5,958 - £40,747) 
0.27 (0.15 - 0.39) 
£52,244 (32,521 - 95,137) 
When these simulations are undertaken, there can be a tendency for replication bias, but 
this is considered insignificant if measured as a ratio of variance of under 0.1. Bias within 
the replication was measured as a ratio of variance of just 0.08 and as such was not 
considered important"". The confidence intervals around the incremental costs and effects 
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alone do not include zero and are positive, whereas the ICER confidence interval is 
stretched somewhat (figure 8.3). 
The results show the cost-effectiveness ratio to be fairly uncertain given the stochastic 
nature of the bootstrapping technique. It is often considered unnecessary to simulate the 
individual cost distributions and instead the difference (CT - CC) is used with a normal 
distribution. This is based on the theory that the distribution around the mean difference 
between two non-normal distributions is itself normal. 
8.4 Undertaking subgroup analysis with the ECMO trial data set. 
Having looked at the analysis of the study as a whole, we now turn our attention to the 
analysis of specific subgroups. The potential subgroups in the study were that of birth 
weight, gestation age, diagnosis and oxygenation index (0! ). These are listed in table 8.6. 
There were two subgroups by birth weight, two by gestation, three by diagnosis; 
congenital diaphragmatic hernia (CDH), idiopathic persistent foetal circulation (IPFC) 
and persistent pulmonary hypertension (PPH), and two by 01. 
A literature search was conducted using `PubMed', `Medline' and `HealthPro', looking 
for evidence of any relationship between a series of patient characteristics at 
randomisation and the likely outcome of the usual treatment of new born babies with 
severe respiratory failure. A search was made for published research showing a strong 
empirical relationship between the primary outcome and the following characteristics; 
sex, age, birth weight, gestation age, diagnosis and initial oxygenation index 
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(OI)108109,110,111,112,113,114, us An empirical relationship between a characteristic variable and 
the primary outcome (survival) was assumed to be present where an odds-ratio for 
survival was significant at the 5% level in at least one paper. 
The selected subgroups for outcome variation were birth weight, diagnosis, gestation age, 
and initial 01. These were selected for having a strong empirical relationship with 
outcomes. Any relationship between the other variables and the primary outcome were 
either too small or inconclusive. The intention is to compare the relative value of the 
various statistical descriptive measures of each distribution, both the overall data and the 
individual subgroups, for relevance to the decision-maker. 
The results in table 8.6 (and in figure 8.4) show that overall the ECMO intervention had 
relatively wide confidence intervals (95%) spanning from £35,521 to £95,137, which 
would, under classical analysis, make the acceptance of the intervention unlikely. The 
subgroups show a wide variety in both means and their measures of variance, shown here 
in terms of confidence intervals. Although many have confidence intervals (C. I. ) that are 
extremely wide, such as the `CDH diagnosis', the `gestation > 275 days' and `0! > 60', 
there are also a number which have very narrow C. I., such as the `diagnosis of IPFC' or 
`PPH' and `0I = 40-59' 
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Table 8.6: Deterministic ICERs of subgroups with confidence intervals of stochastic 
analysis 
Subgroup (no. ) f ICER 95 percentile Percentile< 
confidence intervals £50,000/LS 
Birth weight < 3300 (1) 65,627 (39,639 - 137,317) 20% 
> 3300 (2) 28,738 (9,498 - 75,952) 85% 
Gestation < 275days (3) 63,417 (28,638 - 206,888) 30% 
>275 days (4) 39,281 (22,637 91,789) 70% 
Diagnosis CDH (5) 164,900 (81,305 - 539,475) 0% 
IPFC (6) 16,340 (1,958 - 44,430) 95% 
PPH (7) 33,356 (16,568 - 77,879) 80% 
01 category 40-59 (8) 42,359 (22,334 - 86,210) 70% 
>60 (9) 74,218 (29,945 - 318,934) 20% 
Total study (10) £52,244 (32,521 - 95,137) 45% 
For details of simulations see appendix 2. 
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8.5 Using evidence from subgroup analysis and traditional analysis for policy 
To compare the benefits of evidence derived from subgroup analysis and traditional 
analysis in making policy decisions, we need a policy objective to address. For the 
purposes of illustration let us use a hypothetical policy that states that for a new health 
care technology to be incorporated into practice it must achieve a life saved at a cost of 
under £50,000. In essence we are setting an upper limit of incremental cost-effectiveness 
for new interventions that wish scarce resources to be diverted towards them. This is not 
unlike the role that is being asked of the National Institute of Clinical Excellence with 
regard to new technologies, but we have oversimplified it to illustrate and quantify the 
potential benefits of subgroup analysis. 
If we start with the evidence from the overall study it is clear that at a cost per life saved 
of £52,244, our policy makers would be directed to look elsewhere to invest in a new 
technology. Our directive states that if we divert resources away from current activities 
into universal ECMO treatment this will not be a better use of scarce resources. 
Nevertheless if we turn our attention to the results of the subgroup analyses there is 
evidence to suggest that for those neonates diagnosed with IPFC this is very much a cost- 
effective use of resources. As such, our directive, if offered the option, would be clear in 
concluding that the introduction of the ECMO technology for all those diagnosed with 
IPFC would indeed be a worthwhile use of scarce resources. Even in terms of measures of 
uncertainty the upper limit of the 95% confidence intervals for this subgroup does not 
cross the £50,000 threshold. 
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This brings us onto the issue of uncertainty. Although the mean cost per life saved for the 
PPH subgroup is just £33,356, the upper limit of the confidence interval extends beyond 
the £50,000 barrier (at £77,879). This would be thought of by many as a good reason to 
exclude the intervention as not being of statistical significance, whereas in reality 80% of 
the distribution around the mean is below the £50,000 barrier. There are additional 
examples of this with regards to birth weight over 3300 grams (85%), gestation over 275 
days (70%) and 01 category 40-59 (70%). 
With all of these subgroups it is more likely than not that the ECMO technology would, 
for the patient in question, represent a cost-effective treatment option. The decision to 
proceed here, becomes a subjective one. Probability dictates that cost-effective treatment 
is likely, but not certain. The cost-effectiveness ratio of treating this baby with ECMO is 
likely to be very favourable. 
Analysis of the incremental cost-effectiveness of ECMO shows us that with a 
hypothetical limitation of new health care technologies of £50,000 per life saved, ECMO 
would not be considered a cost-effective use of resources. In fact traditional statistical 
norms would probably not allow the introduction of this new technology if the limit were 
set at £60,000 because the 95% confidence intervals do not both lie inside this range. 
Nevertheless the analysis of the subgroups show that within the study overall there are 
those for which the cost-effectiveness of ECMO has its mean value lying under the 
instituted limit of £50,000. In addition it also has the full range of it's confidence intervals 
(IPFC subgroup - 95% C. I. 1,958 - 44,430) under £50,000. If the allocation of resources 
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that leads to a state of optimisation of health benefit relies on performing interventions 
only if they provide that benefit at less than £50,000 then here is a group of patients and 
an intervention that fits the bill. 
Under the same argument of optimisation, we are aware from evidence in table 8.6 that 
other groups of patients would more likely than not benefit from the intervention at a cost 
of less than £50,000. In the case of groups 2,4,6,7 and 8 patients are between 40% and 
70% more likely to benefit at a cost of less than £50,000 per life saved than not. In total 
five of the nine subgroups can justifiably be thought to be more likely than not to receive 
a treatment that will turn out to be cost effective if undertaking ECMO. 
So if our mean ratio as a whole is over the £50,000 barrier, at £52,244, how can it be the 
case that five from nine subgroups have means lying under the same barrier? The answer 
is that the mean of the whole sample is dragged up by those subgroups that are over the 
barrier to a greater extent than the groups that are under (i. e. there is a skewed 
distribution). This is likely to be common wherever you have a distribution that is heavily 
skewed to the right. As can be seen in figure 8.4 (and from table 8.6) those subgroup 
means that lie over the £50,000 have upper distribution intervals that extend away well 
over the £150,000 and three of them over the £200,000 line. In comparison, of the five 
groups that have means lying under the £50,000 line, none approach the zero line. From 
this a logical step may be to calculate the mean ICER for ECMO after truncating the 
distribution through the exclusion of outliers. This would inevitably bring down the 
overall mean for the intervention as a whole, but still would not add the value that the 
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evidence from the subgroup analysis does in pinpointing the areas of best investment for 
the ECMO technology. 
The likelihood of this occurring can be anticipated by looking at figure 8.3, which shows 
that despite the mean lying over £50,000, the bulk of the histogram of the probability 
distribution lies under £50,000. This suggests that a randomly chosen case would be more 
likely to have a cost-effectiveness ratio of under £50,000 than one of over £50,000. 
Having acknowledged this it is the use of subgroup analysis that allows us to better 
identify those patients that lie under the £50,000 line and those that lie over it. This will 
not always be possible as in many circumstances there will be no defining covariates (as 
was the case in ECMO) and the distribution will be truly random. 
The use of a hypothetical maximum tariff put on health benefit is just an example of one 
method that could be used to direct resource allocation towards the goal of welfare 
maximisation. It is one of the simpler ones, but whatever system were used to achieve this 
end, the concept behind how overall health gain can be increased within a limited budget 
from using subgroup evidence for directing resource allocation is still valid. 
To take our example further let us assume that there was only one need for health care, 
and that was to maximise health benefits for new born infants with severe respiratory 
failure. There are two methods of treatment; conventional management and conventional 
management with the addition of ECMO. We are left with a policy decision with which to 
make the best use of our limited resources which involves choosing from one of three 
options. 
114 
1. Incorporate ECMO into standard care 
2. Do not incorporate ECMO into standard care 
3. Selectively incorporate ECMO into standard care 
If the choice were between 1 and 2, then given that the average cost-effectiveness 
(ACER) of conventional treatment without ECMO is estimated at £ 18,000 per survivor 
without severe disability, and with ECMO it is estimated at £32,000 it is unlikely that 
ECMO would be funded. Nevertheless if the policy were selective within subgroups, then 
the marginal cost of ECMO would be considered an efficient use of resources within a 
limited budget for neonates diagnosed with IPFC. In fact every pound spent on ECMO in 
these groups would result in more health gain than a pound spent on conventional 
management. 
Furthermore if we look at multi-characteristic subgroups such as neonates with a birth 
weight over 3300 grams and a diagnosis of IPFC, we find an ICER of just £9,513. Here, a 
pound spent on ECMO for this group of patients is likely to gain twice the health gain of 
a pound spent on conventional management. The probability is not 95% but the 
simulation shows it to be 70% likely that the ICER of ECMO for this group will fall 
under the ACER of conventional management. To continue with a strategy of not 
incorporating ECMO into treatment for such a group of patients is to disregard a likely 
improvement in overall health gain. 
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8.6 Comparing evidence from traditional and subgroup analysis 
To measure the potential value of subgroup analysis there is a need to compare the results 
of a policy decision based on this method with a policy decision based on the more 
traditional methods. To do this we will take the evidence from both types of analysis and 
assume the appropriate decision based on our hypothetical directive. This is to ensure that 
new technologies must show that they save lives at a cost of less than £50,000. We also 
assume that this figure is chosen due to the fact that the health care that is already funded 
is done so at a level not above the cost of £50,000 for every life year gained. 
The decision given traditional methods of analysis is a simple one. The ICER is £52,244 
and as such the ECMO technology would not be considered cost-effective and as such 
there will be no change to resource allocation and no resulting increase or decrease in 
overall health gain. 
In the case of subgroup analysis, the results can be used in two ways; to incorporate those 
subgroups for which the 95% confidence intervals fall below £50,000 (option one). 
Option two would be to incorporate those subgroups for which more than 50% of the 
likely distribution has a cost-effectiveness that falls below £50,000. 
For option one this is simply the subgroup who are diagnosed with IPFC with a mean 
ICER of £16,340 (95% C. I. £1,958 - £44,430). If the ECMO technology was offered just 
to this group the resulting mean health gain per patient would be £33,660 (£50,000 - 
£16,340) per patient treated, or the equivalent to 
=1x life saved x £33,660 
£50,000 
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= 0.67 lives saved per patient treated. 
We would also be 95% certain that the mean health gain would be at least £5,570 per 
patient treated or 
=1 x life saved x £5,570 
£50,000 
= 0.11 lives saved per patient treated. 
Table 8.7: Mean ICERs for subgroups, proportionate confidence in mean and 
proportion of total patients. 
Subgroup (no) ICER Percentile< 
X50,000/LS 
Proportion 
of n (total) 
Allocate 
resources to 
Birthweight < 3300 (1) 65,627 20% 51% No 
> 3300 (2) 28,738 85% 49% Yes 
Gestation < 275days (3) 63,417 30% 46% No 
>275 days (4) 39,281 70% 54% Yes 
Diagnosis CDH (5) 164,900 0% 20% No 
IPFC (6) 16,340 95% 17% Yes 
PPH (7) 33,356 80% 63% Yes 
01 category 40-59 (8) 42,359 70% 60% Yes 
>60 (9) 74,218 20% 40% No 
Total study (10) £52,244 45% 100% - 
With option two the conclusion would be to incorporate the ECMO technology far more 
than with option one, as it would include subgroups 2,4,6,7 and 8. This would leave us 
with the policy summarised in table 8.7. We can show that the mean health gain per 
patient treated can be estimated if we assume the same proportions of each subgroup as 
was witnessed in the study. As with option one we can show the anticipated mean health 
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gain on the basis of resources gained or an equivalent lives saved per patient treated 
assuming that all other interventions currently being provided have a marginal cost- 
effectiveness of £50,000 per life saved. 
Table 8.8: Mean ICERs for subgroups, proportionate confidence in mean, 
proportion of total patients and marginal lives saved per patient treated. 
Subgroup selected (no) ICER Percentile< Proportion Marginal 
f50,000/LS of n (total) lives saved 
per patient 
treated 
Birthweight > 3300 (2) 
Gestation >275 days (4) 
Diagnosis IPFC (6) 
PPH (7) 
01 category 40-59 (8) 
28,738 85% 49% 0.43 
39,281 70% 54% 0.21 
16,340 95% 17% 0.67 
33,356 80% 63% 0.33 
42,359 70% 60% 0.15 
Total I- 80% 100% 0.27 
The results in table 8.8 show the mean lives saved per subgroup per patient treated, and 
also the total mean health gain per person treated given the weighting of the proportion of 
total patients from each subgroup. However this figure of a mean 0.27 lives saved per 
person treated is not significant at the 5% level. We do however have 80% confidence 
that there will be a positive mean improvement in overall health gain given this strategy. 
In other words it is 80% probable that for every 100 babies treated with ECMO 27 lives 
(without severe disability) will be saved at a cost of less than £50,000 per life year saved. 
The obvious conclusion from this is that without the use of subgroup analysis in making a 
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decision on funding ECMO technology for certain groups of new born babies the result 
could be a not considerable number of lives lost. 
8.7 Summary 
We have shown in the analysis of this particular data set that when the goal of health care 
is to maximise health gain within the financial constraints set upon it, whatever they may 
be, the decision to treat is a complex one. The choice as to whether to introduce 
treatments in health care has historically tended to be a simple yes or no. This has merit in 
having a transparency and measure of robustness that ensures that policy makers are never 
seen to be making the wrong decision. The question this chapter and indeed this thesis 
puts forward is while being seen to be making the right decision, are we in fact denying 
ourselves the opportunity to get closer to achieving our primary goal, that of maximising 
health gain. 
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9. Discussion 
9.1 Introduction 
Policy makers with the goal of maximising health gain for a population require evidence 
on the health benefits of potential uses of scarce health care resources and the cost of 
achieving them. This evidence has historically been based on the average effectiveness of 
an intervention on a representative sample, with the assumption that questions about the 
value to a population of a given intervention should be answered with a single value. The 
problem with this is that it ignores the fact that a population is heterogeneous. Just as it is 
important for a doctor to relate the results of a trial specifically to the characteristics of the 
patient, it is imperative that policy makers take the evidence from economic evaluations 
and relate them to any given population or elements within that population. 
The mean cost-effectiveness ratio of an intervention is the average of a group of patient 
specific total costs and patient specific measures of effectiveness for a heterogeneous 
sample. As such the population from which the study was sampled will often be made up 
of some patients for whom an intervention is highly cost-effective and some for which 
that intervention will not be cost-effective. The question is whether it is possible for us to 
predict those people for whom the cost-effectiveness ratios will be high and those people 
for which a specific intervention will have a low cost-effectiveness ratio. If this is 
possible, will the ability to do this lead to a better use of finite resources to improve 
overall health gain? 
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This thesis started with the hypothesis that policy decisions regarding resource allocation 
in health care could be improved by a greater concentration on the use of the results of 
subgroup analysis. It is argued that information on the heterogeneity of populations is 
valuable in maximising health gain. The methods used in economic evaluation have 
progressed enormously over the last twenty years, and one of the biggest areas of progress 
has been in the movement away from deterministic measurement of cost-effectiveness 
ratios and towards stochastic methods. It is these methods that have allowed us to 
measure uncertainty and show the distributions around the means of these ratios. The 
most common measure of this variance has been the confidence interval. 
The purpose of the confidence interval, and of statistical inference in general, is to 
measure the degree of certainty we have in our estimated mean. The reason such a 
technique is required is that most of the things we wish to measure we cannot do with 
great accuracy, and as such attempt to cancel out this `white noise' by making our 
measurement repeatedly and taking an average. If our method of measurement were 100% 
reliable this technique would not be required. 
When collecting the patient specific costs and outcomes that are required for stochastic 
analysis the variation in our data is not just made up of the white noise of measurement 
distortion, but also includes genuine variation due to real heterogeneity of our sample. 
This in turn is due to the fact that true heterogeneity exists within a population. The use of 
statistical inference where we know that any variation will be due to the inadequacies of 
the measurement tool is sensible and scientific. Where we aware that the cause of 
variation is at least in part due to the heterogeneity of the variable being measured, 
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consideration must be given to whether this method is less reliable. In truth, we know that 
if another sample, however large, was used to measure this variable we could not 
guarantee a similar result without a similarly heterogeneous sample. 
These issues raise a number of issues that relate both to study design for cost- 
effectiveness analyses and the interpretation of the results of these studies when 
translating them into policy. We look at both of these areas in turn. 
9.2 Implications for cost-effectiveness analysis 
As we seek to describe in more detail the relationship between specific health care 
technologies and their relative value in different situations we start to question the 
reliance on classical statistical inference methods, which rely so heavily on certainty. 
Where we have a closer grasp of what, and by how much, other determinant variables 
effect our chosen measure of outcome this will inevitably help to determine the extent to 
which that outcome was achieved by the intervention being studied. 
The purpose of inference is to try to show that a relationship between an intervention and 
an outcome exists beyond any reasonable doubt. This will be the goal of a study where, 
prior to the start of the trial, our knowledge of any relationship is zero. However, this is 
rarely the case as we often do have knowledge of relationships between factors and likely 
outcomes, both in terms of cost (as shown in chapter 7) and in effects (as shown in 
chapter 8). As such what we are searching for is not so much proof as a greater belief in 
what we already anticipated. 
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In the previous chapter we compared the relative merits of traditional analysis against 
subgroup analysis. The conclusions were that subgroup analysis could achieve an 
improvement in overall health gain based on the hypothetical objectives described. These 
conclusions were based on a higher likelihood of a positive increase in health gain 
compared to traditional analysis. The difference was not measured by inference, but by 
probability. This brings us onto assessing the relative merits of policy decisions based on 
probability versus those based on the need to prove an outcome beyond any reasonable 
doubt. 
9.3 Implications for policy decisions 
This thesis argues for optimisation in the use of data from economic evaluations rather 
than the current aspiration for certainty. It is the evidence that an event is more likely than 
not to happen that most decisions are made on. More certainty becomes necessary when 
the costs of getting the decision wrong outweigh the benefits of getting it right. This is 
often the case in medical research, where society needs to be assured that a new drug is 
both effective and safe. The question remains is - is this a lesser concern when dealing 
with less dichotomous outcomes such as cost-effectiveness? 
The costs of approving a new drug or technology that turn out to have significant negative 
side effects are likely to be high. However, the approving of a new drug or technology 
that has been shown to be effective based on less certain proof of its cost-effectiveness is 
unlikely to be considered by society as such a high cost if proved later to be incorrect. 
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It can be argued that it is just as important to measure cost-effectiveness correctly as it is 
to measure the effects of an intervention correctly as the results of getting it wrong are the 
misallocation of resources. This could lead to someone somewhere missing out on 
valuable treatment. This is not in dispute, but it is suggested that a measurement of a 
continuous variable such as a cost-effectiveness ratio is more transparent represented as a 
measure of probability. Whereas a dichotomous outcome, for example to answer whether 
something is to be considered safe or not, may benefit more from being measured using a 
method that has the intention of showing some degree of confidence or certainty. 
In theory for every potential intervention and for every potential receiver of that 
intervention there is a specific relationship that will produce a unique cost-effectiveness 
ratio. The maximisation of health gain comes from finding the cost-effectiveness of every 
intervention for every individual within our population. Only then can decisions be made 
on a shift in resource allocation that will improve overall health gain. The problem can 
therefore be seen as one of availability of information more than of economic theory. 
This thesis has shown that there is a wide variance in a singular measure of cost- 
effectiveness and therefore there exists the possibility for an improvement in health gain 
if decision-makers were given access to more of the information available in a form that 
would aid them in making decisions. It is suggested that a greater use of subgroup 
evidence should be made available to decision-makers. This use of more specific cost- 
effectiveness ratios for more specific groups within the population could be a movement 
towards welfare maximisation, which could result in greater efficiency in the delivery of 
health care. 
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9.4 In defence of subgroup analysis 
A number of concerns could be raised in the increased use of subgroup analysis to inform 
policy decisions. Two of these are that of sample size and that of `fishing' for results that 
may not be there. It is commonly believed that because subgroups have smaller sample 
sizes, the rigour of the results may suffer. Statistical power, however, relies on two things, 
effect size and sample size, and as such subgroups can often have narrower confidence 
intervals and by definition be more robust than the overall effect size of a study due to the 
greater effect size outweighing the smaller sample size. In addition the greater 
homogeneity of subgroups, chosen on the basis of reducing the heterogeneity present in 
the overall study population, will reduce the measure of variance (standard deviation) and 
correspondingly reduce the width of the confidence intervals. 
In terms of the issue of `fishing' it is imperative that subgroups are selected based on 
sound evidence as was done in chapters 7&8. On a more instinctive level it seems that 
those against the use of subgroup analysis are actually saying we should put our faith in 
statistical techniques for one group of numbers (the overall trial results), but that the 
techniques may be unreliable used in another set of numbers (the subgroups). This is both 
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illogical and lacks objectivity. 
9.5 Summary 
Inevitably the response to a proposal for a greater use of subgroup analysis as a means of 
increasing overall health gain is an argument for optimisation over certainty, for 
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probability over statistical significance. It is argued that it is imperative that we are able to 
assess whether an intervention can improve the health of a patient, but the question we 
really want an answer to is to what extent can it improve the health of the patient? The 
certainty associated with statistical significance can only be used to answer a normative 
question. If the p value is less than 0.05 or the confidence intervals do not include zero we 
are 95% certain we have an effective intervention. We are not 95% certain that the level 
of effectiveness is equivalent to the mean. 
Such a normative answer would not allow us to assess the value of the intervention 
compared to others that could be funded in its place. In most cases we are using an 
estimate of the effectiveness of an intervention for decision making that has no greater 
specific validity than any other figure that might lie within the confidence range. The 
confidence is in the range not in the mean. As such the mean provides a measure of 
likelihood, not of certainty. 
The use of such an estimate is not something that this thesis is intending to degrade. It is 
the belief of this thesis that most effect-size information at our disposal is not much more 
than a measure of likelihood and those measures of likelihood gained from subgroup 
analysis are just as robust and valuable as those gained from the totals of trials. It is also 
suggested that in many cases the measure of likelihood in a subgroup might be more 
robust than those based on a total, due to the variation of the subgroup being limited to 
the white noise of measurement distortion and not the effects of heterogeneity. 
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Figure 9.1: Mean, variance and distribution for total study and for subgroup I& II 
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40 
Variance 
Effect size 
For example, we have a variable that we believe to be a factor in the effect size of an 
intervention and we therefore define two subgroups (I & II) of those with and those 
without the presence of this variable. If the variable is a factor that does influence the 
effect size it is likely that the distribution around the mean effect within each of those 
subgroups will be narrower than that around those receiving the intervention as a whole as 
the variation will be limited solely to measurement distortion. As such the variance 
around that mean would be smaller (see figure 9.1). When an intervention is introduced 
on the basis of an anticipated effectiveness defined by the estimated mean, the benefit will 
be maximised where the true effectiveness lies closest to that estimated mean, or where 
the true variance from that mean is small. 
The value of evidence from subgroup analysis will always be a matter of debate as far as 
statisticians are concerned because it is their objective to search for a definitive proof. 
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This they have subjectively categorised as 95% probable and for which in general we 
require sizeable sample sizes to achieve. In reality we must question whether the value of 
this definition of certainty has been pitched too high, and whether the trade-off of being 
able to use data to answer more questions with less certainty may indeed outweigh the 
benefits from answering fewer questions with greater certainty. 
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10. Conclusions 
The goal of health economics and of most health systems is primarily one of welfare 
improvement with an underlying trend towards the maximisation of expected welfare. 
This thesis questions whether the current system of collecting and using evidence for 
policy making in health care is the best available method, given this goal, and concludes 
that it may well not be. 
Given the heterogeneous nature of a population, it is likely that for most health care 
interventions the cost of care and the outcome from that intervention will vary widely as a 
result of this heterogeneity. The mean ICERs that we tend to use for policy decisions will 
therefore be surrounded by a distribution of patient specific ICERs that may differ greatly 
from the mean. This thesis believes the variation surrounding these ICERs can be traced 
specifically to the heterogeneity of the population, and in some instances be used to 
greater predict the likely ICER of an intervention for that population. 
In addition it is believed that using the relationship between different characteristics of a 
population and the outcomes of different health care interventions, will lead to a more 
efficient use of health care resources. The under-utilisation of this information could mean 
that we continue with an inefficient use of health care resources. 
This thesis suggests that there remains an over reliance in cost-effectiveness analysis on 
classical statistical techniques. This dependency on certainty stems from the fact that the 
methods involved were originally devised to measure dichotomous outcomes not 
continuous outcomes such as cost-effectiveness ratios. 
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It is argued that more consideration be given to the heterogeneous nature of populations 
when both analysing and using data from economic evaluations in making policy 
decisions. In addition it is suggested that optimisation in resource allocation can be 
improved with a greater concentration on likelihood of relative cost-effectiveness rather 
than the current over reliance on arbitrary measures of certainty. 
It is the belief of this thesis that the implications of this given the evidence from chapter 8 
are that the health benefits being produced from the scarce health care resources are not 
being maximised. It is also the belief of this thesis that this is due to the fact that the 
heterogeneity of populations are not considered enough in decision-making and that 
subgroup analysis is underused. 
These points can only be confirmed with greater research into available evidence from 
large trials where subgroup analysis is likely to be advantageous, or where there are 
empirical predictors of outcomes. In addition there needs to be an audit of interventions or 
technologies which have been accepted into clinical practice due to its overall cost- 
effectiveness, but which may have subgroups of the population receiving treatment which 
may not be cost-effective for them and therefore not an optimal use of scarce resources. 
Such research would serve to validate the results of this thesis and potentially confirm the 
value of greater use of subgroup analysis in policy decision-making. 
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Appendix 1 
Results of simulations of PRAIS UK data set 
Figures 1-6 Histograms of simulation results 
Data tables of PRAIS UK 
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Figure 1: Histogram of total sample - PRAIS UK 
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Figure 2: Histogram of subgroup by age: < 60 - PRAIS UK 
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Figure 3: Histogram of subgroup by age: 60-74 - PRAIS UK 
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Age - 75+ subgroup plot 
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Figure 4: Histogram of subgroup by age: 75+ - PRAIS UK 
152 
ECG-Normal subgroup plot 
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Figure 5: Histogram of subgroup by ECG: Normal - PRAIS UK 
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ECG - Complications subgroup plot 
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Figure 6: Histogram of subgroup by ECG: complications - PRAIS UK 
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PRAIS UK study data (n=1046) 
Patient Procedures Hospital Drug cost Admission 
study no. cost stay cost cost 
1 500.00 833.00 9.87 1342.87 
2 0.00 357.00 5.49 362.49 
3 0.00 357.00 3.42 360.42 
4 1428.00 476.00 5.64 1909.64 
5 0.00 943.00 6.06 949.06 
6 0.00 934.00 2.88 936.88 
7 0.00 586.00 20.79 606.79 
8 0.00 824.00 11.60 835.60 
9 620.00 1190.00 10.10 1820.10 
10 0.00 476.00 7.04 483.04 
11 120.00 1529.00 89.50 1738.50 
12 0.00 1547.00 18.33 1565.33 
13 0.00 952.00 8.08 960.08 
14 0.00 0.00 0.00 0.00 
16 120.00 595.00 7.05 722.05 
17 0.00 238.00 2.86 240.86 
18 0.00 943.00 20.82 963.82 
19 0.00 119.00 1.12 120.12 
20 0.00 1062.00 21.54 1083.54 
21 0.00 357.00 0.87 357.87 
22 0.00 0.00 0.00 0.00 
23 0.00 238.00 3.66 241.66 
24 0.00 824.00 7.15 831.15 
25 0.00 467.00 4.06 471.06 
26 0.00 238.00 2.90 240.90 
27 1428.00 238.00 2.24 1668.24 
28 0.00 833.00 12.32 845.32 
29 0.00 952.00 17.28 969.28 
30 120.00 476.00 4.48 600.48 
31 120.00 943.00 26.94 1089.94 
32 500.00 952.00 11.28 1463.28 
33 0.00 595.00 3.60 598.60 
34 120.00 824.00 25.30 969.30 
35 0.00 238.00 2.94 240.94 
36 0.00 595.00 5.05 600.05 
37 0.00 595.00 5.70 600.70 
38 120.00 1172.00 8.58 1300.58 
39 0.00 595.00 5.90 600.90 
40 1548.00 2133.00 53.30 3734.30 
41 1548.00 2948.00 70.78 4566.78 
42 0.00 2234.00 66.53 2300.53 
43 0.00 1776.00 34.83 1810.83 
44 0.00 1520.00 7.07 1527.07 
45 1428.00 1172.00 41.58 2641.58 
46 0.00 2600.00 60.72 2660.72 
47 0.00 714.00 10.98 724.98 
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Patient Procedures Hospital Drug cost Admission 
study no. cost stay cost cost 
48 1428.00 357.00 2.37 1787.37 
49 0.00 1904.00 22.88 1926.88 
50 0.00 357.00 1.56 358.56 
51 1428.00 467.00 20.82 1915.82 
52 1428.00 2023.00 13.77 3464.77 
53 0.00 714.00 0.60 714.60 
54 0.00 357.00 5.10 362.10 
55 0.00 467.00 19.32 486.32 
56 0.00 833.00 7.98 840.98 
57 120.00 595.00 3.95 718.95 
58 0.00 952.00 6.48 958.48 
59 0.00 2838.00 61.60 2899.60 
60 120.00 119.00 0.52 239.52 
61 0.00 119.00 0.79 119.79 
62 0.00 467.00 2.28 469.28 
63 0.00 238.00 0.78 238.78 
64 0.00 119.00 0.50 119.50 
65 0.00 348.00 0.52 348.52 
66 0.00 943.00 4.74 947.74 
67 0.00 1547.00 10.53 1557.53 
68 0.00 1520.00 2.73 1522.73 
69 0.00 1529.00 3.51 1532.51 
70 0.00 476.00 1.56 477.56 
71 0.00 824.00 7.70 831.70 
72 0.00 357.00 4.80 361.80 
73 0.00 824.00 1.45 825.45 
74 0.00 467.00 4.28 471.28 
75 0.00 1172.00 2.34 1174.34 
76 120.00 1300.00 27.39 1447.39 
77 0.00 824.00 3.95 827.95 
78 0.00 943.00 3.00 946.00 
79 120.00 357.00 2.43 479.43 
80 0.00 0.00 14.52 14.52 
81 0.00 952.00 6.48 958.48 
82 0.00 467.00 0.78 467.78 
83 0.00 357.00 3.36 360.36 
84 0.00 2243.00 64.50 2307.50 
85 0.00 476.00 3.16 479.16 
86 0.00 3561.00 33.88 3594.88 
87 0.00 3406.00 97.89 3503.89 
88 0.00 595.00 6.05 601.05 
89 2810.00 1904.00 20.00 4734.00 
91 500.00 476.00 0.40 976.40 
92 120.00 476.00 0.40 596.40 
93 500.00 0.00 1.58 501.58 
94 0.00 476.00 3.24 479.24 
95 0.00 1291.00 38.53 1329.53 
96 120.00 952.00 9.68 1081.68 
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97 2048.00 1181.00 22.98 3251.98 
98 0.00 595.00 4.05 599.05 
99 2810.00 1181.00 17.30 4008.30 
100 0.00 476.00 4.84 480.84 
101 0.00 0.00 0.00 0.00 
102 0.00 119.00 0.81 119.81 
103 0.00 238.00 0.78 238.78 
104 0.00 1071.00 3.51 1074.51 
105 0.00 0.00 0.00 0.00 
106 0.00 1071.00 14.40 1085.40 
107 0.00 348.00 0.39 348.39 
108 0.00 348.00 0.29 348.29 
109 0.00 119.00 0.79 119.79 
110 0.00 0.00 0.00 0.00 
111 0.00 833.00 10.78 843.78 
112 0.00 238.00 1.62 239.62 
113 0.00 1547.00 10.53 1557.53 
114 0.00 595.00 7.70 602.70 
115 0.00 586.00 2.43 588.43 
116 0.00 348.00 1.21 349.21 
117 0.00 238.00 1.58 239.58 
118 0.00 0.00 0.00 0.00 
119 0.00 119.00 0.39 119.39 
120 0.00 119.00 1.21 120.21 
121 120.00 238.00 3.08 361.08 
122 0.00 586.00 21.99 607.99 
123 0.00 1062.00 5.67 1067.67 
124 0.00 943.00 25.08 968.08 
125 0.00 357.00 5.49 362.49 
126 120.00 586.00 20.73 726.73 
127 0.00 586.00 21.78 607.78 
128 0.00 595.00 7.15 602.15 
129 0.00 476.00 6.16 482.16 
130 0.00 476.00 4.56 480.56 
131 0.00 824.00 7.05 831.05 
132 0.00 824.00 9.15 833.15 
133 1428.00 357.00 4.35 1789.35 
135 1428.00 833.00 9.45 2270.45 
136 1428.00 1053.00 40.15 2521.15 
137 0.00 714.00 8.58 722.58 
138 0.00 705.00 1.56 706.56 
139 1428.00 595.00 10.80 2033.80 
140 0.00 357.00 5.49 362.49 
141 0.00 934.00 1.56 935.56 
142 0.00 357.00 4.74 361.74 
143 1428.00 833.00 8.47 2269.47 
144 0.00 119.00 0.39 119.39 
145 0.00 357.00 2.43 359.43 
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146 0.00 0.00 0.00 0.00 
147 0.00 476.00 6.16 482.16 
148 0.00 586.00 3.42 589.42 
149 120.00 714.00 4.74 838.74 
150 0.00 348.00 0.39 348.39 
151 0.00 714.00 12.18 726.18 
152 0.00 705.00 3.24 708.24 
153 120.00 238.00 1.58 359.58 
154 0.00 595.00 4.05 599.05 
155 0.00 467.00 1.62 468.62 
156 0.00 357.00 2.43 359.43 
157 0.00 714.00 2.34 716.34 
158 0.00 1190.00 19.30 1209.30 
159 120.00 595.00 3.95 718.95 
160 120.00 1859.00 4.74 1983.74 
161 120.00 238.00 0.58 358.58 
162 0.00 714.00 9.24 723.24 
163 0.00 238.00 2.28 240.28 
164 0.00 714.00 4.74 718.74 
165 0.00 238.00 1.62 239.62 
166 0.00 714.00 7.26 721.26 
167 0.00 238.00 0.58 238.58 
168 0.00 705.00 6.32 711.32 
169 500.00 0.00 0.85 500.85 
170 0.00 595.00 6.05 601.05 
171 0.00 119.00 1.21 120.21 
172 0.00 357.00 4.62 361.62 
173 120.00 0.00 0.00 120.00 
174 120.00 943.00 25.20 1088.20 
175 500.00 0.00 0.00 500.00 
176 620.00 1071.00 12.69 1703.69 
177 0.00 714.00 8.64 722.64 
178 0.00 1053.00 5.20 1058.20 
179 0.00 238.00 1.58 239.58 
180 0.00 119.00 0.79 119.79 
181 0.00 119.00 1.43 120.43 
182 0.00 586.00 4.29 590.29 
183 0.00 238.00 2.02 240.02 
184 0.00 357.00 3.03 360.03 
185 0.00 357.00 2.43 359.43 
186 0.00 0.00 0.00 0.00 
187 0.00 238.00 1.62 239.62 
188 0.00 586.00 5.49 591.49 
189 0.00 1291.00 40.07 1331.07 
190 0.00 705.00 8.64 713.64 
191 0.00 952.00 11.28 963.28 
192 0.00 705.00 8.64 713.64 
193 0.00 238.00 2.86 240.86 
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194 0.00 705.00 6.96 711.96 
195 0.00 238.00 1.58 239.58 
196 0.00 1309.00 22.66 1331.66 
197 0.00 943.00 8.46 951.46 
198 0.00 705.00 3.16 708.16 
199 2810.00 3689.00 56.73 6555.73 
200 120.00 586.00 4.23 710.23 
201 120.00 238.00 1.58 359.58 
202 0.00 4156.00 29.37 4185.37 
203 0.00 1062.00 7.77 1069.77 
204 120.00 238.00 1.42 359.42 
205 2310.00 2820.00 43.52 5173.52 
206 0.00 476.00 1.56 477.56 
207 0.00 1776.00 32.23 1808.23 
208 0.00 476.00 4.84 480.84 
209 1928.00 238.00 2.28 2168.28 
210 500.00 1895.00 15.68 2410.68 
211 0.00 934.00 3.24 937.24 
212 0.00 467.00 1.04 468.04 
213 500.00 5485.00 247.68 6232.68 
214 500.00 714.00 10.98 1224.98 
215 0.00 1282.00 10.05 1292.05 
216 500.00 1282.00 58.65 1840.65 
217 0.00 815.00 2.07 817.07 
218 2048.00 815.00 1.50 2864.50 
219 500.00 1053.00 48.25 1601.25 
220 0.00 476.00 4.44 480.44 
221 500.00 238.00 3.74 741.74 
222 1928.00 476.00 9.64 2413.64 
223 0.00 1062.00 26.51 1088.51 
224 120.00 1520.00 12.81 1652.81 
225 0.00 1071.00 3.51 1074.51 
226 120.00 238.00 2.82 360.82 
227 0.00 357.00 5.49 362.49 
228 120.00 238.00 1.04 359.04 
229 500.00 1071.00 10.08 1581.08 
230 500.00 467.00 1.44 968.44 
231 500.00 1071.00 12.69 1583.69 
232 500.00 705.00 20.98 1225.98 
233 500.00 357.00 5.49 862.49 
234 0.00 357.00 4.23 361.23 
235 120.00 238.00 4.86 362.86 
236 500.00 476.00 11.32 987.32 
237 0.00 238.00 2.82 240.82 
238 500.00 952.00 14.64 1466.64 
239 2810.00 2023.00 23.97 4856.97 
240 0.00 476.00 5.72 481.72 
241 0.00 714.00 7.68 721.68 
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242 0.00 476.00 4.04 480.04 
243 500.00 705.00 22.22 1227.22 
244 2810.00 1776.00 39.38 4625.38 
245 0.00 119.00 1.12 120.12 
246 620.00 595.00 9.15 1224.15 
247 0.00 119.00 0.10 119.10 
248 2048.00 1309.00 27.94 3384.94 
249 0.00 824.00 7.35 831.35 
250 0.00 1648.00 43.10 1691.10 
251 120.00 357.00 3.93 480.93 
252 0.00 357.00 2.43 359.43 
253 0.00 1419.00 10.10 1429.10 
254 0.00 119.00 0.81 119.81 
255 0.00 348.00 0.72 348.72 
256 0.00 0.00 0.00 0.00 
257 0.00 2737.00 32.89 2769.89 
258 0.00 1657.00 33.66 1690.66 
259 0.00 238.00 0.78 238.78 
260 0.00 1071.00 11.52 1082.52 
261 0.00 1630.00 71.46 1701.46 
262 2310.00 2856.00 67.92 5233.92 
263 0.00 595.00 10.30 605.30 
264 0.00 348.00 0.91 348.91 
265 0.00 586.00 3.03 589.03 
266 0.00 476.00 3.24 479.24 
267 0.00 3927.00 47.19 3974.19 
268 500.00 2582.00 91.62 3173.62 
269 0.00 1053.00 40.15 1093.15 
270 120.00 1428.00 17.16 1565.16 
271 0.00 1291.00 45.32 1336.32 
272 0.00 705.00 21.82 726.82 
273 0.00 586.00 21.99 607.99 
274 0.00 824.00 8.00 832.00 
275 2310.00 1309.00 20.13 3639.13 
276 2310.00 7086.00 167.64 9563.64 
277 0.00 833.00 10.01 843.01 
278 500.00 1895.00 38.06 2433.06 
279 2810.00 4798.00 190.59 7798.59 
280 0.00 119.00 1.21 120.21 
281 0.00 1309.00 11.44 1320.44 
282 0.00 476.00 7.72 483.72 
283 0.00 833.00 11.20 844.20 
284 0.00 1172.00 4.86 1176.86 
285 0.00 1776.00 37.30 1813.30 
286 0.00 2023.00 22.27 2045.27 
287 120.00 1428.00 19.20 1567.20 
288 0.00 2380.00 16.20 2396.20 
289 0.00 4376.00 81.74 4457.74 
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290 0.00 3561.00 33.04 3594.04 
291 500.00 238.00 2.42 740.42 
292 0.00 1172.00 4.86 1176.86 
293 0.00 1062.00 22.17 1084.17 
294 0.00 1181.00 6.32 1187.32 
295 0.00 2362.00 57.16 2419.16 
296 1428.00 357.00 2.76 1787.76 
297 120.00 357.00 1.17 478.17 
298 120.00 476.00 2.00 598.00 
299 0.00 1657.00 4.68 1661.68 
300 0.00 714.00 3.00 717.00 
301 0.00 238.00 1.62 239.62 
302 0.00 1547.00 18.72 1565.72 
303 120.00 238.00 3.66 361.66 
304 0.00 476.00 1.56 477.56 
305 0.00 238.00 3.08 241.08 
306 1928.00 1895.00 46.74 3869.74 
307 0.00 119.00 1.21 120.21 
308 0.00 586.00 4.29 590.29 
309 0.00 357.00 3.63 360.63 
310 0.00 586.00 5.49 591.49 
311 500.00 2124.00 57.64 2681.64 
312 0.00 714.00 10.56 724.56 
313 0.00 238.00 2.86 240.86 
314 0.00 357.00 5.28 362.28 
315 0.00 119.00 0.50 119.50 
316 0.00 952.00 20.40 972.40 
317 1928.00 2142.00 38.88 4108.88 
318 0.00 238.00 3.52 241.52 
319 0.00 586.00 6.00 592.00 
320 0.00 833.00 12.81 845.81 
321 0.00 467.00 1.00 468.00 
322 0.00 595.00 1.95 596.95 
323 0.00 943.00 7.26 950.26 
324 0.00 357.00 2.43 359.43 
325 0.00 824.00 2.15 826.15 
326 0.00 476.00 8.04 484.04 
327 0.00 467.00 3.86 470.86 
328 0.00 595.00 6.05 601.05 
329 0.00 119.00 0.79 119.79 
330 0.00 943.00 4.74 947.74 
331 0.00 238.00 1.62 239.62 
332 0.00 2975.00 12.50 2987.50 
333 0.00 714.00 10.44 724.44 
334 0.00 0.00 0.00 0.00 
335 0.00 119.00 0.40 119.40 
336 0.00 467.00 1.00 468.00 
337 0.00 238.00 1.00 239.00 
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338 0.00 0.00 0.00 0.00 
339 0.00 714.00 4.86 718.86 
340 0.00 476.00 2.00 478.00 
341 120.00 595.00 7.15 722.15 
342 0.00 833.00 17.85 850.85 
343 0.00 1062.00 28.82 1090.82 
344 0.00 952.00 4.16 956.16 
345 0.00 1785.00 18.15 1803.15 
346 0.00 238.00 3.52 241.52 
347 0.00 595.00 4.05 599.05 
348 500.00 1785.00 26.40 2311.40 
349 0.00 1062.00 31.62 1093.62 
350 120.00 0.00 0.00 120.00 
351 0.00 357.00 4.23 361.23 
352 120.00 1190.00 7.20 1317.20 
353 0.00 238.00 2.86 240.86 
354 0.00 2142.00 24.12 2166.12 
355 0.00 833.00 7.84 840.84 
356 0.00 595.00 9.15 604.15 
357 0.00 705.00 4.04 709.04 
358 0.00 934.00 4.04 938.04 
359 0.00 0.00 0.00 0.00 
360 120.00 238.00 3.08 361.08 
361 1428.00 0.00 17.10 1445.10 
362 120.00 0.00 4.56 124.56 
363 1428.00 0.00 8.69 1436.69 
364 0.00 0.00 9.68 9.68 
365 0.00 0.00 7.98 7.98 
366 0.00 0.00 1.17 1.17 
367 0.00 0.00 0.00 0.00 
368 0.00 0.00 13.77 13.77 
369 0.00 0.00 7.32 7.32 
370 1428.00 0.00 2.37 1430.37 
371 0.00 0.00 7.26 7.26 
372 0.00 0.00 2.37 2.37 
373 1428.00 0.00 12.10 1440.10 
374 0.00 0.00 8.47 8.47 
375 0.00 0.00 11.76 11.76 
376 0.00 0.00 0.00 0.00 
377 0.00 0.00 5.04 5.04 
378 0.00 0.00 1.95 1.95 
379 0.00 0.00 3.24 3.24 
380 120.00 0.00 8.47 128.47 
381 0.00 1062.00 5.53 1067.53 
382 0.00 238.00 2.36 240.36 
383 120.00 357.00 2.37 479.37 
384 0.00 595.00 5.70 600.70 
385 0.00 357.00 4.32 361.32 
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386 0.00 357.00 3.54 360.54 
387 0.00 833.00 8.47 841.47 
388 120.00 595.00 6.05 721.05 
389 0.00 238.00 1.62 239.62 
390 0.00 119.00 0.79 119.79 
391 0.00 238.00 0.78 238.78 
392 1428.00 952.00 9.12 2389.12 
393 0.00 357.00 2.43 359.43 
394 0.00 824.00 3.95 827.95 
395 0.00 0.00 0.00 0.00 
396 0.00 595.00 3.55 598.55 
397 0.00 238.00 2.22 240.22 
398 0.00 1172.00 40.26 1212.26 
399 0.00 238.00 1.44 239.44 
400 0.00 238.00 1.58 239.58 
401 0.00 119.00 0.50 119.50 
402 0.00 238.00 1.58 239.58 
403 0.00 705.00 19.66 724.66 
404 0.00 1181.00 3.12 1184.12 
405 120.00 357.00 1.50 478.50 
406 620.00 1776.00 32.23 2428.23 
407 2810.00 5712.00 73.92 8595.92 
408 0.00 238.00 0.78 238.78 
409 0.00 119.00 0.81 119.81 
410 0.00 1785.00 1.50 1786.50 
411 0.00 714.00 2.34 716.34 
412 500.00 476.00 2.00 978.00 
413 120.00 476.00 4.48 600.48 
414 0.00 0.00 0.00 0.00 
415 120.00 833.00 12.67 965.67 
416 0.00 586.00 21.30 607.30 
417 120.00 1181.00 4.00 1305.00 
418 120.00 943.00 0.60 1063.60 
419 0.00 357.00 5.10 362.10 
420 0.00 357.00 1.17 358.17 
421 0.00 1181.00 11.28 1192.28 
422 0.00 833.00 9.87 842.87 
423 0.00 1172.00 8.04 1180.04 
424 0.00 357.00 4.23 361.23 
425 0.00 357.00 4.23 361.23 
426 0.00 1300.00 29.19 1329.19 
427 500.00 357.00 6.90 863.90 
428 0.00 1776.00 41.59 1817.59 
429 0.00 4084.00 23.97 4107.97 
430 0.00 1538.00 23.76 1561.76 
431 0.00 0.00 0.00 0.00 
432 0.00 943.00 4.86 947.86 
433 0.00 595.00 7.15 602.15 
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434 0.00 1520.00 12.81 1532.81 
435 0.00 714.00 4.32 718.32 
436 0.00 824.00 7.05 831.05 
437 0.00 595.00 7.05 602.05 
438 2810.00 2023.00 19.04 4852.04 
439 0.00 696.00 3.22 699.22 
440 0.00 943.00 12.96 955.96 
441 120.00 1071.00 17.10 1208.10 
442 0.00 238.00 87.24 325.24 
443 0.00 4495.00 133.34 4628.34 
444 0.00 476.00 4.56 480.56 
445 120.00 476.00 3.16 599.16 
446 0.00 476.00 7.04 483.04 
447 0.00 238.00 3.08 241.08 
448 0.00 476.00 7.32 483.32 
449 0.00 238.00 1.62 239.62 
450 0.00 824.00 5.60 829.60 
451 0.00 952.00 8.88 960.88 
452 0.00 238.00 3.08 241.08 
453 0.00 815.00 38.19 853.19 
454 0.00 833.00 10.57 843.57 
455 120.00 119.00 1.83 240.83 
456 120.00 833.00 12.81 965.81 
457 120.00 467.00 1.64 588.64 
458 0.00 586.00 21.72 607.72 
459 120.00 238.00 0.20 358.20 
460 0.00 705.00 23.82 728.82 
461 0.00 595.00 0.50 595.50 
462 0.00 952.00 2.32 954.32 
463 0.00 595.00 2.50 597.50 
464 0.00 1053.00 7.70 1060.70 
465 0.00 357.00 2.13 359.13 
466 0.00 714.00 3.00 717.00 
467 0.00 348.00 0.39 348.39 
468 500.00 0.00 0.00 500.00 
469 0.00 1181.00 3.12 1184.12 
470 0.00 476.00 1.56 477.56 
471 0.00 348.00 0.00 348.00 
472 0.00 1538.00 4.29 1542.29 
473 0.00 476.00 4.88 480.88 
474 0.00 2335.00 7.90 2342.90 
475 0.00 705.00 4.48 709.48 
476 0.00 595.00 5.70 600.70 
477 0.00 238.00 0.78 238.78 
478 0.00 1547.00 20.02 1567.02 
479 500.00 3451.00 73.66 4024.66 
480 0.00 357.00 2.37 359.37 
481 0.00 705.00 7.72 712.72 
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482 120.00 705.00 3.24 828.24 
483 500.00 952.00 6.48 1458.48 
484 0.00 119.00 0.00 119.00 
485 120.00 1053.00 36.95 1209.95 
486 120.00 1300.00 10.89 1430.89 
487 0.00 119.00 0.39 119.39 
488 500.00 1300.00 23.79 1823.79 
489 0.00 348.00 0.81 348.81 
490 0.00 476.00 4.84 480.84 
491 0.00 934.00 37.84 971.84 
492 120.00 595.00 3.95 718.95 
493 0.00 714.00 4.74 718.74 
494 0.00 238.00 1.58 239.58 
495 0.00 696.00 2.62 698.62 
497 500.00 2014.00 46.95 2560.95 
498 120.00 476.00 3.24 599.24 
499 120.00 833.00 8.47 961.47 
500 120.00 238.00 1.62 359.62 
501 0.00 586.00 1.17 587.17 
502 1428.00 1181.00 4.16 2613.16 
503 0.00 238.00 1.58 239.58 
504 0.00 943.00 4.74 947.74 
505 0.00 833.00 0.00 833.00 
506 0.00 238.00 1.58 239.58 
507 0.00 1053.00 6.05 1059.05 
508 0.00 348.00 0.39 348.39 
509 0.00 586.00 2.37 588.37 
510 0.00 586.00 2.43 588.43 
511 0.00 238.00 2.42 240.42 
512 0.00 238.00 1.58 239.58 
513 0.00 833.00 4.34 837.34 
514 0.00 952.00 12.32 964.32 
515 0.00 238.00 1.04 239.04 
516 0.00 595.00 2.00 597.00 
517 0.00 476.00 3.24 479.24 
518 0.00 357.00 1.50 358.50 
519 0.00 1428.00 6.24 1434.24 
520 0.00 1062.00 2.73 1064.73 
521 0.00 357.00 2.43 359.43 
522 500.00 1071.00 10.26 1581.26 
523 0.00 476.00 3.40 479.40 
524 0.00 357.00 3.75 360.75 
525 0.00 833.00 5.67 838.67 
526 0.00 119.00 1.21 120.21 
527 0.00 1547.00 20.80 1567.80 
528 0.00 357.00 2.07 359.07 
529 0.00 1776.00 9.36 1785.36 
530 0.00 1309.00 10.12 1319.12 
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531 0.00 0.00 0.00 0.00 
532 620.00 238.00 0.78 858.78 
533 0.00 0.00 0.00 0.00 
534 500.00 714.00 7.68 1221.68 
535 500.00 3718.00 9.48 4227.48 
536 0.00 238.00 0.20 238.20 
537 120.00 238.00 1.62 359.62 
538 0.00 1401.00 60.48 1461.48 
539 120.00 3828.00 189.42 4137.42 
540 120.00 357.00 1.50 478.50 
551 0.00 705.00 3.16 708.16 
552 0.00 833.00 10.08 843.08 
553 0.00 476.00 3.24 479.24 
554 500.00 0.00 3.42 503.42 
555 0.00 943.00 9.24 952.24 
556 0.00 348.00 1.41 349.41 
557 1428.00 119.00 0.10 1547.10 
558 0.00 4870.00 36.00 4906.00 
559 0.00 467.00 4.00 471.00 
560 500.00 0.00 0.00 500.00 
561 0.00 238.00 2.42 240.42 
562 0.00 833.00 7.84 840.84 
563 0.00 467.00 1.00 468.00 
564 0.00 238.00 1.58 239.58 
565 500.00 1776.00 36.52 2312.52 
566 1548.00 833.00 3.50 2384.50 
567 120.00 119.00 0.79 239.79 
568 0.00 238.00 1.00 239.00 
569 0.00 943.00 21.24 964.24 
570 0.00 824.00 19.00 843.00 
571 0.00 119.00 1.21 120.21 
572 0.00 0.00 6.16 6.16 
573 0.00 595.00 6.25 601.25 
574 0.00 357.00 0.30 357.30 
575 1428.00 238.00 0.20 1666.20 
576 0.00 238.00 2.30 240.30 
577 0.00 1547.00 6.50 1553.50 
578 0.00 595.00 93.80 688.80 
579 1428.00 476.00 9.32 1913.32 
580 0.00 348.00 1.21 349.21 
581 0.00 1053.00 3.95 1056.95 
582 1548.00 1053.00 6.05 2607.05 
583 0.00 2124.00 49.94 2173.94 
584 0.00 119.00 0.43 119.43 
585 0.00 357.00 0.87 357.87 
586 1428.00 0.00 0.00 1428.00 
587 0.00 1428.00 20.88 1448.88 
588 1428.00 1071.00 10.89 2509.89 
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589 1548.00 952.00 9.68 2509.68 
590 120.00 2023.00 15.64 2158.64 
591 0.00 3076.00 8.58 3084.58 
592 0.00 467.00 1.62 468.62 
593 0.00 943.00 4.74 947.74 
594 0.00 357.00 4.62 361.62 
595 0.00 696.00 2.28 698.28 
596 0.00 1181.00 22.98 1203.98 
597 0.00 595.00 2.50 597.50 
598 0.00 348.00 1.14 349.14 
599 0.00 238.00 1.62 239.62 
600 0.00 833.00 5.67 838.67 
601 1428.00 476.00 3.24 1907.24 
602 0.00 934.00 3.16 937.16 
603 0.00 696.00 2.24 698.24 
604 0.00 1309.00 21.23 1330.23 
605 0.00 934.00 39.16 973.16 
606 0.00 348.00 1.21 349.21 
607 0.00 1282.00 2.50 1284.50 
608 0.00 595.00 5.70 600.70 
609 0.00 348.00 0.92 348.92 
610 0.00 595.00 4.05 599.05 
611 0.00 0.00 12.32 12.32 
612 0.00 0.00 0.39 0.39 
613 0.00 0.00 1.95 1.95 
614 0.00 0.00 4.05 4.05 
615 0.00 0.00 2.43 2.43 
616 0.00 0.00 1.84 1.84 
617 0.00 0.00 2.00 2.00 
618 0.00 0.00 5.53 5.53 
619 0.00 0.00 0.50 0.50 
620 0.00 0.00 4.86 4.86 
621 0.00 0.00 2.37 2.37 
622 0.00 0.00 5.37 5.37 
623 0.00 0.00 7.70 7.70 
624 0.00 0.00 3.66 3.66 
625 0.00 0.00 6.00 6.00 
626 0.00 0.00 0.58 0.58 
627 120.00 0.00 0.00 120.00 
628 0.00 0.00 4.00 4.00 
629 0.00 0.00 0.79 0.79 
630 0.00 0.00 0.58 0.58 
631 1548.00 0.00 3.16 1551.16 
652 0.00 0.00 0.00 0.00 
653 500.00 1071.00 12.69 1583.69 
654 0.00 595.00 7.05 602.05 
655 0.00 2023.00 6.63 2029.63 
656 0.00 1657.00 14.52 1671.52 
167 
Patient Procedures Hospital Drug cost Admission 
study no. cost stay cost cost 
657 1428.00 1401.00 2.34 2831.34 
658 0.00 4394.00 10.15 4404.15 
659 0.00 1062.00 3.50 1065.50 
660 2810.00 2133.00 29.14 4972.14 
661 500.00 1785.00 26.40 2311.40 
662 500.00 1181.00 32.74 1713.74 
663 0.00 238.00 0.78 238.78 
664 0.00 357.00 1.17 358.17 
665 500.00 357.00 3.63 860.63 
666 500.00 714.00 12.00 1226.00 
667 0.00 119.00 0.50 119.50 
668 0.00 2005.00 9.23 2014.23 
669 1928.00 4870.00 60.96 6858.96 
670 0.00 1062.00 28.40 1090.40 
671 2810.00 2142.00 14.22 4966.22 
675 0.00 357.00 2.37 359.37 
676 0.00 714.00 9.24 723.24 
677 0.00 1172.00 43.56 1215.56 
678 1428.00 4165.00 152.90 5745.90 
692 0.00 357.00 2.07 359.07 
693 120.00 1300.00 30.90 1450.90 
694 0.00 1648.00 44.40 1692.40 
695 1928.00 2618.00 29.26 4575.26 
696 0.00 586.00 0.30 586.30 
697 0.00 2261.00 57.95 2318.95 
698 120.00 1071.00 13.86 1204.86 
699 0.00 943.00 25.74 968.74 
700 0.00 595.00 5.05 600.05 
701 0.00 1062.00 20.00 1082.00 
702 0.00 238.00 0.80 238.80 
703 0.00 943.00 4.86 947.86 
704 500.00 595.00 7.05 1102.05 
705 0.00 476.00 2.00 478.00 
706 0.00 1181.00 22.82 1203.82 
707 0.00 238.00 1.00 239.00 
708 0.00 595.00 5.70 600.70 
709 0.00 1071.00 14.22 1085.22 
710 0.00 714.00 7.26 721.26 
711 120.00 952.00 11.28 1083.28 
712 0.00 357.00 4.23 361.23 
713 0.00 824.00 8.80 832.80 
714 120.00 714.00 4.74 838.74 
715 0.00 1886.00 106.96 1992.96 
716 0.00 943.00 10.98 953.98 
717 0.00 238.00 1.00 239.00 
718 0.00 1410.00 17.28 1427.28 
719 0.00 238.00 1.00 239.00 
720 0.00 476.00 8.88 484.88 
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721 0.00 357.00 5.22 362.22 
722 0.00 238.00 2.82 240.82 
723 0.00 833.00 9.87 842.87 
724 0.00 705.00 3.24 708.24 
725 0.00 714.00 12.96 726.96 
726 0.00 595.00 9.15 604.15 
727 0.00 1776.00 13.13 1789.13 
728 0.00 476.00 3.16 479.16 
729 0.00 952.00 6.48 958.48 
730 0.00 476.00 4.84 480.84 
732 0.00 1547.00 25.09 1572.09 
733 120.00 238.00 1.58 359.58 
734 0.00 0.00 0.00 0.00 
735 0.00 119.00 0.79 119.79 
736 0.00 1071.00 10.89 1081.89 
737 0.00 705.00 3.16 708.16 
738 0.00 348.00 0.71 348.71 
739 0.00 467.00 1.62 468.62 
740 0.00 238.00 1.58 239.58 
741 0.00 119.00 0.79 119.79 
742 0.00 833.00 5.67 838.67 
743 0.00 119.00 0.81 119.81 
744 120.00 119.00 0.79 239.79 
745 0.00 595.00 3.95 598.95 
746 0.00 595.00 7.05 602.05 
747 0.00 348.00 1.21 349.21 
748 0.00 348.00 0.79 348.79 
749 0.00 1062.00 8.47 1070.47 
750 0.00 348.00 1.21 349.21 
751 0.00 119.00 2.00 121.00 
752 0.00 357.00 3.42 360.42 
753 0.00 952.00 6.48 958.48 
754 0.00 476.00 7.64 483.64 
755 0.00 476.00 4.84 480.84 
756 120.00 238.00 2.22 360.22 
757 120.00 1190.00 17.00 1327.00 
758 120.00 238.00 2.24 360.24 
759 0.00 0.00 0.00 0.00 
760 0.00 0.00 0.00 0.00 
761 0.00 1172.00 7.08 1179.08 
762 0.00 696.00 2.42 698.42 
763 120.00 1190.00 12.10 1322.10 
764 500.00 1895.00 38.06 2433.06 
765 0.00 119.00 0.39 119.39 
766 0.00 119.00 0.81 119.81 
767 120.00 238.00 1.58 359.58 
768 0.00 2499.00 17.01 2516.01 
769 0.00 595.00 4.05 599.05 
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770 0.00 833.00 5.04 838.04 
771 0.00 0.00 12.32 12.32 
772 0.00 0.00 11.22 11.22 
773 0.00 0.00 2.68 2.68 
774 0.00 0.00 5.10 5.10 
775 0.00 0.00 5.60 5.60 
776 0.00 238.00 2.82 240.82 
777 120.00 0.00 1.00 121.00 
778 0.00 0.00 8.82 8.82 
779 0.00 0.00 2.16 2.16 
780 0.00 0.00 5.80 5.80 
781 0.00 0.00 5.22 5.22 
782 120.00 0.00 2.82 122.82 
784 0.00 0.00 0.00 0.00 
785 0.00 0.00 30.24 30.24 
786 1428.00 0.00 0.00 1428.00 
787 0.00 0.00 4.56 4.56 
788 0.00 0.00 8.80 8.80 
789 1428.00 0.00 7.32 1435.32 
790 1428.00 0.00 10.80 1438.80 
791 0.00 238.00 1.62 239.62 
792 120.00 238.00 0.58 358.58 
793 0.00 595.00 8.50 603.50 
794 0.00 467.00 1.44 468.44 
795 0.00 943.00 6.72 949.72 
796 0.00 824.00 2.60 826.60 
797 1428.00 467.00 2.42 1897.42 
798 0.00 119.00 0.10 119.10 
799 0.00 1895.00 11.06 1906.06 
800 0.00 467.00 1.00 468.00 
801 0.00 943.00 7.86 950.86 
802 0.00 595.00 7.90 602.90 
803 0.00 476.00 4.04 480.04 
804 0.00 1172.00 41.58 1213.58 
805 0.00 2838.00 53.20 2891.20 
806 120.00 1428.00 20.88 1568.88 
807 0.00 357.00 3.03 360.03 
808 0.00 0.00 0.00 0.00 
809 0.00 476.00 4.04 480.04 
810 0.00 952.00 8.96 960.96 
811 0.00 467.00 3.66 470.66 
812 0.00 2142.00 32.94 2174.94 
813 0.00 595.00 7.15 602.15 
814 120.00 943.00 24.96 1087.96 
815 0.00 1987.00 81.66 2068.66 
816 0.00 2380.00 63.20 2443.20 
817 0.00 238.00 0.20 238.20 
818 0.00 119.00 0.72 119.72 
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820 0.00 3204.00 35.75 3239.75 
821 0.00 238.00 2.02 240.02 
822 0.00 357.00 3.03 360.03 
823 0.00 833.00 12.81 845.81 
824 0.00 1529.00 43.08 1572.08 
825 0.00 238.00 1.42 239.42 
826 1428.00 357.00 4.23 1789.23 
827 0.00 824.00 25.65 849.65 
828 0.00 833.00 7.07 840.07 
829 0.00 0.00 0.00 0.00 
830 0.00 833.00 7.84 840.84 
831 0.00 815.00 5.79 820.79 
832 0.00 357.00 3.63 360.63 
833 500.00 238.00 2.42 740.42 
834 0.00 357.00 3.63 360.63 
835 0.00 357.00 1.50 358.50 
836 120.00 238.00 0.20 358.20 
837 0.00 357.00 3.42 360.42 
838 0.00 1547.00 25.09 1572.09 
839 0.00 824.00 6.05 830.05 
840 0.00 119.00 1.14 120.14 
841 0.00 833.00 97.81 930.81 
842. 815.00 1.17 #VALUE! 
843 0.00 934.00 2.00 936.00 
844 0.00 238.00 2.42 240.42 
845 0.00 1062.00 8.47 1070.47 
846 0.00 0.00 0.00 0.00 
847 0.00 2719.00 15.39 2734.39 
848 0.00 586.00 2.43 588.43 
849 0.00 119.00 0.50 119.50 
850 0.00 595.00 6.40 601.40 
851 0.00 595.00 2.60 597.60 
852 0.00 0.00 0.00 0.00 
853 0.00 348.00 0.79 348.79 
854 0.00 348.00 1.14 349.14 
855 0.00 119.00 0.79 119.79 
856 0.00 348.00 0.39 348.39 
857 0.00 0.00 0.00 0.00 
858 0.00 0.00 0.00 0.00 
859 0.00 348.00 1.21 349.21 
860 500.00 1785.00 1.50 2286.50 
861 0.00 119.00 0.10 119.10 
862 0.00 1181.00 3.12 1184.12 
863 0.00 238.00 0.20 238.20 
864 0.00 833.00 10.78 843.78 
865 0.00 2609.00 32.00 2641.00 
866 0.00 0.00 0.00 0.00 
867 500.00 3727.00 170.06 4397.06 
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868 0.00 119.00 0.39 119.39 
869 0.00 1776.00 1.30 1777.30 
870 0.00 348.00 0.79 348.79 
871 0.00 357.00 1.17 358.17 
872 0.00 0.00 0.00 0.00 
873 0.00 1666.00 32.48 1698.48 
874 500.00 943.00 33.48 1476.48 
875 0.00 238.00 0.20 238.20 
876 120.00 714.00 8.46 842.46 
877 2810.00 1419.00 34.80 4263.80 
878 0.00 952.00 8.08 960.08 
879 0.00 1062.00 7.07 1069.07 
880 120.00 357.00 3.03 480.03 
881 620.00 1071.00 13.86 1704.86 
882 500.00 586.00 4.23 1090.23 
883 500.00 714.00 10.98 1224.98 
884 2810.00 2600.00 25.38 5435.38 
885 0.00 1071.00 9.09 1080.09 
886 0.00 1062.00 3.50 1065.50 
887 0.00 833.00 12.81 845.81 
888 2810.00 2252.00 32.30 5094.30 
889 120.00 943.00 4.32 1067.32 
890 500.00 1300.00 9.09 1809.09 
891 500.00 1053.00 45.05 1598.05 
892 0.00 0.00 6.72 6.72 
893 0.00 0.00 0.00 0.00 
894 0.00 1785.00 15.60 1800.60 
895 620.00 595.00 8.65 1223.65 
896 0.00 0.00 0.00 0.00 
897 0.00 0.00 15.84 15.84 
898 0.00 1071.00 0.90 1071.90 
899 0.00 0.00 11.90 11.90 
900 0.00 0.00 3.66 3.66 
901 0.00 0.00 8.58 8.58 
902 0.00 0.00 4.05 4.05 
903 0.00 0.00 1.01 1.01 
904 0.00 2142.00 27.72 2169.72 
905 0.00 0.00 0.00 0.00 
906 0.00 0.00 0.00 0.00 
907 0.00 0.00 0.00 0.00 
908 0.00 0.00 18.48 18.48 
909 120.00 0.00 4.29 124.29 
910 120.00 0.00 0.00 120.00 
911 0.00 0.00 0.00 0.00 
912 120.00 2499.00 38.43 2657.43 
913 0.00 824.00 25.65 849.65 
914 1428.00 595.00 7.35 2030.35 
915 0.00 1291.00 45.32 1336.32 
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916 120.00 595.00 3.60 718.60 
917 0.00 2380.00 36.80 2416.80 
918 0.00 476.00 6.96 482.96 
919 0.00 476.00 6.16 482.16 
920 0.00 2499.00 45.36 2544.36 
921 0.00 476.00 1.56 477.56 
922 0.00 833.00 10.29 843.29 
923 0.00 1428.00 18.48 1446.48 
924 0.00 1181.00 3.12 1184.12 
953 120.00 0.00 11.28 131.28 
954 0.00 0.00 1.04 1.04 
955 0.00 0.00 0.00 0.00 
956 120.00 952.00 11.28 1083.28 
957 0.00 0.00 4.29 4.29 
958 0.00 0.00 11.00 11.00 
959 0.00 0.00 0.00 0.00 
960 0.00 0.00 3.08 3.08 
961 0.00 0.00 0.00 0.00 
962 0.00 0.00 0.00 0.00 
963 0.00 0.00 5.28 5.28 
964 120.00 0.00 0.00 120.00 
965 0.00 0.00 0.00 0.00 
966 1548.00 0.00 6.72 1554.72 
967 0.00 0.00 9.50 9.50 
968 0.00 0.00 7.15 7.15 
969 0.00 0.00 0.00 0.00 
970 0.00 0.00 0.00 0.00 
971 0.00 0.00 0.00 0.00 
972 120.00 0.00 0.00 120.00 
973 0.00 2811.00 11.34 2822.34 
974 120.00 1181.00 30.10 1331.10 
975 500.00 2014.00 12.15 2526.15 
976 0.00 467.00 0.58 467.58 
977 120.00 815.00 1.56 936.56 
978 0.00 586.00 2.37 588.37 
979 0.00 0.00 0.00 0.00 
980 620.00 943.00 23.76 1586.76 
981 0.00 1172.00 41.58 1213.58 
982 0.00 1767.00 8.69 1775.69 
983 120.00 1300.00 10.26 1430.26 
984 120.00 1172.00 39.84 1331.84 
985 0.00 705.00 19.34 724.34 
986 0.00 586.00 19.86 605.86 
987 2930.00 5712.00 38.88 8680.88 
988 500.00 1181.00 25.62 1706.62 
989 0.00 476.00 3.24 479.24 
990 0.00 1767.00 7.92 1774.92 
991 0.00 2582.00 76.08 2658.08 
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992 0.00 586.00 3.63 589.63 
1002 120.00 833.00 10.01 963.01 
1007 500.00 1419.00 27.90 1946.90 
1009 0.00 238.00 2.28 240.28 
1010 0.00 357.00 1.17 358.17 
1011 0.00 238.00 2.08 240.08 
1012 120.00 952.00 6.48 1078.48 
1013 120.00 1181.00 6.48 1307.48 
1014 620.00 6080.00 343.48 7043.48 
1015 0.00 2133.00 45.78 2178.78 
1016 120.00 943.00 21.36 1084.36 
1017 0.00 476.00 4.84 480.84 
1018 0.00 586.00 3.75 589.75 
1019 0.00 934.00 4.84 938.84 
1020 0.00 357.00 4.62 361.62 
1021 620.00 3085.00 77.46 3782.46 
1022 0.00 1062.00 10.78 1072.78 
1023 500.00 2719.00 36.67 3255.67 
1024 0.00 1190.00 11.40 1201.40 
1025 500.00 4147.00 70.51 4717.51 
1026 0.00 476.00 3.24 479.24 
1027 1428.00 1767.00 12.54 3207.54 
1028 0.00 1190.00 15.40 1205.40 
1029 0.00 348.00 0.79 348.79 
1030 0.00 943.00 104.50 1047.50 
1031 0.00 467.00 0.58 467.58 
1032 0.00 815.00 2.43 817.43 
1033 120.00 1163.00 52.66 1335.66 
1034 120.00 467.00 2.42 589.42 
1035 0.00 357.00 2.43 359.43 
1036 0.00 714.00 10.26 724.26 
1037 0.00 357.00 2.43 359.43 
1038 0.00 586.00 2.37 588.37 
1039 0.00 952.00 3.12 955.12 
1040 0.00 586.00 1.17 587.17 
1041 0.00 1053.00 1.45 1054.45 
1042 0.00 1044.00 2.13 1046.13 
1043 0.00 934.00 36.24 970.24 
1044 0.00 348.00 0.40 348.40 
1045 0.00 705.00 3.24 708.24 
1046 0.00 952.00 6.32 958.32 
1047 0.00 1071.00 18.27 1089.27 
1048 0.00 238.00 0.78 238.78 
1049 0.00 238.00 2.42 240.42 
1050 0.00 238.00 1.00 239.00 
1051 0.00 3671.00 54.87 3725.87 
1052 0.00 833.00 5.67 838.67 
1053 0.00 1529.00 16.20 1545.20 
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1054 0.00 586.00 0.30 586.30 
1055 0.00 238.00 4.00 242.00 
1056 0.00 348.00 0.81 348.81 
1057 0.00 1904.00 20.48 1924.48 
1058 0.00 3094.00 10.14 3104.14 
1059 0.00 119.00 1.21 120.21 
1060 0.00 238.00 1.62 239.62 
1061 0.00 952.00 10.48 962.48 
1062 0.00 348.00 0.50 348.50 
1063 0.00 119.00 0.79 119.79 
1064 0.00 476.00 4.84 480.84 
1065 0.00 476.00 87.88 563.88 
1066 0.00 119.00 0.79 119.79 
1067 120.00 476.00 2.08 598.08 
1068 0.00 467.00 2.62 469.62 
1069 0.00 0.00 0.50 0.50 
1070 120.00 0.00 8.28 128.28 
1071 0.00 0.00 0.00 0.00 
1072 0.00 0.00 14.21 14.21 
1073 0.00 0.00 0.81 0.81 
1074 0.00 0.00 0.50 0.50 
1075 0.00 0.00 0.00 0.00 
1076 0.00 0.00 0.00 0.00 
1077 0.00 0.00 0.20 0.20 
1078 0.00 0.00 0.00 0.00 
1079 0.00 0.00 0.00 0.00 
1080 0.00 0.00 2.43 2.43 
1081 0.00 0.00 0.00 0.00 
1082 120.00 0.00 3.00 123.00 
1083 0.00 0.00 1.16 1.16 
1084 0.00 0.00 2.34 2.34 
1085 0.00 0.00 1.54 1.54 
1086 0.00 0.00 1.56 1.56 
1087 0.00 0.00 0.00 0.00 
1088 0.00 0.00 0.00 0.00 
1089 0.00 357.00 6.99 363.99 
1090 0.00 595.00 3.95 598.95 
1091 500.00 952.00 14.64 1466.64 
1092 0.00 119.00 0.39 119.39 
1093 0.00 238.00 2.42 240.42 
1094 500.00 357.00 3.63 860.63 
1095 0.00 595.00 4.05 599.05 
1096 1428.00 238.00 1.44 1667.44 
1097 0.00 119.00 0.39 119.39 
1098 0.00 714.00 7.08 721.08 
1099 0.00 119.00 0.39 119.39 
1100 0.00 2802.00 122.16 2924.16 
1401 0.00 1053.00 1.45 1054.45 
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1402 0.00 348.00 0.71 348.71 
1403 0.00 1172.00 7.26 1179.26 
1404 0.00 238.00 1.62 239.62 
1405 0.00 1410.00 36.12 1446.12 
1406 0.00 1181.00 9.68 1190.68 
1407 0.00 1071.00 7.11 1078.11 
1408 0.00 824.00 21.55 845.55 
1409 0.00 238.00 1.62 239.62 
1421 0.00 357.00 3.63 360.63 
1422 0.00 714.00 2.34 716.34 
1423 0.00 705.00 4.84 709.84 
1424 0.00 4414.00 11.06 4425.06 
1425 0.00 0.00 1.12 1.12 
1426 120.00 705.00 20.18 845.18 
1427 0.00 1181.00 3.12 1184.12 
1428 0.00 357.00 2.37 359.37 
1429 500.00 1300.00 7.11 1807.11 
1430 0.00 1172.00 40.74 1212.74 
1431 0.00 586.00 3.63 589.63 
1432 0.00 476.00 6.16 482.16 
1441 0.00 1190.00 8.10 1198.10 
1442 0.00 815.00 3.63 818.63 
1443 500.00 714.00 3.00 1217.00 
1444 500.00 3397.00 130.11 4027.11 
1445 2930.00 0.00 0.00 2930.00 
1446 120.00 476.00 3.24 599.24 
1447 120.00 1181.00 23.86 1324.86 
1448 0.00 357.00 3.63 360.63 
1449 500.00 476.00 4.04 980.04 
1450 0.00 238.00 1.58 239.58 
1451 0.00 1309.00 17.60 1326.60 
1452 500.00 1419.00 30.60 1949.60 
1453 120.00 1053.00 2.50 1175.50 
1454 0.00 1053.00 6.05 1059.05 
1455 620.00 952.00 14.08 1586.08 
1456 0.00 1062.00 0.70 1062.70 
1457 120.00 119.00 0.50 239.50 
1458 0.00 476.00 3.68 479.68 
1459 0.00 934.00 36.16 970.16 
1460 0.00 357.00 4.74 361.74 
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Appendix 2 
Results of simulations of ECMO data set 
Tables I- 10 Simulation statistics 
Figures 1- 10 Histograms of simulation results. 
Data tables of the ECMO study 
Subgroup 1 Birth weight < 3300 grams 
Subgroup 2 Birth weight > 3300 grams 
Subgroup 3 Gestation < 275 days 
Subgroup 4 Gestation > 275 days 
Subgroup 5 Diagnosis CDH 
Subgroup 6 Diagnosis IPFC 
Subgroup 7 Diagnosis PPH 
Subgroup 8 OI category I (<60) 
Subgroup 9 01 category II (>60) 
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Table 1: Descriptive statistics of probability distribution - subgroupl 
Name Ee - Ec R effect E effect C Ce - Cc 
Minimum = - 0.03 - 5,772,243 0.28 0.02 7,875 
Maximum = 0.68 3,197,265 0.88 0.46 29,973 
Mean = 0.30 75,847 0.54 0.24 19,711 
Std Deviation = 0.09 99,133 0.07 0.06 3,003 
Variance = 0.01 9,827,286,000 0.00 0.00 9,017,402 
Skewness = 0.01 - 10 0.01 - 0.01 -0 
Kurtosis = 3.06 1,517 3.04 2.97 3 
Mode = 0.19 54,404 0.46 0.17 18,020 
5% Perc = 0.15 39,639 0.42 0.14 14,731 
10% Perc = 0.18 44,183 0.45 0.16 15,871 
15% Perc = 0.20 47,349 0.47 0.18 16,575 
20% Perc = 0.22 50,424 0.48 0.19 17,153 
25% Perc = 0.24 52,877 0.49 0.20 17,700 
30% Perc = 0.25 55,517 0.50 0.21 18,151 
35% Perc = 0.26 58,028 0.51 0.22 18,562 
40% Perc = 0.28 60,416 0.52 0.23 18,941 
45% Perc = 0.29 62,982 0.53 0.23 19,325 
50% Perc = 0.30 65,716 0.54 0.24 19,735 
55% Perc = 0.31 68,795 0.55 0.25 20,104 
60% Perc = 0.32 71,967 0.56 0.25 20,478 
65% Perc = 0.34 75,418 0.57 0.26 20,879 
70% Perc = 0.35 79,531 0.58 0.27 21,286 
75% Perc = 0.36 84,395 0.59 0.28 21,730 
80% Perc = 0.38 90,397 0.60 0.29 22,237 
85% Perc = 0.39 98,819 0.61 0.30 22,815 
90% Perc = 0.42 111,543 0.63 0.32 23,569 
95% Perc = 0.45 137,317 0.65 0.34 24,637 
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Figure 1: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 1 
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Table 2: Descriptive statistics of probability distribution - subgroup 2 
Name Ee - Ec R Ce - Cc effect 
E effect C 
Minimum =- 0.11 - 4,211,902 - 
4,369 0.55 0.29 
Maximum = 0.60 50,114,870 18,954 
1.04 0.80 
Mean = 0.26 38,628 7,430 0.79 
0.53 
Std Deviati 0.09 506,517 2,847 0.06 0.07 
Variance = 0.01 256,559,800,000 8,107,124 
0.00 0.00 
Skewness 0.01 97 0 - 0.02 
0.01 
Kurtosis = 2.97 9,554 3 
3.05 3.03 
Mode = 0.25 24,940 6,506 
0.71 0.53 
5% Perc = 0.11 9,498 2,736 
0.69 0.42 
10% Perc = 0.14 13,273 3,754 
0.71 0.44 
15% Perc = 0.16 15,808 4,484 
0.73 0.46 
20% Perc = 0.18 17,821 5,028 
0.74 0.47 
25% Perc = 0.20 19,716 5,524 
0.75 0.48 
30% Perc = 0.21 21,457 5,953 
0.76 0.49 
35% Perc = 0.22 23,165 6,334 
0.77 0.50 
40% Perc = 0.24 24,984 6,735 
0.78 0.51 
45% Perc = 0.25 26,714 7,090 
0.78 0.52 
50% Perc = 0.26 28,488 7,432 
0.79 0.53 
55% Perc = 0.27 30,451 7,782 
0.80 0.54 
60% Perc = 0.28 32,448 8,166 0.81 
0.55 
65% Perc = 0.29 34,897 8,553 
0.81 0.56 
70% Perc = 0.31 37,493 8,923 
0.82 0.57 
75% Perc = 0.32 40,582 9,332 0.83 
0.58 
80% Perc = 0.34 44,434 9,801 0.84 
0.59 
85% Perc = 0.35 49,899 10,350 
0.85 0.60 
90% Perc = 0.38 59,009 11,053 
0.87 0.62 
95% Perc = 0.41 75,952 12,100 
0.89 0.64 
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Figure 2: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 2 
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Table 3: Descriptive statistics of probability distribution - subgroup 3 
Name Ee - Ec R Ce - Cc effect E effect C Minimum =- 0.15 - 186,882,300 1,342 0.26 0.06 
Maximum = 0.62 106,551,000 29,496 0.84 0.65 
Mean = 0.24 63,290 15,271 0.58 0.34 
Std Deviati 0.11 2,424,596 3,636 0.07 0.08 
Variance = 0.01 5,878,665,000,000 13,220,320 0.00 0.01 
Skewness 0.02 - 39 0 0.00 - 0.02 Kurtosis = 2.98 4,024 3 3.02 3.03 
Mode = 0.20 45,575 11,752 0.52 0.25 
5% Perc = 0.07 28,638 9,241 0.47 0.21 
10% Perc = 0.10 34,349 10,659 0.49 0.24 
15% Perc = 0.13 38,753 11,507 0.51 0.26 
20% Perc = 0.15 42,270 12,208 0.52 0.27 
25% Perc = 0.17 45,642 12,842 0.53 0.29 
30% Perc = 0.19 48,733 13,344 0.54 0.30 
35% Perc = 0.20 51,977 13,866 0.55 0.31 
40% Perc = 0.21 55,395 14,340 0.56 0.32 
45% Perc = 0.23 58,804 14,816 0.57 0.33 
50% Perc = 0.24 63,015 15,242 0.58 0.34 
55% Perc = 0.25 67,156 15,697 0.59 0.35 
60% Perc = 0.27 71,653 16,171 0.60 0.36 
65% Perc = 0.28 77,036 16,633 0.61 0.37 
70% Perc = 0.29 83,127 17,148 0.62 0.38 
75% Perc = 0.31 90,862 17,665 0.63 0.39 
80% Perc = 0.33 100,698 18,306 0.64 0.41 
85% Perc = 0.35 115,578 19,039 0.65 0.42 
90% Perc = 0.38 141,539 19,953 0.67 0.44 
95% Perc = 0.42 206,888 21,340 0.70 0.47 
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Figure 3: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 3 
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Table 4: Descriptive statistics of probability distribution - subgroup 4 
Name Ee - Ec R Ce - Cc effect E effect C 
Minimum =- 0.08 - 5,921,415 3,987 0.42 0.14 
Maximum = 0.66 1,148,895,000 22,214 0.99 0.70 
Mean = 0.30 163,231 12,229 0.73 0.43 
Std Deviati 0.10 11,488,450 2,413 0.07 0.07 
Variance = 0.01 131,984,500,000,000 5,820,236 0.00 0.00 
Skewness - 0.00 100 0 0.01 - 0.01 
Kurtosis = 2.99 9,996 3 3.04 3.08 
Mode = 0.23 35,917 10,764 0.65 0.36 
5% Perc = 0.14 22,637 8,247 0.61 0.31 
10% Perc = 0.17 25,691 9,143 0.64 0.34 
15% Perc = 0.20 28,186 9,721 0.66 0.36 
20% Perc = 0.22 30,167 10,203 0.67 0.37 
25% Perc = 0.23 31,826 10,603 0.68 0.38 
30% Perc = 0.25 33,525 10,943 0.69 0.39 
35% Perc = 0.26 35,302 11,286 0.70 0.40 
40% Perc = 0.27 37,024 11,593 0.71 0.41 
45% Perc = 0.29 38,831 11,898 0.72 0.42 
50% Perc = 0.30 40,650 12,218 0.73 0.43 
55% Perc = 0.31 42,823 12,535 0.74 0.44 
60% Perc = 0.33 44,936 12,859 0.75 0.45 
65% Perc = 0.34 47,456 13,168 0.76 0.46 
70% Perc = 0.35 50,287 13,515 0.77 0.47 
75% Perc = 0.37 53,707 13,860 0.78 0.48 
80% Perc = 0.38 57,918 14,284 0.79 0.49 
85% Perc = 0.40 63,594 14,747 0.80 0.50 
90% Perc = 0.43 72,668 15,336 0.82 0.52 
95% Perc = 0.46 91,789 16,175 0.85 0.54 
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Figure 4: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 4 
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Table 5: Descriptive statistics of probability distribution - subgroup 5 
Name Ee - Ec R Ce - Cc effect E 
Minimum =- 0.15 - 55,851,440 10,571 - 0.15 
Maximum = 0.65 370,262,000 62,112 0.65 
Mean = 0.22 250,358 36,201 0.22 
Std Deviati 0.10 3,995,778 6,319 0.10 
Variance = 0.01 15,966,240,000,000 39,933,830 0.01 
Skewness 0.00 80 -0 0.00 
Kurtosis = 3.03 7,370 3 3.03 
Mode = 0.07 128,624 35,654 0.07 
5% Perc = 0.05 81,035 25,530 0.05 
10% Perc = 0.09 94,586 28,042 0.09 
15% Perc = 0.12 104,707 29,675 0.12 
20% Perc = 0.14 113,024 30,974 0.14 
25% Perc = 0.15 120,561 31,990 0.15 
30% Perc = 0.17 128,391 32,927 0.17 
35% Perc = 0.18 136,066 33,791 0.18 
40% Perc = 0.19 144,085 34,645 0.19 
45% Perc = 0.21 152,598 35,445 0.21 
50% Perc = 0.22 162,146 36,234 0.22 
55% Perc = 0.23 171,819 37,029 0.23 
60% Perc = 0.25 183,749 37,821 0.25 
65% Perc = 0.26 197,361 38,658 0.26 
70% Perc = 0.27 213,739 39,511 0.27 
75% Perc = 0.29 233,056 40,491 0.29 
80% Perc = 0.30 261,027 41,560 0.30 
85% Perc = 0.32 300,422 42,764 0.32 
90% Perc = 0.35 371,911 44,285 0.35 
95% Perc = 0.38 539,475 46,581 0.38 
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Figure 5: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 5 
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Table 6: Descriptive statistics of probability distribution - subgroup 6 
Name Ee - Ec R Ce - Cc effect E effect 
C 
Minimum 0.05 -1042598 -8816.766 0.52 - 0.09 
Maximum = 1.11 3441217 23747.1 1.21 0.80 
Mean = 0.49 20105.52 8235.314 0.87 0.38 
Std Deviati 0.16 42040.23 4274.482 0.09 0.13 
Variance = 0.02 1.77E+09 1.83E+07 0.01 0.02 
Skewness 0.04 54.75468 -6.83E-02 - 0.04 - 0.00 
Kurtosis = 2.98 4471.903 2.985778 3.00 2.95 
Mode = 0.50 12585.84 11473.76 0.80 0.30 
5% Perc = 0.23 1957.928 967.4439 0.72 0.17 
10% Perc = 0.29 5339.917 2747.382 0.75 0.22 
15% Perc = 0.32 7587.487 3842.766 0.78 0.25 
20% Perc = 0.36 9139.431 4672.26 0.79 0.27 
25% Perc = 0.38 10540.44 5371.251 0.81 0.29 
30% Perc = 0.41 12005.91 6017.742 0.82 0.31 
35% Perc = 0.43 13259.48 6637.041 0.84 0.33 
40% Perc = 0.45 14495.47 7218.548 0.85 0.35 
45% Perc = 0.47 15747.94 7751.034 0.86 0.37 
50% Perc = 0.49 16927.39 8303.717 0.87 0.38 
55% Perc = 0.51 18283.21 8795.231 0.88 0.40 
60% Perc = 0.53 19654 9346.19 0.89 0.41 
65% Perc = 0.55 21322.99 9918.157 0.90 0.43 
70% Perc = 0.57 22950.97 10506.01 0.92 0.45 
75% Perc = 0.59 24867.26 11165.74 0.93 0.47 
80% Perc = 0.62 27231.59 11853.43 0.94 0.49 
85% Perc = 0.65 30425.55 12682.44 0.96 0.51 
90% Perc = 0.69 35061.55 13708.04 0.99 0.55 
95% Perc = 0.75 44429.67 15148.89 1.02 0.59 
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Figure 6: Probability distribution of R= (CE - CC) / (EE - Ec) - subgroup 6 
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Table 7: Descriptive statistics of probability distribution - subgroup 7 
Name Ee - Ec R Ce - Cc effect 
E effect C 
Minimum - 0.05 - 2,078,959 575 
0.52 0.25 
Maximum 0.57 4,609,683 15,838 0.97 0.72 
Mean = 0.25 39,502 8,325 0.75 0.50 
Std Deviat 0.08 72,574 2,120 0.06 0.06 
Variance 0.01 5,266,931,000 4,492,929 0.00 0.00 
Skewness 0.06 25 0 0.01 - 0.04 
Kurtosis = 3.00 1,905 3 2.96 3.02 
Mode = 0.26 20,599 8,603 0.66 0.41 
5% Perc = 0.11 16,568 4,919 0.65 0.40 
10% Perc 0.14 19,319 5,665 0.67 0.42 
15% Perc 0.16 21,522 6,159 0.69 0.44 
20% Perc 0.18 23,129 6,519 0.70 0.45 
25% Perc 0.19 24,891 6,865 0.71 0.46 
30% Perc 0.21 26,504 7,165 0.72 0.47 
35% Perc 0.22 28,036 7,459 0.73 0.48 
40% Perc 0.23 29,629 7,751 0.73 0.48 
45% Perc 0.24 31,267 8,035 0.74 0.49 
50% Perc 0.25 33,037 8,306 0.75 0.50 
55% Perc 0.26 34,966 8,563 0.76 0.51 
60% Perc 0.27 37,013 8,847 0.77 0.51 
65% Perc 0.28 39,341 9,142 0.77 0.52 
70% Perc 0.30 41,758 9,442 0.78 0.53 
75% Perc 0.31 44,932 9,762 0.79 0.54 
80% Perc 0.32 48,455 10,120 0.80 0.55 
85% Perc 0.34 53,762 10,548 0.81 0.56 
90% Perc 0.36 61,427 11,106 0.83 0.58 
95% Perc 0.40 77,879 11,833 0.85 0.60 
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Figure 7: Probability distribution of R= (CE - Cc) / (EE - EC) - subgroup 7 
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Table 8: Descriptive statistics of probability distribution - subgroup 8 
Name Ee - Ec 
=R mrvý Ce - Cc effect E effect C 
Minimum - 0.05 - 1,934,004 1,956 ! 0.54 0.17 Maximum 0.68 32,194,780 22,127 0.97 0.73 
Mean = 0.30 49,793 1 12,242 0.76 0.46 
Std Deviat 0.09 325,215 ! 2,647 0.06 0.07 
Variance 0.01 105,764,500,000 . 7,007,751 0.00 0.00 
Skewness- 0.00 97 0 0.02 ' 0.01 
Kurtosis =3 03 9,545.3 2 93 3.02 
Mode =0 27 20,859 12,184.0.66 0.37 
5% Pere. 0.65 0.33 
10 /o Perc 0.18 25 766 8,843 , 0.67 0.36 15% Perc 0 21 28,142 9,511 0.69 0.38 
20 °ßa Pe rc 0 22 30,081 10,048 0.70 0.39 
0.40 25% Perc 0.24 31,896 10,492 ; 0.71 
25 33 733 10,884 I 0.72 0.41 
', 
30% Pe rc 0.26t' 
35% Perc 0.26 
__35,528 
11,235 0 73 0.42 
40% Pe rc 0.28 37,265 11,562 0.73 0.43 
45% Perc 0.29 
.. _. 
39,018 11866 0.74 0.44 
4 
Perc 0.30 40,861 
55 
12,212 !0 75 0.45 
° Perc 0.31 42,859 12,561 ' 0.76 0.46 
60% Perc 0.32 44,928 12,902 0.77 0.47 
65% Perc 0.33 47,235 j 13,275 0.77 0.48 
70% Perc 0.35 49 698 13,624 0.78 0.49 
75% Perc 0.36 2,95 14,028 0 79 0.50 
80% Perc 0.38 57,061 t 14,472 0.80.0.51 
85% Perc 0.39 ; 62 324 14 973 0.811- 
, 
0.52 
90% Perc 0.42 70,671 15,651 ý. _ _.. 0.83.0.54 
95% Perc 0.45: 86.210 16,624 0.85 ' 0.56 
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Figure 8: Probability distribution of R= (CE - Cc) / (EE - Ec) - subgroup 8 
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Table 9: Descriptive statistics of probability distribution - subgroup 9 
Name Ee - Ec R Ce Cc effect E effect C Minimum - 0.18 1,253 970 - 
65 
- - - 
0.23 0.00 
Maximum 0.67 324,426 9,6J7 2 , 0.81 0.57 
Mean - 0.21 153,227 16,278 0.51 0.30 
Std Deviat 0.11 3,447,760 3,530. 0 08 0.08 
Variance 0.01 11,887,050,007,000 12,459,730 0.01 0.01 
Skewness - 0.01 85ý 0 0 02 0.01 
Kurtosis '=' _ ..... 2.96 
Mode = 
5% Perc 
10% Perc 
15% Perc 
20% Perc 
25% Perc 
30% Perc 
35% Perc 
40% Perc 
'45% Perc 
50°ßo Perc 
55% Perc 
60% Perc 
65% Perc 
70% Perc 
75% Perc 
80% Perc 
85% Perc 
90% Pert 
95% Perc 
0.13 
0.03 
0.07 
0.09 
51,353 
29,945 
ýý. 38,990 
43,778 
0.12 48,048 
0 13 52,221 
0.15 56,124 
0.17 .... ____. _ _ .... ý.... 60,166 
.. , ___. 0.18 " . 64,804 
0.20 69,441 
0.21 74,564 
0.22 79,487 
0.24 65,513 
0.25 9.. 461 
0.27 101,976 
0.29 113751 
0.30 129,637 
0.33 154,528 
0.35 
... . . _. 
196,576 
0.39 318,934 
12,219 0.41, 
. 
0.21 
__,. _ 
10,494 Q. 38ä 0.17 
11,745 0.41 i; 0.20 
12,633 ä__. 
.... _. 
0.43 
,... _ . 
0.22 
_. ý _.. 0.23 
13,905 0.46 0.25 
14,468 0.47 0.26 
14,933 0.48 0.27 
15,46i 'l 0.49 0.28 
15'm . 
50 0.29 
16277 0.51 0.30 
16,720 0.62 0.31 
_. __.. _..... 
17,157 0.53 
_. _ .. 
0.32 
17 
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19,221 0.58. 0.37 
19,916 0.59 0.38 
20,836 , 0.61 0.40 22,160 0.64 0.43 
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Figure 9: Probability distribution of R= (CE - CC) / (EE - Ec) - subgroup 9 
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Table 10: Descriptive statistics of probability distribution - ECMO study 
Name Et-Ec R Et Ec 
1 
Ct-Cc 
Minimum 0.01 16,949 0.44 0.19 6,271 
Maximum 0.54 2,214,339 0 85 0.58 22,597 
Mean = 0.27 56,757. 
_ ,.. _. 
0.66 s_. 0.39 13,868 
Std Deviat 0.07 33,675 . 0.05,0.05 2,110 
Variance 0.01 
.. __. _.. 
1,134,020, ä00 0.00 0.00 4,454,027 
: Skewness- 0.01 31 0.01 0 Q3 
__.. __ .... _. 
0 
Kurtosis = 3.05 1,821 3.02 3.0,2, 
_ 
3 
Mode =0 19 38,791 1 0.58 0.35 13,497 
5% Perc 0.15 32,351 0.57 1 0.31 10,397 
1O% Pere 0.18 35,939 0.59 0.33 
_ __ . __11.181 15% Pere 0.20 38,329 0.61 i 0.34 11,692 
11 20% Pere 0.21 40,357 0.62 0.35 12,104 
25% Pere 0.22 42.431 0.62 0 36 , 12,441 
30°fo Pere 0.23 44,238_ 0.63 
_ 
0.36 j 12,760 
35% Perc 0.24 45,961 0.64 1 0.37 13,051 
40% Pere 0.25 47,754 0.65 0.38 13,319 
45% Pere 0.26 49,543.0.65 0 38 13,585 
50% Pere 0.27 51,383 3 066 0.39 13,848 
55% Pere 0.28 53,459 0 67 0.40 14,122 
60% Pere 0.29 55,687 0 67 0.40 14,391 
65% Pere 0.30 50,23 4j 068 041 , 41 14,652 70°l° Pere 0.31 60,997 0.68 0,42 I 14, µW 955 4 
75°7° Pere 0.32 64,365 0 69 1 0.42 115,284 
80% Pere 0.33 68.154 j 0.70T- 0 43 15,663 
85% Pere 0.34 73.187 p 0.71 0 44 1 16,078 
90% Pere 0.36 81,462 0.72 
_0 
45 1,6,612 
95% Pere 0.38 95.137 ' 0.74 0.47 17,325 
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Figure 10: Probability distribution of R= (CE - C(') / (Ei; - E() - ECMO study 
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ECMO Study data tables 
Patient Survival w/o Admission Transport Readmission Post- Total costs Total costs 
Study no. severe costs costs costs discharge at one year 
disability costs 
1 1 7181.00 640.74 879.20 2446.20 10267.94 10404.20 
2 0 2071.50 0.00 0.00 0.00 2071.50 2233.35 
3 1 4345.00 0.00 0.00 1439.00 5784.00 6496.14 
4 1 14630.50 653.24 220.10 1202.60 16486.34 16630.17 
5 1 19765.50 640.74 592.50 2682.50 23088.74 23429.39 
6 0 2664.00 0.00 0.00 0.00 2664.00 2922.96 
7 1 5925.00 303.97 2567.50 4115.50 10344.47 11315.57 
8 1 14349.30 5262.97 659.40 2212.40 21824.67 21494.68 
9 0 23954.00 0.00 0.00 0.00 23954.00 24135.68 
10 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
11 1 9888.70 753.20 0.00 1236.00 11877.90 11562.23 
12 0 12357.00 459.67 0.00 0.00 12816.67 12831.81 
13 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
14 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
15 1 7033.60 298.14 1978.20 3570.70 10902.44 11224.68 
16 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
17 0 1281.50 627.05 0.00 0.00 1908.55 1940.92 
18 1 12189.50 640.74 0.00 1075.50 13905.74 14094.99 
19 1 5377.70 737.89 0.00 484.00 6599.59 7428.38 
20 0 12159.50 822.00 0.00 0.00 12981.50 12989.07 
21 0 10346.50 369.67 0.00 0.00 10716.17 10723.74 
22 0 1281.50 338.07 0.00 0.00 1619.57 1651.94 
23 0 13921.50 0.00 0.00 0.00 13921.50 16025.55 
24 1 3555.00 1126.49 879.80 1614.80 6296.29 6432.55 
25 0 1303.80 450.56 0.00 0.00 1754.36 1764.43 
26 1 7019.00 640.74 0.00 1749.00 9408.74 9469.30 
27 1 97086.40 1095.19 0.00 0.00 98181.59 93451.24 
28 0 25832.50 634.50 8887.50 10203.00 36670.00 36965.23 
29 0 1281.50 366.33 0.00 0.00 1647.83 1655.40 
30 0 6811.50 0.00 0.00 0.00 6811.50 7750.23 
31 0 1303.80 0.00 0.00 0.00 1303.80 1313.87 
32 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
33 0 1479.00 280.66 0.00 0.00 1759.66 1824.40 
34 1 3077.20 0.00 3160.00 4502.50 7579.70 7720.68 
35 1 6122.50 0.00 1580.00 3676.50 9799.00 10802.47 
36 1 7019.00 1190.19 440.20 1691.20 9900.39 9960.95 
37 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
38 1 8132.60 0.00 0.00 1501.50 9634.10 10006.69 
39 1 13482.40 1423.33 0.00 1452.00 16357.73 15901.92 
40 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
41 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
42 0 19411.50 5000.00 0.00 0.00 24411.50 24419.07 
43 1 12422.50 6694.94 0.00 1471.00 20588.44 20717.13 
44 1 14433.00 6732.58 0.00 3360.50 24526.08 24662.34 
45 1 3752.50 1811.05 0.00 1563.50 7127.05 7742.08 
198 
Patient Survival w/o Admission Transport Readmission Post- Total costs Total costs 
Study no. severe costs costs costs discharge at one year 
disability costs 
46 1 3297.00 0.00 879.20 3098.20 6395.20 6546.25 
47 0 1304.10 0.00 0.00 0.00 1304.10 1313.87 
48 1 16876.30 728.21 1320.60 4069.10 21673.61 21417.27 
49 0 2906.10 295.23 0.00 0.00 3201.33 3448.06 
50 1 11794.50 0.00 0.00 954.00 12748.50 12922.61 
51 1 5424.90 280.66 0.00 1024.50 6730.06 7281.78 
52 0 2071.50 0.00 0.00 0.00 2071.50 2233.35 
53 1 9108.70 815.68 0.00 1062.50 10986.88 10803.37 
54 1 9723.50 1267.23 0.00 2874.50 13865.23 13682.13 
55 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
56 0 1874.00 0.00 0.00 0.00 1874.00 2003.48 
57 1 6193.50 6693.27 0.00 1312.00 14198.77 14297.18 
58 1 11931.50 646.99 0.00 1408.50 13986.99 13819.03 
59 1 10395.30 12524.65 660.30 2033.80 24953.75 24886.50 
60 0 1304.10 0.00 0.00 0.00 1304.10 1313.87 
61 1 13188.00 0.00 220.10 1473.10 14661.10 15265.30 
62 1 37412.20 331.66 11652.50 14218.50 51962.36 52539.32 
63 0 45070.10 977.25 0.00 0.00 46047.35 46964.14 
64 1 8995.60 722.34 0.00 1393.50 11111.44 11770.38 
65 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
66 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
67 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
68 1 5201.90 1164.87 0.00 1790.00 8156.77 8286.69 
69 0 1874.00 403.80 0.00 0.00 2277.80 2407.28 
70 0 37475.00 814.83 0.00 0.00 38289.83 39198.23 
71 1 12800.70 1032.25 0.00 1598.50 15431.45 15042.13 
72 1 24172.90 1534.81 1077 5.00 13238.00 38945.71 38644.77 
73 0 1281.50 342.60 0.00 0.00 1624.10 1656.47 
74 1 10017.00 640.74 197.50 1088.50 11746.24 11852.22 
75 0 2071.50 0.00 0.00 0.00 2071.50 2233.35 
76 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
77 1 17664.00 922.25 0.00 2645.50 21231.75 21352.87 
78 1 5816.70 298.14 0.00 1610.00 7724.84 8574.37 
79 1 2962.50 765.68 0.00 999.50 4727.68 4841.23 
80 1 5495.00 0.00 0.00 2233.00 7728.00 7979.75 
81 1 18885.00 280.66 879.20 2501.70 21667.36 21140.77 
82 1 80777.50 0.00 0.00 1868.00 82645.50 95884.83 
83 0 1281.50 344.87 0.00 0.00 1626.37 1658.74 
84 1 17988.00 280.66 0.00 1106.50 19375.16 19647.68 
85 0 6517.50 0.00 2567.50 4791.00 11308.50 12376.71 
86 1 10392.90 709.47 0.00 1063.00 12165.37 12100.52 
87 1 4740.00 280.66 2765.00 4343.50 9364.16 10141.04 
88 1 9191.50 634.50 0.00 1714.50 11540.50 11684.33 
89 1 3383.00 634.27 1318.80 2768.80 6786.07 7080.99 
90 1 3580.50 359.34 0.00 2092.00 6031.84 5937.53 
91 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
92 1 12645.50 4444.22 0.00 672.50 17762.22 17667.91 
199 
Patient Survival w/o Admission Transport Readmission Post- Total costs Total costs 
Study no. severe costs costs costs discharge at one year 
disability costs 
93 0 13662.60 6955.82 6278.60 6278.60 26897.02 26563.97 
94 1 12110.40 856.17 0.00 548.00 13514.57 14736.63 
95 1 7967.20 1280.03 660.30 1741.30 10988.53 10921.17 
96 1 3516.80 0.00 0.00 1096.00 4612.80 4773.92 
97 0 4046.50 0.00 0.00 0.00 4046.50 4532.05 
98 0 13972.50 4099.00 0.00 0.00 18071.50 18079.07 
99 0 24617.50 0.00 0.00 0.00 24617.50 24685.63 
100 1 8679.10 418.63 0.00 2483.50 11581.23 11589.62 
101 1 8690.00 0.00 0.00 954.50 9644.50 11068.78 
102 1 12817.50 499.67 0.00 921.00 14238.17 14382.00 
103 0 3454.00 492.08 0.00 0.00 3946.08 4334.52 
104 0 45710.00 904.79 0.00 0.00 46614.79 47391.67 
105 1 15634.40 709.47 1758.40 2982.90 19326.77 19254.35 
106 1 3736.60 0.00 1318.80 2577.80 6314.40 6485.59 
107 1 7110.00 0.00 3297.30 4281.80 11391.80 12557.12 
108 1 27215.00 6327.55 0.00 1452.00 34994.55 35342.77 
109 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
110 1 34697.30 1203.26 1758.40 3812.90 39713.46 39561.05 
111 1 17628.50 646.99 0.00 1688.50 19963.99 20153.24 
112 0 41167.50 4069.99 0.00 0.00 45237.49 45245.06 
113 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
114 0 1303.80 0.00 0.00 0.00 1303.80 1313.87 
115 0 11263.00 709.36 0.00 0.00 11972.36 12154.04 
116 1 10110.80 0.00 0.00 1001.50 11112.30 11575.52 
117 0 30289.50 0.00 0.00 0.00 30289.50 30297.07 
118 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
119 0 66270.30 1487.03 0.00 0.00 67757.33 64814.42 
120 1 11217.60 1167.10 0.00 1030.50 13415.20 13378.56 
121 0 47310.00 906.61 0.00 0.00 48216.61 48807.07 
122 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
123 1 12360.60 1886.42 0.00 1043.50 15290.52 15276.04 
124 1 3425.30 562.45 219.80 1205.30 5193.05 5675.54 
125 0 28836.00 1283.64 0.00 0.00 30119.64 30210.48 
126 0 1281.50 5000.00 0.00 0.00 6281.50 6313.87 
127 0 1303.80 0.00 0.00 0.00 1303.80 1313.87 
128 1 9768.10 878.82 2417.80 4480.80 15127.72 14900.02 
129 1 3357.50 0.00 0.00 1234.50 4592.00 5142,29 
130 1 5537.30 790.69 0.00 1169.00 7496.99 7431.32 
131 1 52031.40 1138.23 1538.60 5037.10 58206.73 57862.26 
132 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
133 0 1303.80 280.66 0.00 0.00 1584.46 1594.53 
134 1 2765.00 0.00 879.20 1988.20 4753.20 4859.18 
135 0 2466.50 516.95 0.00 0.00 2983.45 3210.04 
136 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
137 0 10687.60 280.66 0.00 0.00 10968.26 12693.64 
138 0 18118.20 653.24 0.00 0.00 18771.44 18331.18 
139 1 7216.50 6096.59 0.00 951.50 14264.59 14332.72 
200 
Patient Survival w/o Admission Transport Readmission Post- Total costs Total costs 
Study no. severe costs costs costs discharge at one year 
disability costs 
140 1 10270.00 286.49 0.00 1154.00 11710.49 13393.73 
141 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
142 1 9207.00 568.99 0.00 2264.00 12039.99 11790.81 
143 1 13558.50 765.61 0.00 1846.50 16170.61 16156.02 
144 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
145 1 6912.50 280.66 220.10 2454.60 9647.76 10780.71 
146 1 32871.10 667.30 197.50 1541.50 35079.90 34996.66 
147 1 4587.70 347.69 0.00 1972.50 6907.89 7607.20 
148 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
149 0 1676.50 902.41 0.00 0.00 2578.91 2601.62 
150 1 8295.00 0.00 1320.60 3052.60 1134 7.60 12707.14 
151 1 22996.10 810.69 4615.80 7629.30 31436.09 30974.35 
152 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
153 1 16392.10 709.65 0.00 2001.50 19103.25 18920.97 
154 0 60107.50 6337.04 0.00 0.00 66444.54 66830.61 
155 0 3651.50 0.00 0.00 0.00 3651.50 4072.31 
156 0 1479.00 0.00 0.00 0.00 1479.00 1543.74 
157 1 9464.30 0.00 1320.60 3813.10 13277.40 13697.51 
158 1 18780.10 412.10 0.00 1513.00 20705.20 20563.13 
159 1 12027.50 646.99 0.00 968.50 13642.99 13756.54 
160 1 4345.00 1002.24 0.00 1419.50 6766.74 7478.88 
161 0 55671.50 0.00 0.00 0.00 55671.50 55679.07 
162 1 15811.70 790.69 0.00 2060.50 18662.89 18618.24 
163 1 13627.50 0.00 5135.00 7426.50 21054.00 23287.53 
164 1 2962.50 0.00 592.50 1391.00 4353.50 4839.05 
165 1 8006.50 634.50 0.00 1267.00 9908.00 10006.41 
166 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
167 0 25245.50 8444.33 0.00 0.00 33689.83 33712.54 
168 1 10143.50 665.73 0.00 688.00 11497.23 11747.04 
169 0 2269.00 283.57 0.00 0.00 2552.57 2746.79 
170 1 27736.50 659.90 0.00 813.50 29209.90 29717.09 
171 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
172 1 2567.50 0.00 395.00 1711.00 4278.50 4699.31 
173 1 11652.50 280.66 0.00 2317.50 14250.66 16160.49 
174 1 6547.10 878.82 0.00 750.00 8175.92 8125.80 
175 1 9857.70 6734.82 0.00 767.00 17359.52 17247.29 
176 1 13410.00 280.66 0.00 1047.50 14738.16 14904.70 
177 0 55020.30 2951.77 0.00 0.00 57972.07 57955.13 
178 0 1303.80 0.00 0.00 0.00 1303.80 1313.87 
179 1 13379.10 306.89 2417.80 3670.80 17356.79 18459.50 
180 0 1281.50 0.00 0.00 0.00 1281.50 1313.87 
181 0 13901.50 0.00 0.00 0.00 13901.50 14045.33 
182 0 3256.50 343.31 0.00 0.00 3599.81 3955.88 
183 0 1281.50 0.00 0.00 0.00 1281.50 1289.07 
184 0 1281.50 359.67 0.00 0.00 1641.17 1648.74 
191 0 1303.80 0.00 0.00 0.00 1303.80 1313.87 
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SUMMARY 
The statistic of interest in most health economic evaluations is the incremental cost-effectiveness ratio. Since 
the variance of a ratio estimator is intractable, the health economics literature has suggested a number of 
alternative approaches to estimating confidence intervals for the cost-effectiveness ratio. In this paper, 
Monte Carlo simulation techniques are employed to address the question of which of the proposed methods 
is most appropriate. By repeatedly sampling from a known distribution and applying the different methods 
of confidence interval estimation, it is possible to calculate the coverage properties of each method to see if 
these correspond to the chosen confidence level. As the results of a single Monte Carlo experiment would be 
valid only for that particular set of circumstances, a series of experiments was conducted in order to examine 
the performance of the different methods under a variety of conditions relating to the sample size, the 
coefficient of variation of the numerator and denominator of the ratio, and the covariance between costs and 
effects in the underlying data. Response surface analysis was used to analyse the results and substantial 
differences between the different methods of confidence interval estimation were identified. The methods, 
both parametric and non-parametric, which assume a normal sampling distribution performed poorly, as 
did the approach based on simply combining the separate intervals on costs and effects. The choice of 
method for confidence interval estimation can lead to large differences in the estimated confidence limits for 
cost-effectiveness ratios. The importance of such differences is an empirical question and will depend to 
a large extent on the role of hypothesis testing in economic appraisal. However, where it is suspected that the 
sampling distribution is skewed, normal approximation methods produce particularly poor results and 
should be avoided. Copyright © 1999 John Wiley & Sons, Ltd. 
1. INTRODUCTION 
The purpose of the economic appraisal of health care interventions is to inform public health 
decision makers of the relative value for money (or cost-effectiveness) of funding alternative 
interventions. Where the intervention in question generates improved health outcomes for 
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patients, but at increased overall cost, the appropriate summary measure of cost-effectiveness is 
the incremental cost-effectiveness ratio (ICER). The ICER measures the additional cost of one 
intervention over another (say treatment A and treatment B) per unit difference in effectiveness. 
Where data have been obtained from two samples of patients receiving the different treatments, 
the ICER is calculated as in equation (1): 
CA - CAC 
,, 
k- 
-EB-äE 
(1) 
where CA and EA are the mean costs and effects for the sample receiving treatment A and C and 
Ea are the mean costs and effects for the sample receiving treatment B. 
When sample data on costs and effects are available it is natural to consider the use of 
statistical techniques to calculate confidence intervals around such point estimates. Unfortunate- 
ly, the calculation of confidence intervals for a ratio is far from straightforward since the 
probability of obtaining a zero or near zero value on the denominator of the ratio is non- 
negligible, which suggests that the moments of the ICER may be undefined. In practice, this is 
a very real problem since it is common for clinical trials to be designed to detect the smallest 
meaningful clinical difference between treatments and is likely to lead to a large number of studies 
showing differences in treatment effects which are close to zero. ' Clearly, this presents a problem 
for the use of standard parametric statistical methods. Recent research has focused on parametric 
approximations to the confidence interval for the ICER. 2-5 In addition, several commentators 
have also proposed the non-parametric approach of bootstrapping as a method for estimating 
confidence intervals, ' 2.6,7 and this approach has been successfully demonstrated using clinical 
trial data. " In the face of all the possible methods, one question quickly surfaces. Which of these 
methods is the most appropriate? 
In this paper we present the results of a Monte Carlo simulation exercise designed to evaluate 
the alternative-methods of calculating confidence intervals for the ICER statistic, under a variety 
of different conditions. The experiments require a massive number of iterations which, even a few 
years ago, would have put this exercise beyond our reach, but which is now possible thanks to the 
increasing power of personal computers. 
2. METHODS 
This section is split into three. The first two parts describe in some detail the alternative 
parametric and non-parametric methods that have been proposed for estimating the confidence 
limits for the ICER. The third part of this section presents the overall Monte Carlo simulation 
experiment designed to evaluate each of the methods. 
2.1. Parametric approaches to estimating the ICER confidence interval 
Three main methods, based on the parametric approach for calculating confidence intervals for 
an ICER, have recently appeared in the literature. " Each of these methods is explored in turn, 
highlighting the assumptions on which it is based. 
2.1.1. The confidence box approach 
A number of commentators have advocated the cost-effectiveness plane (CE plane) for presenting 
the results of economic evaluation and for aiding policy decisions. 9"0 O'Brien and colleagues 
Copyright © 1999 John Wiley & Sons, Ltd. Statist. Med. 1!, 3245-3262 (1999) 
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Figure I. Confidence limits on the cost-effectiveness plane and the `confidence box' approach to estimating confidence 
limits for the ICER 
showed how the CE plane could also be used to present the confidence limits for the estimate of 
incremental cost-effectiveness. 2 Figure 1, which is based on the representation by O'Brien and 
colleagues, shows the results of a hypothetical prospective economic evaluation on the CE plane. 
The difference in effect between two therapies is shown on the horizontal axis with mean effect 
difference AE and upper and lower confidence limits for the effect difference (AE' and AE`) 
represented by the horizontal `I' bar. Similarly, the difference in cost between two therapies is 
shown on the vertical axis with mean cost difference AC, and upper and lower confidence limits 
for the cost difference (AC' and iCL) represented by the vertical 'I' bar. These 'I' bars intersect at 
point (DE, AC), hence the ray that connects this point of intersection to the origin has a slope 
equal to the value of the ICER. O'Brien and colleagues argue that combining the limits of the 
confidence intervals for costs and effects separately gives natural best and worst case limits on the 
ratio; that is, the upper limit of the cost difference over the lower limit of the effect difference 
(AC"/4E') gives the highest values of the ratio (worst case) and the lower limit of costs divided by 
the upper limit of effects (, &C'/AE) gives the lowest (best) value of the ratio. 
2.1.2. The Taylor series approximation 
Rather than use these extreme limits, which are likely to overestimate the true interval, O'Brien 
and colleagues argue that it is possible to use the Taylor series approximation of the variance of 
a function of two random variables to estimate the variance of a ratio. ' The advantage of this 
method is that it accounts for the covariance between the numerator and denominator. Having 
approximated the variance of the ICER statistic in this way, assuming the sampling distribution 
of the ICER to be normal allows the confidence interval to be estimated in the traditional manner. 
The Taylor approximation shows that where y is a function of two random variables x1 and x2, 
the variance of y can be expressed in terms of the partial derivatives of y with respect to xI and x2, 
weighted by the variances and covariance of x1 and x2. The Taylor series formula is 
(3)2 i 
var(y) zi var(xj) + 
ay 
var(xz) + 2( 
ay 
1) _) 
cov(xs, x=). (2) 
Copyright © 1999 John Wiley & Sons, Ltd. Statam. Med. 1!, 3245-3262 (1999) 
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Equation (2) can now be solved for the case of the ICER presented in equation (1) by substituting 
AC for xl and zE for x2. * Hence equation (3) gives the Taylor series approximation of the 
variance of the ratio estimator, using the sample estimates of the means and variances (since by 
definition, the population values cannot be observed): 
i 
var(fZ) xz var(dC) + 
e-R4 
var(0 -23 cov(i , 
dE). (3) 
Factoring Rz = OC2/DE2 from the right-hand side simplifies (3) to 
var(R) ., 
Rz rvar(AC) + var(eE) _2 
cov(AC, AE)I 
Noting that the coefficient of variation for a random variable x is defined cv(x) = Jvar(x)/z and 
that the correlation coefficient between two random variables x and y is defined 
px,, = cov(x, y)/, / var(x) var(y)) further simplifies the exposition: 
var(ft) -- kz [cv(AC)2 + cv(4 2- 2pcv(61C)cv(4E)]. (4) 
Employing standard parametric assumptions gives the confidence interval as 
(h - Z, /2 -, 
/var(k), E+ za/2 Jvar(R)) 
where z812 = qb - I[1 - a/2], 0' 
1 is the inverse of the cumulative distribution of the standard 
normal function, and 100(1 - a) per cent is the confidence level. 
O'Brien and colleagues recognize that although the assumption of a normal distribution may 
be justified in the case of large samples, it is unlikely that the distribution of a ratio will follow 
a well-behaved distribution in general. 2 However, even if samples are large, the distribution is 
likely to be skewed where the coefficient of variation of the denominator of the ICER (effect 
difference) is high. ' 
2.1.3. Fieller's method 
An alternative method of calculating confidence intervals around ratios has been described by 
Fieller. " This approach has been advocated for use in calculating confidence intervals around 
ICERs by both Willan and O'Brien3 and Chaudhary and Stearns. 5 The method is described in 
general terms by Cochran. 12 
The advantage of Fieller's method over the Taylor series expansion is that it takes into account 
the skew of the ratio estimator. The method assumes that the numerator and denominator of the 
ratio follow a joint normal distribution function such that (in the case of the ICER) AC - RAE is 
normally distributed. Hence, dividing through by the standard deviation equation (5) follows the 
standard normal distribution: 
AC - RAE N(0,1). (5) 
. 
J{var(iC) + R2 var(AE) - 2R cov(AC, AE)) 
' The partial derivatives of the ICER with respect to AC and AE are 1/AE -and AC/sE3, respectively. 
Copyright © 1999 John Wiley & Sons, Ltd Statist. Med. It 3245-3262 (1999) 
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Setting this expression equal to z212 and rearranging gives the following quadratic equation in 
R (using the simplified notation introduced in equation (4)): 
R2[1 - z;, zcv(OL)2] - 2Rf[1 - zCO pcv(0E)co(0C)] + IA2[1 - z, 2cu(AC)] =0 (6) 
where R is defined from equation (1). 
Solving equation (6) for R using the standard quadratic formula* gives the confidence inter- 
val as 
R 
rl 
- Za/2 pcv(eC)CV(AE)1 
L1- ZQ CV(AE)2 J 
±ZQ, 
Z 
RLý/{CV(AC + CV(AE)2 - 
2ý0(eC)CV(A 'E)- 
Where the sampling distribution of the ICER is skewed, this confidence interval will not be 
symmetrically positioned around the point estimate. This method has been criticized on the 
grounds that the assumption of joint normality may be hard to justify where sample sizes are 
small. 5 
2.2. Bootstrap approaches to estimating the ICER confidence interval 
Given the unknown nature of the ICER's sampling distribution, there is reason to be cautious of 
the parametric approaches to confidence interval estimation. A number of commentators have 
suggested the non-parametric approach of bootstrapping as a possible method of estimating 
confidence limits for the ICER. 1.2.6.7 The advantage of such intervals is that they do not depend 
on parametric assumptions concerning the sampling distribution of the ICER. 
The bootstrap approach for the simple one sample case is straightforward. Suppose a particu- 
lar population has a real but unobserved probability distribution F from which a random sample 
x of n observations is taken, and the statistic of interest s(x) is calculated. The concern of 
inferential statistics is to make statements about the population parameter 0 based on the sample 
drawn from that population. In the `bootstrap world', the observed random sample x is treated as 
the empirical estimate of F by weighting each observation in x by the probability l/n. Successive 
random samples of size n are then drawn from x with replacements to give the bootstrap samples 
(re-samples from the original sample). The statistic of interest is calculated for each of these 
samples and these bootstrap replicates of the original statistic make up the empirical estimate of 
the sampling distribution for that statistic. This estimated sampling distribution can be used in 
a variety of ways to construct confidence intervals. 
In principle, the bootstrap estimate of the ICER sampling distribution can be obtained in 
a very similar way to that of the simple one sample case. However, since the ICER is estimated on 
the basis of four estimators from two samples (equation (1)) care must be taken to bootstrap each 
sample appropriately. For data structures which are more complicated than a one sample 
structure, Efron and Tibshirani advocate that the bootstrap mechanism for the observed data 
The solution formula for a quadratic equation of the form ax2 + bx +c-0 is -b± (J(b' - 4ac))/2a. Clearly, sampling from x without replacement would simply yield x itself. Hence it is the sampling with replacement 
which provides the variability through the chance that some observations will appear in the bootstrap sample more than 
once while others will be omitted altogether. 
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Figure 2. Bootstrap estimation of the sampling distribution of the ICER calculated from clinical trial data (overlaid is 
a normal distribution with the same mean and variance) 
mirror the mechanism by which those original data were obtained. '-' In the case of the IC R, 
where data on resource use and outcome exists for two groups of patients of size n, and 
nº, receiving treatments A and B, respectively, this will involve a three-stage process: 
1. Sample with replacement n, cost/effect pairs from the sample of patients who received 
treatment A and calculate the bootstrap estimates CZ and F* for the bootstrap 
sample. 
2. Sample with replacement nºº cost/effect pairs from the sample of patients receiving treatment 
B and calculate the bootstrap estimates C, *, * and £; for the bootstrap sample. 
3. Calculate the bootstrap replicate of the ICER given by the equation 
R*=C"-C"-AC* (7) 
A*-ý, *, 
-0E*. 
Repeating this three-stage process many times gives a vector of bootstrap estimates, which is an 
empirical estimate of the sampling distribution of the ICER statistic. For example, the histogram 
in Figure 2 shows the estimated sampling distribution from a previously reported study which 
used the bootstrap to estimate the sampling distribution of the ICER calculated from data 
generated by an economic evaluation conducted alongside a clinical trial. " 
Once the sampling distribution of the ICER has been estimated in this wary, several 
approaches exist to estimate confidence limits using the bootstrap estimate of the sampling 
distribution. 
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2.2.1. Normal approximation 
One method for confidence interval estimation is to take the bootstrap estimate of standard error, 
given by 
R*b)2} (8) 
tl b=1 ll 
(where B is the total number of bootstrap replications) and assume that the sampling distribution 
of the statistic is normal. The resulting 100(1 - a) per cent confidence interval is 
(A - zQ12 , 
fi +Zog/26" 
While comfortingly familiar, this method may be seriously misleading if the sampling distribution 
is not normal. It ignores the wealth of information in the bootstrap estimate of the sampling 
distribution, which, as can be seen clearly from Figure 2, may be far from normal. 
2.2.2. Percentile 
The percentile method avoids this problem by making direct use of the empirical sampling 
distribution. The 1O0(a/2) and 100(1 - a/2) percentile values of the bootstrap sampling 
distribu- 
tion estimate are used as the upper and lower confidence limits for the ICER. The attraction of 
this method is its simplicity and its avoidance of the assumption of normality for the ICER. 
However, it has received considerable criticism from some commentators; for example, Hall 
(reference 14, p. 36) describes the percentile method as equivalent to ` ... 
looking up the wrong 
statistical tables backwards'. " That is, skewed estimation can cause trouble for the percentile 
method. In particular, in this context, the percentile method assumes that the bootstrap replicates 
of the ICER are unbiased, whereas it is known that ratio estimators are biased and that bootstrap 
replicates will magnify the bias of the sample estimate. ' 5 
2.2.3. Bias-corrected and accelerated 
Efronlb suggests a modification of the percentile method, which seeks to adjust for the bias and 
skew of the sampling distribution. This is the bias-corrected and accelerated (BCa) percentile 
method, which involves algebraic adjustments to the percentiles selected to serve as the confi- 
dence interval endpoints. The adjusted percentiles are given by 
lr + Zs/2 
1 
Of + Z., 2)) 
2+Z(1--12) 
GC2=ý ý-}- ý9ý 
1 
-Q(1+z(1-. 120 
where b(. ) is the standard normal cumulative distribution function and z. is the 100a percentile 
point of the standard normal distribution. Two adjustments to the percentiles are incorporated 
into equation (9): 1 adjusts the sampling distribution for the bias of the estimator, while a adjusts 
for the skew of the sampling distribution. Setting B-0 yields the adjustment for bias on the 
percentiles chosen to serve as endpoints, and is equivalent to the bias-corrected method 
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advocated by Chaudhary and Stearn: ' 
al = 4)(21 + z«12) 
«z = «(2i + Z(1-a/2))" (1O) 
This bias correction, i, is given by 1= c -1(Q) where Q is the proportion of bootstrap replicates 
which are less than the sample estimate, R. Therefore, if the bootstrap sampling distribution has 
median R, Q=0.5 which gives i=0 and (in the absence of a skew adjustment) the percentiles 
from equation (10) correspond to those from the straightforward percentile method. However, 
where the sampling distribution is not centred on Ra correction is made for this bias. Notice that 
the non-linear relationship between the z-score and its probability results in the percentile end 
points being shifted at unequal rates. It is also worth noting that the bias correction adjustment of 
the BCa method, while not employing distributional assumptions concerning the sampling 
distribution of the ICER itself, does make use of parametric assumptions concerning the 
distribution of the observed bias. This reliance on parametric assumptions has been cited as 
a potential weakness of the BCa method. " 
The acceleration constant adjusts for the skew of the sampling distribution. Efron and 
Tibshirani suggest using a jack-knife estimate for &: 13 
U 1) 
where R! `* is the jack-knife replicate of the ICER with the ith observation removed, R** =ER'*ln 
for i=I to n and n= nc + nT. In terms of the adjustments to the percentiles given in equation (9), 
in the absence of a bias correction adjustment, the skew adjustment is given by 
1aý2 
a1 - ý(1 
- &zýyz (12) 
z(l 
_ Q/z) 
a2 - ý(1 - &z ti -adz) 
Equation (11) shows that if the sampling distribution is symmetric, ä=0 and equation (12) shows 
that no adjustment to the percentile interval endpoints is made. 
2.2.4. Parametric bootstrap 
Efron and Tibshirani outline a simulation-based method of confidence interval estimation that 
they refer to as a parametric bootstrap approach. 13 Notice that from equation (1), the difference 
in costs on the numerator and the difference in effects on the denominator of the ICER are both 
simply the difference between two normally distributed variables, the two sample means* The 
difference of two means is also normally distributed. The parametric bootstrap approach involves 
using this property of the distribution of the numerator and denominator in combination with the 
observed means, variance and covariance to estimate the parameters of the sampling distribution 
of the cost and effect differences. Sampling from each of these two distributions, while allowing for 
* They are normally distributed if the sample sizes are large enough to invoke the central limit theorem or if both costa 
and effects are normally distributed. 
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the estimated covariance between them, gives an estimate of the ICER. Repeating this process 
many times generates an empirical estimate of the sampling distribution of the ICER. The 
100(a/2) and 100(1 - a/2) percentiles of this estimated distribution are used as estimates for the 
upper and lower limits of the confidence interval, as with the percentile method. 
2.3. The Monte Carlo simulation experiments 
A simulation experiment was designed to test the coverage properties of each method for 
calculating confidence intervals in terms of the percentage number of times the true parameter 
falls outside the interval. Recall that a precise 100(1 - a) per cent confidence interval will contain 
the true population parameter 100(1 - a) per cent of the time in repeated sampling. Therefore, the 
expectation is that in 100a per cent of samples, the true population parameter lies outside of the 
interval. In deciding the levels of power and significance to accept, analysts trade off between type 
I and type II errors. If ä, the observed proportion of Monte Carlo trials where the true population 
parameter lies outside of the interval, is greater than a, too many type I errors are committed. If 
ä is less than a, too many type II errors are committed. Clearly, if an analyst has specified an 
acceptable rate of error in advance, the method employed should deliver that chosen rate of error. 
The Monte Carlo experiments employed the same population parameter values for the average 
costs and average effects of two hypothetical treatments A and B as those used in the experiments 
conducted by Wakker and Klaassen ` The population mean cost for the group receiving 
treatment A was set at 40,000 and for group B was set at 30,000; the population mean effects for 
groups A and B were set as 60 and 50, respectively. Hence the population value of the ICER can 
be calculated as 
R- 
CA - CB 40,000 - 30,000 10,000 - 1000. (13) EA - EB 60 - 50 10 
However, in the experiments conducted by Wakker and Klaassen, the standard deviations 
specified for the population parameters were unrealistically low. ` Recall that the coefficient of 
variation for a random variable x is defined as cv(x) = 
ý/var(x)/z. Employing the standard 
deviations and population values specified by Wakker and Klaassen' suggests that the average 
observed coefficient of variation on the numerator of the ratio (the difference in costs) in their 
simulation experiments was 0.12, while the average observed coefficient of variation of the 
denominator (effect difference) was approximately 0.02. Low coefficients of variation such as these 
are likely to give a sampling distribution for the ICER that is very close to a normal sampling 
distribution. -' However, we believe this is unrealistic and that many economic evaluations will 
have much higher coefficients of variation on both the numerator and denominator of the ratio 
leading to sampling distributions which are significantly skewed. For example, the coefficients of 
variation for the original data on which Figure 2 is based were 0.55 for the numerator and 0.27 for 
the denominator. As Figure 2 shows, the estimated sampling distribution was far from normal. 
Hence the standard deviations of the individual population parameters employed in the Monte 
Carlo experiments were set such that they generated a range of specified levels of coefficient of 
variation in the numerator and denominator (details of these calculations are given in the 
Appendix). 
The problem with a single Monte Carlo experiment is that it will be valid only for the chosen 
parameters and conditions set in that experiment. Hence we designed a series of experiments 
which systematically varied the underlying conditions most crucial to the shape of the ICER 
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Table I. Overall performance of the different methods across the 480 experiments 
Confidence 
interval 
Lower 
alpha 
Upper 
alpha 
Overall 
alpha 
Low 
error 
Upper 
error 
Overall 
error 
Taylor 0.0051 0.0615 0.0665 -0.0199 0.0365 0.0165 
Fieller 0.0205 0.0139 0.0524 -0.0045 0.0069 0.0024 Confidence box 0.0019 0.0047 0.0066 -0.0231 -0.0203 -0.0434 Norm approx 0.0047 0-0507 0-0554 -0-0203 0.0257 0-0054 Percentile 0.0185 0.0376 0.0561 -0.0066 0.0216 0.0061 BCa 0.0229 0.0364 00593 -0.0021 0-0114 0.0093 BC *0.0252 0-0416 0.0668 *0.0002 0.0166 0-0168 
Paraboot 0-0155 0.0342 *0.0497 -0.0095 0.0092 *-0.0003 
* Non-significant at t-ratio < 2, employing an estimated standard error of a proportion of 
se(p) ={p(1 - p)/n} = 0.0007 (for lower/upper alpha/error) and 0.0010 (for overall alpha/error) 
sampling distribution. Five different correlation coefficients for the covariance between the costs 
and effects in the two groups were set: -0.90; -045; 0; 0.45, and 0.90. Coefficients of variation 
for the numerator and denominator were independently specified as 10,20,30 and 40 per cent. Six 
sample sizes were tested: 10; 30; 50; 60; 80, and 100. Population cost and effect data are rarely 
normally distributed; in particular, cost data is often significantly skewed. Hence, we set the 
underlying cost and effect data for groups A and B generated in the Monte Carlo experiments to 
be log-normally distributed. 
Each experiment involved taking a random sample of values from one of the specified 
populations described above. On the basis of the values obtained in these samples, confidence 
intervals were, calculated by each of the seven methods described in Sections 2.1 and 2.2. In 
addition, the straightforward bias-corrected (BC) bootstrap interval, as employed by Chaudhary 
and Stearns, 5 was estimated by simply ignoring the accelerator adjustment described in Section 
2.2.3. The estimated intervals were then compared to the true ICER from equation (13). Where 
the true value lay outside of the calculated interval, this result was recorded. This process was 
repeated 1000 times for each experiment. Hence the number of times the true ICER lay outside 
the interval divided by the 1000 simulations was the estimated alpha level for that experiment. 
The upper alpha level recorded the number of times the true ICER lay above the interval, the 
lower alpha recorded the number of times the true ICER lay below the interval, and the overall 
alpha was the addition of the upper and lower alphas. Varying all of the conditions above 
represents 480 different experiments (5 correlation coefficients x4 coefficients of variation for the 
numerator x4 coefficients of variation for the denominator x6 sample sizes) for which eight 
confidence intervals were calculated, giving a total of 3840 data points. 
3. RESULTS 
The overall results across the 480 experiments are presented in Table I. For each of the eight 
methods the estimated upper, lower and overall alpha rates are shown. To aid interpretation 
`error rates' are also shown. These are simply the value of (d - a), the estimated value of alpha less the nominal value of alpha chosen for the experiments. The nominal value of alpha appropriate for the upper and lower results is 0.025 and for the overall results is 0.05. Each of the estimated 
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alpha/error rates was tested for significance using the binomial approximation for the standard 
error of a proportion. * All were significantly different from the nominal levels except for the lower 
estimate of the BC bootstrap method and the overall estimate for the parametric bootstrap 
method. 
Care must be taken when interpreting the results of the overall error values. Systematic 
overestimation in one tail of the distribution combined with underestimation in the other tail can 
lead to a small overall error generated by large upper and lower errors of opposite sign. This effect 
is most noticeable in the parametric bootstrap method where the overall alpha is not significantly 
different from the nominal alpha level. However, it is clear that this is a result of the errors in the 
upper and lower alpha values cancelling each other out. Similar, although not so dramatic, effects 
are also apparent in the results for the Fieller and Taylor series methods and the normal 
approximation, percentile and BCa bootstrap methods. 
On the basis of the results from Table 1, Fieller's method appears to be performing most 
consistently across experiments, since it has the lowest upper error, the second lowest lower error 
and the lowest overall error. The BCa and parametric bootstrap performing best of the non- 
parametric methods and also outperforming the Taylor method and the box approach. However, 
since these results are based on summing across the 480 separate experiments, the results 
presented in Table I could potentially mask underlying variation in the estimated errors between 
experiments if overestimates in some experiments cancel out with underestimates in other 
experiments. These variations may be systematically related to experimental factors, which would 
have significant practical importance. 
In order to analyse the effect of these experimental factors on the overall accuracy of the eight 
confidence interval methods, a technique known as response surface analysis was used. ` "' This 
is a technique based on simple OLS regression employing dummy variables for each of the 
methods. Since the technique requires a single dependent variable we constructed a performance 
index based on the upper alpha value, defined as -1ä° - aut. The negative sign was included for 
interpretative purposes - the greater the number, the better the performance. 
The upper alpha 
value was chosen partly due to the problem with the overall alpha value detailed above, but 
mainly due to the fact that economic analysts are more interested in deciding whether an 
observed ICER is below some threshold value used for decision making and might therefore be 
more interested in the upper alpha value being close to its chosen nominal level. ' 
The results of the response surface analysis are presented in Table H. The reference interval 
chosen was the Fieller method since it seemed to perform best from the results presented in Table 
1. The natural log of the sample size was chosen as an explanatory variable since it was 
hypothesized that performance would improve with sample size asymptotically to some limit. 
The seven confidence interval dummies are presented on separate rows, with the first row being 
the reference (Fieller) interval. The majority of the coefficients were significant at the standard 
levels, indicating that there are important differences between the Fieller interval and other 
methods across the different experiments. 
The key to interpreting the results of the analysis lies in the sign of the coefficient, positive 
coefficients indicate an improvement in performance relative to Fieller's method for that variable 
and negative coefficients indicate worsening performance relative to the Fieller method. However, 
* The binomial approximation for the standard error of a proportion pis given by se(p) - V{p(1 - p)/n} where n is the 
sample size. 
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Table II. Results of the response surface analysis: estimated coetºicients* 
Dummy variables Intercept Interactions 
Log of Coefficient of Coefficient of Correlation 
sample size variation for variation for 
numerator denominator 
Ref(Fieller) -0.02171 0.00351 -0.01061 0.0108t 0.00131 Taylor -0.0159 0.00271 0.0433 -0.1362t 0.01591 Confidence box 0.00431 -0.00411 0.0088t -0.0123' -0.00891 Norm approx -0.03381 0.00521 0.0299~ -0.04871 0.01421 Percentile -0.02571 0-00511 -0.0134t 0.01781 0.00311 BCa -0.0198' 0.0044? -0.0101t 0.00791 0.0012+ BC -0.03481 0.0069t -0.02001 0.0192? 0.0056 Para boot -0.0147t 0.00311 -0.0024 0.0056 0.0001 
* Adjusted RZ for the model = 0.74, n= 3840 
t- ratio >2 
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Figure 3. Predicted effect of sample size on the performance variable using results of the response surface analysis 
(coefficients of variation = 0.2, correlation - 0). Performance variable is defined as - IBu - au) 
due to the different intercept values, it is not easy to see the relative performance of each method. 
In order to demonstrate better the relative performance, the results of the response surface 
analysis presented in Table 11 were used to generate predicted performance values for each of the 
methods. By holding three of the four quantitative variables constant, it was possible to examine 
the effect of the fourth on the performance of each method. 
Figure 3 shows the predicted performance of each method for increasing sample size between 
10 and 100, holding the coefficients of variation constant at 0.2 and the correlation coefficient 
constant at 0. The parametric methods are shown with the weightier lines and solid symbols. At 
low sample sizes, Fieller's method performs best and the Taylor series performs worst. The 
confidence box approach appears largely unaffected by sample size. All the other methods 
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Figure 4. Predicted effect of coefficient of variation of the numerator on the performance variable using results of the 
response surface analysis (sample size = 50, coefficient of variation of the denominator - &2, correlation - 0). Perfor- 
mance variable is defined as - I&° - 0°I 
improve with sample size, and by n= 100 there is little to choose between Fieller's method and 
the bootstrap methods with the exception of the normal approximation bootstrap method, 
which, like the Taylor series method, performs poorly. 
Figure 4 shows the predicted performance of each method for values of the coefficient of 
variation of the numerator between 0.1 and 0.4, holding the coefficient of variation of the 
denominator constant at 0.2, the correlation coefficient constant at 0 and the sample size constant 
at 50. Again, Fieller's method performs best for all values of the coefficient of variation of the 
numerator and the Taylor series method performs worst. The normal approximation and Taylor 
series methods improve in performance as the coefficient of variation of the numerator increases 
while the performance of the other methods decrease, with the exception of the confidence box 
method which again appears largely unaffected by changes in the coefficient of variation of the 
numerator. 
Figure 5 shows the predicted performance of each method for values of the coefficient of 
variation of the denominator between 0.1 and 0.4, holding the coefficient of variation of the 
numerator constant at 0.2, the correlation coefficient constant at 0 and the sample size constant at 
50. A similar picture emerges in that Fieller's method performs best overall, Taylor series 
performs worst for all but the lowest coefficients of variation of the denominator and the 
confidence box method seems largely unaffected. This time, however, the performance of the 
Taylor series and normal approximation bootstrap methods worsen as the coefficient of variation 
of the denominator increases while the other methods improve in performance. 
Figure 6 shows the predicted performance of each method for values of the correlation 
coefficient between -0.9 and + 0.9, holding the coefficients of variation constant at 0.2 and the 
sample size constant at 50. Fieller's method again performs best and appears unaffected by 
variation in the correlation coefficient of the underlying data. All methods improve with 
increasing correlation with the exception of the confidence box method, which worsens dramati. 
cally as correlation increases. At the very highest correlation, the confidence box method 
performs worse than the Taylor series method. 
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Figure 5. Predicted effect of coefficient of variation of the denominator on the performance variable using results of the 
response surface analysis (sample size = 50, coefficient of variation of the numerator - 0.2, correlation - 0). Performance 
variable is defined as - Idu - auf 
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Figure 6. Predicted effect of correlation in the underlying date on the performance variable using results of the response 
surface analysis (sample size - 50, coefficients of variation - (4). Performance variable is defined as - Idu - auf 
4. DISCUSSION AND CONCLUSIONS 
The purpose of this paper was to compare a number of parametric approximations of the 
confidence limits around the incremental cost-effectiveness ratio with non-parametric bootstrap. 
ping methods. By devising a series of experiments that represented a realistic range of statistical 
conditions, we are able to make general conclusions about the relative performance of these 
approaches, and the factors affecting their relative performance. 
No single method dominated (or was dominated by) all other methods across all of the 
experiments. However, as is shown by Figures 3-6, Fieller's method consistently performed well 
under a wide variety of assumptions, including small sample sizes, where its assumption of joint 
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normality between the cost and effect differences has been questioned. -' Of the bootstrap methods, 
a clear pattern emerged in terms of the rank ordering of performance. The parametric bootstrap 
performed the best under most circumstances, closely followed by the BCa and then the 
straightforward percentile method. The normal approximation method performed most poorly of 
the bootstrap methods. It is clear that the `accelerator' adjustment presented by Efron as 
a refinement to the straightforward bias corrected approach does improve the performance of the 
method. Although the term `parametric bootstrap' has been adopted by Efron and Tibshirani, 13 
this method is simply a straightforward Monte Carlo simulation of the numerator and denomin- 
ator of the ratio on the basis of parametric assumptions and the observed means and variances of 
the data. To what extent this constitutes `bootstrapping' as the term is commonly applied is an 
open question. 
The predicted effect of increasing sample size is of particular interest. Both the parametric and 
bootstrap methods rely on asymptotics, and it appears from Figure 3 that the asymptotics of the 
parametric methods come in to play more quickly than those of the bootstrap methods. In many 
ways this is a surprising result since bootstrapping has often been linked to the analysis of small 
samples where standard parametric assumptions are thought to be violated. "' 
As the correlation between the cost and effect in the underlying data increased, the performance 
of the confidence box method worsened. This is due to the fact that the combination of limits for 
the confidence box approach is consistent with an assumption of perfect negative covariance 
between cost and effect. For all other methods, performance increased with increasing correla- 
tion. Although there was little to choose between the methods when correlation was high, in 
practical application it would be unusual to observe extremely high positive or negative correla- 
tions. In the data from which Figure 2 was generated, the correlation between cost and effect in 
the treatment arm of the trial was 0.19, while in the control arm of the trial it was -005.8 These 
figures translate into very little covariance between the numerator and denominator of the ICER. 
The predicted effect of the coefficient of variation of the numerator and denominator was 
interesting in that each seemed to influence the methods in the opposite direction. The methods 
based on an assumption of the normal distribution worsened as the coefficient of variation of the 
denominator increased, but improved as the coefficient of variation of the numerator increased. 
For the other methods, the converse was true, with the exception of the confidence box method, 
which seemed largely unaffected by either coefficient of variation. 
One very clear result from these experiments was the inadequacy of methods based principally 
on the assumption of a normal sampling distribution. Both the parametric based Taylor 
approximation method and the bootstrap normal approximation were consistently poor per- 
formers, although the bootstrap normal approximation seemed to outperform the Taylor series 
method in general. It is our belief that the sampling distribution of the ICER will almost certainly 
exhibit an element of skewness in most practical applications, which makes the normal distribu- 
tion assumption rather limiting. 
Recent reviews of economic evaluations have suggested that many authors present only point 
estimates of cost-effectiveness without any representation of the uncertainty associated with their 
estimates, 20'21 which suggests that any method of interval estimation is preferable to point 
estimates alone. However, we have shown that there are substantial differences in the accuracy of 
the methods advocated in the recent health economics literature. We believe that the nominal 
error rates accepted by analysts when calculating confidence intervals should be reflected by the 
actual rates of error that would occur in repeated application of the method. Of course, these 
error rates will only occur if in practice analysts begin to test hypotheses on the basis of the results 
Copyright (0 1999 John Wiley & Sons, Ltd. Statist. Med. 1$, 3243-3262 (1999) 
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of prospective economic evaluation. We believe the time is now ripe for an analysis of the role of 
hypothesis testing in economic appraisal. 
APPENDIX 
This Appendix lays out the method for generating variances of the cost parameters; the same 
method also applies to effects. Suppose the underlying population cost parameters for treatments 
A and B are known to be CA and CB, respectively. Define the mean difference in cost between two 
groups sampled from these populations as AC = CA - Cs. In terms of the Monte Carlo experi- 
ments, we want to set the coefficient of variation of the difference in costs, cv(AC), since it is this 
which is assumed (in tandem with the effect difference) to determine the shape of the ICER 
sampling distribution. Hence, the problem is to work backwards from this coefficient of variation 
to define values for the population cost variance for patients receiving treatments A or B, al and 
oB2, which will generate the desired cv(AC). 
We know that the coefficient of variation for the cost difference is defined as 
hence cv(AC)' = 476, C/AC, 
QoC = ACcv(AC). (14) 
Assuming that random samples of size nA and nB are sampled from the population for treatments 
A and B, respectively, then the treatment costs in each group should be independent. Thus it is 
possible to relate the variance of the cost difference to the variances of the underlying treatment 
and control group cost data: 
i2 
2 CCA Qca (15) Qec+-. 
nA nB 
Combining equations (14) and (15) gives 
[cv(AC)QC]Z = 
ncA 
+ nge 
A 
and rearranging 
nAnB [cv(AC) AZ'] 2= nBQCA + nAOCe. (16) 
Further suppose that the coefficients of variation of the underlying costs are the same, that is, 
(7cA/Cn = ace/CB or equivalently that 
CA 
QCM=oCO C. 
B 
Combining equations (16) and (17) gives 
nAnB[cv(t1C)QL']Z = nsacs( _fl + fA arc's C6 
= 02 e[nti + na 
(£C, 
9-1)'] 
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and rearranging 
_ 
{cv(ec)tC32 UCH ^ WAHR nA + ne(CA/CB)2 (18) 
Clearly, QC',, can now be calculated from equation (17). 
In our experiments, the sample size in each group was the same, that is, nA = nB = n, therefore 
equation (18) simplifies to 
_ 
[cv(EC)AC]2 2 0cB _nI+ (Cn/CB)Z 
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